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ABSTRACT 
 
Specialized bone marrow microenvironments (vascular and osteoblastic 'niches') 
regulate normal haematopoietic stem/progenitor cells.  Recently, the vascular niche has 
also been implicated as an area for preferential engraftment of malignant cells.  The 
cellular and molecular factors that regulate the vascular niche and, in particular, the role 
of megakaryocytes are poorly understood.  The aim of my work was to investigate the 
role of megakaryocytes in homing and engraftment of malignant cells to the bone marrow 
vascular niche using mouse models.  C57Bl/6 wild-type and megakaryocyte-deficient, 
thrombopoietin (TPO)-/- mice were injected with B16 melanoma or EL4 lymphoma cell 
lines and the megakaryocyte-vascular niche investigated by immunohistochemistry, 
confocal microscopy, in vitro culture, co-cultures and gene expression by RT-PCR.   
 
In wild-type mice injected with B16 melanoma, platelet size and megakaryocyte 
numbers significantly increased (P<0.02).  B16 tumour cells were found to produce the 
thrombopoietic factors VEGF, SCF and IL11.  Bone marrow sinusoids were almost 
universally surrounded by one of more megakaryocytes tightly abutting the vascular 
endothelium, forming the megakaryocyte-vascular niche.  Metastatic B16 cells were 
observed in close association with megakaryocytes in the vascular niche, consistent with 
this being a port of entry to the bone marrow.   
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In TPO-/- mice, tumour growth and metastasis was markedly retarded and no 
tumour cells were seen in the bone marrow, suggesting that megakaryocytes play a 
functional role in metastasis.  In TPO-/- bone marrow, vessels were more tortuous and 
larger in diameter (P=0.01); and expression of PF4, TSP1, VEGF and TGFβ was 70%-
90% lower, suggesting that a major proportion of angiogenic regulatory factors is 
producted by megakaryocytes in the bone marrow in wild-type mice.  Furthermore, in 
wild-type mice, expression of VEGF and TGFβ significantly increased during tumour 
growth and metastasis while PF4 expression decreased (P<0.05). 
 
Megakaryocyte-conditioned medium (MCM) enhanced the proliferation rate of 
B16 cells (P<0.001) and also was highly chemotactic for B16 cells (P<0.001), an effect 
mediated by pertussis toxin-sensitive Gi-protein receptors and reduced in the absence of 
TSP1.  Co-culture with B16 cells increased megakaryocyte expression of VEGF, TGFβ 
and TSP1 and decreased PF4, consistent with the in vivo observations, while cocultured 
B16 cells displayed increased expression of VEGF and TGFβ and adhesion integrins.  
Moreover, pretreating B16 cells with MCM prior to tail vein injection enhanced 
metastatic engraftment.   
 
To investigate the role of megakaryocytes in human malignancy, trephine bone 
marrow biopsies from patients with metastatic carcinoma were examined.  Increased 
megakaryocyte numbers and abnormal megakaryocyte clustering were observed in the 
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majority of patients, suggesting that megakaryocyte-tumour interactions may also occur 
in the setting of human metastatic disease. 
 
In conclusion, my findings suggest that megakaryocytes contribute to the integrity 
and function of the bone marrow vascular niche and that cellular/molecular cross talk 
between megakaryocytes and tumour cells may promote metastasis.  Targeting these 
interactions may be useful as adjunctive therapy in metastatic disease.  
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Platelet/endothelial cell adhesion molecule  PECAM  
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Proplatelet formation PPF 
Proteinase-activated receptors PAR 
Regulated upon activation, normal-T cell expressed and secreted 
chemokine RANTES 
Revolutions per minute RPM 
Serum Amyloid A3 SAA3 
Serum free medium (DMEM) SFM 
Signalling lymphocyte activation molecule  SLAM 
Sphingosine 1-phosphate  S1P 
Stem Cell Factor (kit-ligand)  SCF 
Stem cell leukaemia SCL 
Stromal-derived factor 1 (also known as CXCL12) SDF1  
Sympathetic nervous system SNS 
Thrombopoietin TPO 
Thrombospondin TSP 
Total body irradiation TBI 
Trans-Golgi network TGN 
Transforming growth factor TGF 
Tumour necrosis factor TNF 
Tumour-conditioned medium TCM 
Tyrosine-protein kinase receptor-2 TIE-2 
Vascular cell adhesion molecule VCAM 
Vascular endothelial cadherin (CD144) VE-Cadherin 
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Vascular endothelial growth factor VEGF 
Vascular endothelial growth factor receptor VEGFR 
Very late antigen-4 (also known as α4β1) VLA-4 
von Willebrand Factor vWF 
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1.1. Haematopoietic niches in the bone marrow 
 
Haematopoietic stem cells (HSCs) reside within specialized microenvironments.  
These ‘niches’ are not static repositories but are complex, dynamic composites of cells, 
secreted proteins, metabolic constituents and extracellular matrix factors that actively 
regulate stem cell function (Table 1.1)(Adams and Scadden, 2006; Balduino et al., 2005; 
Haylock and Nilsson, 2005; Kaplan et al., 2007; Li and Neaves, 2006; Nilsson et al., 
2001; Scadden, 2006; Yin and Li, 2006).  It has been shown that a supportive 
microenvironment is necessary for the maintenance of a sustainable and responsive HSC 
pool that can give rise to mature blood cells of all lineages in appropriate numbers 
depending on physiological requirements(Adams and Scadden, 2006; Wilson et al., 
2009).  Interactions between stem cells and niches are bidirectional.  The niche may 
regulate stem cell self-renewal and cell fate decisions, and stem cells may in turn 
modulate the nurturing microenvironments in which they reside(Scadden, 2006).  Two 
physiologically distinct HSC niches have been described in the bone marrow; the 
osteoblastic niche at the endosteal lining of the bone, and the vascular niche around the 
bone marrow vascular endothelium (Figure 1.1.)(Kiel and Morrison, 2008).  
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1.1.1. The osteoblastic niche  
 
The majority of long-term repopulating HSCs are found near the endosteal lining 
of the bone where they are in close contact with the bone remodeling cells, osteoblasts 
and osteoclasts(Calvi et al., 2003; Lord et al., 1975; Taichman and Emerson, 1994; Zhang 
et al., 2003a).  Osteoblasts secrete several growth factors required for HSC maintenance, 
including angiopoietin 1 (Ang-1), thrombopoietin (TPO) and stromal-derived factor-1 
(SDF1)(Arai et al., 2004; Yoshihara et al., 2007).  Manipulations that increase the 
numbers of osteoblasts also increase HSC numbers, suggesting that availability of 
osteoblastic niches is a limiting factor for the HSC pool(Calvi et al., 2003; Zhang et al., 
2003a).  The osteoblastic niche appears to be especially important for HSC maintenance 
following irradiation or other forms of bone marrow damage(Xie et al., 2009).  It has 
been proposed that Notch and N-cadherin-mediated interactions between HSCs and 
osteoblasts promote cellular quiescence and self-renewal(Wilson et al., 2004; Zhang et 
al., 2003a).  However, whether direct cell-cell contact between osteoblasts and HSCs is 
essential for haematopoietic maintenance has yet to be resolved(Kiel et al., 2009). 
 
Osteoclasts also contribute to the regulation of the HSC niche.  Release of 
calcium ions by osteoclast bone resorption retains HSCs close to the endosteal 
lining(Adams et al., 2006) and secretion of proteolytic enzymes cleaves anchorage 
proteins such as SDF1 and stem cell factor (SCF) enabling mobilization of HSCs from 
the endosteal region(Kollet et al., 2006).   
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Whether the osteoblastic and vascular niches are indeed anatomically distinct 
entities is unclear.  Recent reports have highlighted that the endosteal lining of the bone is 
heavily invested with blood vessels(Kiel et al., 2005; Lo Celso et al., 2009; Xie et al., 
2009). Therefore, it is possible that the role of osteoblasts may be more indirect, 
influencing a subset of perivascular niches that are close to the endosteum and that 
promote stem cell quiescence and self-renewal, but not constituting a truly independent 
HSC niche.  
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Table 1.1.  Cell-extrinsic soluble factors essential for HSC maintenance and their 
source in bone marrow niches  
Adapted from Kiel & Morrison, Nature Reviews Immunology 2008 
 
Factor Role / Function  Primary Source 
SCF (kit 
ligand) 
Exists both as a membrane-bound and a soluble 
protein.  Interacts with c-Kit receptor.  Important 
for HSC localization, survival and maintenance.   
Bone marrow stromal 
cells(Toksoz et al., 1992)  
SDF1 Principal chemokine regulating localization of 
HSCs and haematopoietic progenitor cells (HPCs) 
via interactions with the CXCR4 receptor 
(Wright et al., 2002).  Promotes surface integrin 
upregulation and HSC survival 
(Broxmeyer et al., 2007; Dhanjal et al., 2007).   
Mesenchymal stem cells 
(Mendez-Ferrer et al., 2008)  
Reticular cells (Sugiyama et 
al., 2006) 
Osteoblasts  
Ang-1 Promotes maintenance of quiescent HSCs via 
interactions with the Tie2 receptor 
Osteoblasts(Arai et al., 
2004), endothelial cells, 
pericytes(Asahara et al., 
1998) 
TPO Regulates stem cell quiescence 
(Qian et al., 2007; Yoshihara et al., 2007) 
Liver, kidney, bone marrow 
stroma, osteoblasts 
(Kaushansky, 2008) 
Ca2+ ions Interaction with a G-protein coupled Ca2+-sensing 
receptor expressed on HSCs maintains 
localization of HSCs near the endosteal bone 
lining(Adams et al., 2006)  
Osteoclast-mediated bone 
degradation  
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1.1.2. The vascular niche  
 
While the osteoblastic niche appears to promote stem cell quiescence, the 
perivascular region is thought to be more conducive for HSC expansion(Kiel et al., 2005; 
Kopp et al., 2005; Rafii et al., 1997a; Rafii et al., 1995).  Although the cellular and 
molecular components of the osteoblastic niche, including osteoblasts, osteoclasts, matrix 
proteins such as osteopontin and soluble factors including calcium ions have been 
reasonably well described, much less is known about the anatomical and physical make 
up of the vascular niche.   
 
1.1.2.1. Bone marrow vascular endothelium supports haematopoiesis 
 
The bone marrow vasculature is a dense network of smooth muscle-invested 
afferent arterioles and capillaries, and thin-walled, fenestrated venous sinusoids.  It has 
been suggested that the endothelium of the vascular sinusoids is uniquely specialized to 
support haematopoiesis over other vessel types(Hooper et al., 2009), however this has not 
been definitively shown and the majority of studies have used panendothelial markers 
such as MECA32 to identify bone marrow vessels.  Unlike other vessels, the bone 
marrow sinusoidal endothelium is devoid of pericytes although they are invested with 
specialized SDF1-secreting reticular cells, as described below.  It is presumed that 
vascular niches in bone marrow and spleen are dedicated for haematopoietic 
stem/progenitor cells, although in non-haematopoietic tissues, organ-specific stem cells 
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such as neural stem cells are thought to reside in analogous vascular niches in their 
resident organs(Colmone and Sipkins, 2008; Shen et al., 2008). 
 
In vitro studies have shown that endothelial cells produce factors that support 
HSC maintenance, and their unique expression of adhesion factors is important for 
trafficking and homing of HSCs to the bone marrow(Kiel and Morrison, 2006; Li et al., 
2004; Naiyer et al., 1999; Rafii et al., 1995; Rafii et al., 1994).  Until very recently, 
detailed investigation of the bone marrow vasculature has been hampered by an inability 
to distinguish between arteriole and sinusoidal vessel types.  Studies have generally 
employed antibodies against pan-endothelial cell antigens, such as PECAM (CD31), 
vWF, or MECA32 (the murine equivalent of CD31).  However, a recent study clarifying 
the immunohistological profile of specific vessel types reported that the sinusoids can be 
specifically identified by their expression of VEGFR3, while arterioles uniquely express 
Sca1(Hooper et al., 2009)(Table 1.2).  This study also reported that the extent and rate of 
recovery of the sinusoidal endothelium following myelosuppresive chemotherapy or 
radiotherapy correlated with haematopoietic recovery, and that this may be inhibited by 
treatment with a VEGFR2 antibody(Hooper et al., 2009).  This implies that VEGF 
stimulation via the VEGFR2 receptor expressed on bone marrow vessels is required for 
angiogenic vessel reassembly and regeneration of the vascular niche.  However, the 
relative contribution of arterioles vs. sinusoids to the haematopoietic niche remains to be 
fully clarified.  
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Table 1.2. Immunohistochemical profile of bone marrow vessels as reported by 
Hooper et al, Cell Stem Cell 2009  
This suggests that the bone marrow sinusoidal endothelium may be distinguised by the 
VEGFR3+ Sca1- immunophenotype  
  
 
Antigen Arterioles / capillaries Sinusoids 
VE-Cadherin + + 
PECAM (CD31) + + 
VEGFR1 + + 
VEGFR2 + + 
VEGFR3 - + 
MECA32 + + 
Sca1 + - 
 
 
One of the first in vivo studies to indicate that the perivascular regions within 
bone marrow are important for haematopoiesis was a report describing restoration of 
thrombopoiesis following chemokine-induced localization of megakaryocytes to the 
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vascular niche in TPO-deficient mice(Avecilla et al., 2004) (this report is considered in 
detail in Section 1.2.3. below).  Subsequently, immunofluorescence studies of 
untransplanted HSCs in situ using antibodies to the CD150 (SLAM) family of receptors 
which are differentially expressed among HSCs and haematopoietic progenitor cells 
(HPCs) suggested that about two-thirds of HSCs in the bone marrow and spleen of the 
mouse are located adjacent to MECA32+ blood vessels(Kiel et al., 2005).   
 
1.1.2.2. Perivascular cells involved in the vascular niche   
 
Apart from the vascular endothelial cells, perivascular reticular cells have been 
shown to be involved in regulating HSCs in the vascular niche.  It has been reported that 
almost all HSCs (97%) are in contact with a small population of perivascular, SDF1-
producing reticular cells, termed CXCL12-abundant reticular cells (CAR cells)(Sugiyama 
et al., 2006).  SDF1-CXCR4 signalling is essential for HSC colonization of the bone 
marrow and for HSC maintenance, and while the CAR cells were highly enriched for 
SDF1, comparatively little SDF1 production was observed at the endosteal 
region(Sugiyama et al., 2006).  Notably, endothelial cells also produced negligible 
amounts of SDF1, although Sugiyama et al reported that the sinusoidal endothelial cells 
were often seen surrounded by the cell bodies or cell processes of the CAR cells.  
 
A second population of perivascular cells identified by their expression of nestin, 
a filament protein typically characteristic of neuroectoderm-derived cells, have also 
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recently been described as key components of the HSC niche(Méndez-Ferrer et al., 
2009).  The nestin+ cells were identified to be mesenchymal stem cells (MSCs), with 
colony-forming capacity and giving rise to osteoblastic, chondrocytic and adipocytic 
lineages(Méndez-Ferrer et al., 2009).  Previous work by this group revealed that the 
release of HSCs from the bone marrow is orchestrated by circadian rhythms via signals 
from the sympathetic nervous system (SNS) that control SDF1 expression(Mendez-Ferrer 
et al., 2008).  Virtually all SNS fibres in the bone marrow were found to be associated 
with the nestin+ cells, which express high levels of SDF1 and therefore are likely to be 
the same or an overlapping population of cells as the CAR cells.  Other groups have 
described similar subendothelial stromal cells expressing Ang-1 that are able to support 
HSCs in the bone marrow and that may also establish heterotopic haematopoietic 
microenvironments following subcutaneous transplantation(Sacchetti et al., 2007).      
 
1.1.2.3. Overlap between vascular and osteoblastic niches: evidence from in vivo studies  
  
Advances in confocal and two-photon microscopy have enabled a dynamic 
exploration of the vascular niche in its physiological context in vivo(Lo Celso et al., 
2009; Xie et al., 2009).  Although classically, dichotomous vascular and osteoblastic 
haematopoietic microenvironments have been proposed, recent insights described below 
suggest that these specialized microenvironments share common cellular and molecular 
components and are unlikely to be distinct entities as was originally proposed (Figure 
1.1). 
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Imaging of the murine calvarium highlighted the very close anatomical 
relationship between osteoblasts and the marrow vasculature at the endosteal bone lining, 
with 90% of osteoblasts being within 20µm of a blood vessel(Lo Celso et al., 2009).  This 
implies that HSCs localized near the endosteum would be influenced both by osteoblastic 
and by perivascular factors while HSC/HPC niches located more centrally in the bone 
marrow cavity are more vascular and not associated with osteoblasts.  These areas 
appeared to be functionally distinct, in that while long-term repopulating HSCs engrafted 
niches localized close to osteoblasts, the more mature progenitor subsets engrafted 
progressively further away from the endosteum(Lo Celso et al., 2009).  In agreement with 
this, Hooper et al also observed that in both the diaphysis and the metaphysis of the bone, 
virtually every osteoblast was in close apposition with sinusoidal endothelial cells, 
supporting the notion that osteoblasts and sinusoids form one continuous haematopoietic 
niche at the endosteal surface(Hooper et al., 2009).  Furthermore, the nestin+ SDF1-
secreting MSCs described by Méndez-Ferrer et al were observed adjacent to HSCs 
regardless of whether they were in osteoblastic or vascular niches, suggesting that this 
niche cell may also be common to both osteoblastic and vascular niches(Méndez-Ferrer 
et al., 2009; Sugiyama et al., 2006) 
 
The use of multiphoton intravital microscopy in intact bone marrow and ex-vivo 
real-time imaging techniques have provided valuable insights into the dynamics of 
haematopoiesis in the bone marrow, as described above.  However, to systematically 
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dissect the functional interactions between HSCs and their microenvironments, 
recapitulation of the HSC niche in vitro is required.  To this end, a novel 3D model 
combining the cellular, physical and biochemical features of the osteoblastic niche has 
recently been described(Pallotta et al., 2009).  This type of system may be used to 
advance our understanding of the haematopoietic niches in the near future.   
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Figure 1.1.  Cells, matrix factors and metabolic constituents contributing to 
osteoblastic and vascular bone marrow niches 
 
The osteoblastic niche.  Osteoblasts and osteoclasts secrete numerous factors that regulate HSCs 
(dark blue).  Bone resorption releases calcium ions (Ca2+) influencing HSCs through the Ca2+-
sensing receptor.  The endosteal surface is also heavily invested with blood vessels.  Vascular and 
perivascular cells, such as CXCL12 (SDF1)-producing reticular cells (CAR) and mesenchymal 
stem cells (MSCs) are also thought to contribute to HSC niches at the endosteum. The relative 
hypoxia and abundance of Type I collagen inhibit proplatelet formation by megakaryocytes 
(MKs).    
The vascular niche.  Perivascular sites maintain HSCs and HPCs (lighter blue) in the bone 
marrow and in extramedullary sites including spleen, liver and the placenta.  A wide variety of 
vascular and perivascular cells are likely to contribute to vascular niches, including endothelial 
cells, CAR cells/MSCs and possibly MKs.  Matrix factors fibronectin, vitronectin and Type III 
and IV collagen are found around blood vessels, which enhance MK development and function.   
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1.2.  MEGAKARYOCYTE DEVELOPMENT AND FUNCTION 
 
Megakaryocytes are terminally differentiated haematopoietic cells responsible for 
the production of platelets.  They primarily reside in the bone marrow, where they are 
localized near the bone marrow sinusoids at the vascular stem cell niche, but may also be 
found in the lung and in peripheral blood(Junt et al., 2007; Levine et al., 1993).  In 
addition to their well-recognized role in haemostasis and thrombosis, accumulating 
evidence indicates that megakaryocytes and platelets play important pathological roles in 
tumourigenesis, metastasis, angiogenesis and inflammation(Gupta and Massague, 2004; 
Karpatkin and Pearlstein, 1981; Nash et al., 2002; Sierko and Wojtukiewicz, 2004).   
 
Ranging from 50-100µm in diameter(Pang et al., 2005), mature megakaryocytes 
constitute around 0.1% of nucleated bone marrow cells(Patel et al., 2005a) and are easily 
identifiable by their size and content of a single, large, multilobulated, polypoid nucleus.  
Unlike other cells, megakaryocytes undergo a process of endomitosis, during which they 
replicate DNA by as much as 64-fold without undergoing cellular division, thereby 
acquiring a DNA content of up to 256N per cell(Odell et al., 1970; Odell et al., 1965). 
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1.2.1. Megakaryopoiesis 
 
Megakaryocytes evolve from haematopoietic stem cells (HSCs) by a lineage 
pathway shared with erythroid cells.  Some controversy remains over whether the 
megakaryocyte-erythroid progenitor cell (MEP) differentiates from a common myeloid 
progenitor (CMP) (classical pathway) or alternatively, if the MEP differentiates directly 
from the HSC (direct pathway, Figure 1.2)(Pang et al., 2005).  
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Figure 1.2. Evolution of megakaryocytes from HSCs  
In the "classical" pathway, a common megakaryocyte-erythroid progenitor (MEP) develops from 
the common myeloid progenitor (CMP).  The proposed "direct" route is that a MEP forms 
directly from a HSC. LT-HSC, long-term haematopoietic stem cell; ST-HSC, short-term HSC; 
ELP, early lymphoid progenitor; GMP, granulocyte/monocyte progenitor; CLP, common 
lymphoid progenitor. Adapted from Pang, et al J. Clin. Invest. 2005 
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1.2.2.  Thrombopoiesis 
 
Thrombopoiesis describes the elaboration of platelets from megakaryocytes and is 
a captivating and elaborate process, culminating in the conversion of the megakaryocyte 
cytoplasm into 100 to 500µm-long branched proplatelets, the platelet precursors (Figure 
1.3).  As megakaryocytes mature, an expansive and interconnected network of cisternae 
and tubules continuous with the megakaryocyte plasma membrane develops.  This 
internal cytoplasmic demarcation system, referred to as the “platelet territories”, is 
thought to be the primary membrane reservoir for prospective platelets(Zucker-Franklin 
and Petursson, 1984).  An open canalicular system is also created, providing a channel 
system for the packaging of granules into nascent platelet capsules (see Section 1.4).  
 
Proplatelet formation generally commences from a single site where 1 or more 
broad pseudopodia form(Patel et al., 2005a).  The pseudopodia elongate and taper into 
proplatelets, decorated with multiple bulges or beads destined to become individual 
platelets.  Additional proplatelets continue to develop in a wave fashion that spreads 
throughout the cell until the entire megakaryocyte is degraded into a complex network of 
interconnected proplatelet strands(Patel et al., 2005a).  Microtubules, hollow polymers 
assembled from αβ-tubulin dimers, are critical in this process(Tablin et al., 1990).  
Overlapping microtubules slide and extend, driven by molecular motor proteins including 
dynein and kinesin which provide the force for proplatelet elongation(Patel et al., 2005b).  
The process of platelet assembly shares much homology with programmed cell death, 
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and in many ways constitutes a specialized form of cellular apoptosis.  Indeed, 
overexpression of apoptosis inhibitory proteins such as Bcl-XL and Bcl-2 has been shown 
to inhibit proplatelet formation(de Botton et al., 2002).  
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Figure 1.3. Transition from immature megakaryoblasts (A) to proplatelet formation 
(D) and platelet release (E). Patel et al (J Clin Invest 2005).  
During megakaryocyte maturation, cells undergo nuclear endomitosis and cytoplasmic 
maturation.  Proplatelet formation commences with development of thick pseudopods.  
Sliding of overlapping microtubules enables proplatelet elongation.  Eventually, the 
entire megakaryocyte cytoplasmic mass will be converted into proplatelets, and the 
nuclear mass is extruded.  Individual platelets are released from the ends of proplatelets.     
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1.2.3. The vascular niche in megakaryopoiesis and thrombopoiesis 
 
While the vascular niche supports expansion of all haematopoietic lineages, it 
appears to be especially critical for megakaryocyte function and platelet 
production(Avecilla et al., 2004; Dhanjal et al., 2007; Junt et al., 2007; Kopp et al., 2005; 
Rafii et al., 1997b; Rafii et al., 1995).  It is well established that mature, polyploid 
megakaryocytes are primarily located adjacent to bone marrow vessels, where they 
extend transendothelial pseudopods or migrate through the endothelium to produce 
platelets.  
 
A role for bone marrow vascular endothelium in supporting megakaryopoiesis 
was first suggested by in vitro studies demonstrating that, in the absence of exogenous 
cytokines, bone marrow endothelial monolayers supported differentiation of human 
CD34+ HSCs to megakaryocyte and myeloid progenitors(Rafii et al., 1995).  This was 
attributed to the constitutive production of the thrombopoietic cytokines SCF and 
interleukin (IL)-6(Rafii et al., 1997a; Rafii et al., 1995).  Notably, endothelial cells 
derived from bone marrow supported significantly greater megakaryocyte differentiation 
than did human umbilical vein endothelial cells (HUVECs) or bone marrow stromal cells, 
suggesting that bone marrow endothelium was uniquely specialized in this regard(Rafii et 
al., 1995).  One explanation for this is that production of haematopoietic cytokines by the 
other types of endothelium is not constitutive but occurs only following stimulation with 
IL-1 or TNF(Rafii et al., 1995).  Furthermore, this study reported that CD34+ cells that 
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were cultured in direct cellular contact with endothelial cells gave rise to a larger number 
of megakaryocyte progenitors than did CD34+ cells separated from the endothelial cells 
by transwell coculture chambers(Rafii et al., 1995).  Further evidence that interactions 
between megakaryocytes and endothelium are important is that administration of SDF1 
enhances platelet production only in the presence of bone marrow sinusoids(Hamada et 
al., 1998; Wang et al., 1998). 
 
Megakaryocyte-vessel interactions were subsequently explored in vivo in 
thrombocytopenic, TPO-deficient mice.  Even in the absence of TPO, administration of 
SDF1 and fibroblast growth factor (FGF)-4 resulted a three-fold increase in the platelet 
count resulting from enhanced interaction of the small number of megakaryocyte 
progenitors with the bone marrow vascular endothelium(Avecilla et al., 2004).  In this 
model, SDF1 augmented the mobility of megakaryocytes and promoted migration to 
sinusoidal junctions, and FGF-4 promoted adherence of Very Late Antigen (VLA) 4+ 
megakaryocytes to sinusoidal endothelial cells via Vascular Cell Adhesion Molecule 
(VCAM)-1 interactions(Avecilla et al., 2004).  Administration of vascular disrupting 
agents, which inhibit bone marrow vascular regeneration after chemotherapy-induced 
myelosuppression, has also been shown to cause prolonged and selective 
thrombocytopenia which continues after restoration of other haematopoietic 
lineages(Kopp and Rafii, 2007).  
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Studies of mice deficient in platelet/endothelial cell adhesion molecule 1 
(PECAM-1, also known as CD31) provided evidence that megakaryocyte positioning at 
the vascular niche is important in thrombopoiesis(Dhanjal et al., 2007).  Following 
antibody-induced thrombocytopenia, recovery of the peripheral platelet count was 
impaired in PECAM-1-/- mice even though megakaryocyte maturation, proplatelet 
formation, and platelet production in vitro was unaffected.  This finding was attributed to 
reduced directional migration in response to SDF1, due to defective polarization of the 
CXCR4 receptor in the PECAM-1-/- megakaryocytes(Dhanjal et al., 2007).  Movement of 
PECAM-1-/- megakaryocytes towards an SDF1 gradient was less than 1/3 of that of wild 
type megakaryocytes, and PECAM-1 deficiency was also associated with an increase in 
adhesion to the matrix protein fibronectin due to constitutive activation of the fibronectin-
binding surface integrin, αIIbβ3(Dhanjal et al., 2007).  These data indicate that PECAM-
1 is required for migration of megakaryocytes from osteoblastic to perivascular sites by 
regulating their directional movement and adhesion to matrix proteins in the bone 
marrow microenvironment.  Notably, PECAM is also expressed on tumour cell lines 
(human and murine), and involved in adhesion of tumor cells to microvascular 
endothelial cells(Timar et al., 2005).     
 
Remarkably, although proplatelet formation (PPF) by megakaryocytes is a 
spontaneous process in vitro, it appears to be temporally regulated in vivo by interactions 
between megakaryocytes and extracellular matrix proteins.  Although PPF is initially 
accelerated following adhesion to fibrinogen, fibronectin and von Willebrand Factor 
(vWF), PPF amplitude and duration is then substantially decreased(Balduini et al., 2008).  
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Furthermore, it has been reported that while Type I collagen strongly inhibits proplatelet 
formation, collagen types IV and III support PPF(Balduini et al., 2008; Nilsson et al., 
1998).  As Type I collagen is particularly abundant at the osteoblastic zone while types 
III and IV are found around the bone marrow vessels, it is possible that this mechanism 
serves to prevent premature release of platelets in the bone marrow prior to 
megakaryocyte localization at the bone marrow – blood vascular interface.  Similarly, the 
relative hypoxia at the endosteal regions also inhibits PPF(Pallotta et al., 2009), and 
adhesion to perivascular fibronectin and vitronectin enhance megakaryopoiesis and PPF 
(Figure 1.1.)(Fox and Kaushansky, 2005; Leven and Tablin, 1992).      
 
In addition to growth factor support, cell-cell and cell-matrix interactions, 
mechanical forces at the vascular niche are also pivotal to platelet release.  The 
development of intravital multiphoton fluorescence microscopy techniques has recently 
enabled direct visualization of thrombopoiesis.  Such studies have confirmed that blood 
flow-induced hydrodynamic stress is required for platelet release from proplatelet-
forming megakaryocytes, sheering off fragments of megakaryocyte protrusions and 
enabling release of proplatelets/platelets into the circulation(Junt et al., 2007).  In 
agreement with this report, an in vitro study of human megakaryocytes perfused in a flow 
chamber demonstrated that exposure to high sheer rates resulted in deformation of the 
megakaryocyte cytoplasm, with PPF along the direction of flow and generation of 
functional platelets(Dunois-Larde et al., 2009).     
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1.2.4. The role of megakaryocytes in haematopoietic niches 
 
 There is evidence to suggest that megakaryocytes both support and regulate the 
bone marrow niches that they inhabit via their abundant production and transport of 
growth factors and cytokines (Table 1.3.).  In genetic mouse models in which 
megakaryocyte numbers are increased, such as mice overexpressing TPO or GATA-1 and 
NF-E2 knock-out strains, the increase in numbers of megakaryocytes is associated with 
an osteosclerotic phenotype(Kacena et al., 2006a).  In addition, both mature and 
immature megakaryocytes stimulate the proliferation and differentiation of osteoblasts in 
vitro and inhibit osteoclast differentiation(Ciovacco et al., 2010; Kacena et al., 2006b).  
Although the precise mechanism for the stimulation of osteoblast proliferation remains 
unclear, recent data suggests that the fibronectin-binding integrins α3β1 (VLA4) and 
α5β which mediate megakaryocyte-osteoblast adhesion and activation are 
important(Lemieux et al., 2010).      
   
Unlike the majority of other haematopoietic cells, megakaryocytes remain 
functional for around 7 days following irradiation and bone marrow 
transplantation(Tanum, 1984).  It has therefore been postulated that megakaryocytes may 
play a role in reconstitution of bone marrow niches and haematopoietic recovery.  An 
investigation of the bone marrow of mice 48 hours after lethal total body irradiation 
(TBI) revealed that megakaryocytes had translocated from the central vascular marrow 
areas to the diaphysial bone regions (also noted to be an area of the endosteum that was 
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relatively low in collagen I expression)(Dominici et al., 2009).  This occurred in response 
to upregulation of SDF1 in these areas(Dominici et al., 2009).  More than 1/3 of 
megakaryocytes were observed to be in physical contact with bone lining cells following 
TBI, as compared to just over 7% in normal mice(Dominici et al., 2009).  Furthermore, 
expression of platelet-derived growth factor (PDGF)-β and FGF-2, two megakaryocyte-
derived factors known to stimulate osteoblast differentiation and proliferation was 
significantly increased following TBI(Dominici et al., 2009).  These data suggest that 
megakaryocytes play an important role in recovery of osteoblastic niches following bone 
marrow damage.   
  
Considering the extensive research on the vital contribution of platelets in 
angiogenesis and the maintenance of blood vessel integrity, surprisingly few studies have 
examined the functional contribution of megakaryocytes to the regulation of the bone 
marrow vasculature.  Megakaryocytes are a major source of both proangiogenic and 
antiangiogenic factors in the bone marrow (see Table 1.4), support the survival of bone 
marrow-derived sinusoidal endothelial cells in vitro(Mohle et al., 1997), and there is in 
vivo evidence from murine studies that angiogenic processes both in the bone marrow 
and in other tissues are regulated by the absolute number of megakaryocytes in the bone 
marrow and their content of angiogenic regulatory factors(Kopp et al., 2006; Varner, 
2006).  Examining mouse bone marrow by immunohistological staining for 
thrombospondin (TSP)1, the first endogenous angiogenesis inhibitor to be 
recognized(Good et al., 1990), revealed that bone marrow TSP1 expression was limited 
to megakaryocytes, platelets and the endosteal surface.  Other groups have shown that 
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bone marrow vascularity is increased in TSP1-/- mice(Kopp et al., 2006).  Recovery of the 
bone marrow vasculature following 5-FU treatment occurred significantly faster in TSP1 
and TSP2 double knock-out (TSP-DKO) mice than in wild-type mice.  Furthermore, 
vessel sprouting in Matrigel plugs loaded with TSP-DKO megakaryocytes was nearly 2-
fold higher in mice receiving TSP-DKO megakaryocytes than wild-type megakaryocytes, 
and revascularization of ischaemic hind limbs was also accelerated(Kopp et al., 2006).   
 
Therefore, megakaryocyte content of vascular regulatory factors appears to be a 
key determinant of bone marrow vascularity and by regulating osteoblast proliferation, 
megakaryocytes may therefore influence the number and function of both osteoblastic 
and haematopoietic vascular niches (Table 1.3. and Figure 1.4.).   
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Table 1.3. Megakaryocyte-derived factors that may influence haematopoietic niches  
 
Osteoclastogenic promoters  RANKL(Bord et al., 2004) 
Osteoclastogenic inhibitors  Osteoprotegerin(Bord et al., 2004; 
Kacena et al., 2006b) 
Osteoblast promoters / 
Mesenchymal growth factors 
PDGF, FGF2, TGFβ, fibronectin-
binding surface integrins(Ciovacco et 
al., 2010; Kacena et al., 2006a)  
Osteoblastic 
niche 
Bone matrix proteins Osteocalcin, osteonectin, osteopontin, 
bone sialoprotein, BMP-2, -4 and -6. 
(Kacena et al., 2006a) 
Proangiogenic factors VEGF, TGFβ, FGF2, MMPs(Italiano 
et al., 2008; Nachman and Rafii, 2008) 
(see Table 1.4. for others) 
Antiangiogenic factors TSP1, PF4, endostatin(Italiano et al., 
2008; Nachman and Rafii, 2008)  
(See Table 1.4. for others) 
Vascular 
niche 
  
Chemokines SDF1(Jin et al., 2006a; Kopp et al., 
2006) (synthesized in low amounts by 
megakaryocytes-largely taken up from 
the microenvironment),  
PF4(Lambert et al., 2007)  
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Figure 1.4.  Megakaryocyte-endothelial cell cross-talk in the bone marrow(Nachman 
and Rafii, 2008) (modified).  
Through platelet production and release of endothelial cell growth factors, 
megakaryocytes determine the integrity and viability of the bone marrow vascular bed.   
In return, the endothelial cells regulate megakaryocyte differentiation and function. 
[Vascular endothelial growth factor A (VEGF-A); stromal cell-derived growth factor 
(SDF) 1; angiopoietin 1 (ANG1); brain-derived neurotrophic factor (BNDF); fibroblast 
growth factor (FGF); epidermal growth factor (EGF); stem cell factor (SCF); platelet-
activating factor (PAF); platelet-derived growth factor (PDGF); thrombopoietin (TPO); 
granulocyte-macrophage colony stimulating factor (GM-CSF)]    
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1.3. HUMOURAL REGULATION OF MEGAKARYOPOIESIS AND 
THROMBOPOIESIS  
 
Megakaryopoiesis and thrombopoiesis are orchestrated by a complex array of 
haematopoietic cytokines and growth factors which promote commitment of HSCs to the 
megakaryocytic lineage, proliferation and maturation of MK progenitors and culminating 
in platelet release (Table 1.4.)(Ciurea and Hoffman, 2007; Kaushansky, 2005).  TPO is 
the ‘master regulator’ of megakaryopoiesis and thrombopoiesis, supporting all aspects of 
megakaryocyte and platelet development, regulating differentiation and proliferation of 
megakaryocyte progenitors and their maturation into proplatelet-forming, polyploid 
cells(Kaushansky, 2005; Kaushansky and Drachman, 2002).  TPO and SCF are essential 
for normal and stress-induced thrombopoiesis; other nonessential cytokines that promote 
different aspects of megakaryopoiesis include IL-3, IL-6, IL-11, GM-CSF and leukaemia 
inhibitory factor (LIF, Table 1.4)(Kaushansky, 2009).  In addition to these growth 
factors, several transcription factors, including GATA-1, friend of GATA-1 (FOG-1), 
stem cell leukaemia (SCL), LIM domain only 2 (LMO2), LIM domain binding protein-1 
(Ldb-1), and nuclear factor erythroid-derived 2 (NF-E2), are also required for 
megakaryocyte differentiation and platelet production(Fock et al., 2008; Goldfarb, 2007; 
McCormack et al., 2006).   
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The role of thrombopoietic cytokines in angiogenesis, including tumour-
associated angiogenesis(Jin et al., 2006a) is discussed in Section 1.5.  The thrombopoietic 
cytokines of particular relevance to this project are discussed in more detail below.  
 
 
1.3.1. Thrombopoietin (TPO) 
 
The discovery and cloning of TPO in 1994 was pivotal to the study of 
thrombopoiesis, enabling in vitro culture systems and transgenic murine models to be 
developed(de Sauvage et al., 1996; de Sauvage et al., 1994; Kaushansky et al., 1994; Lok 
et al., 1994).  TPO synthesis primarily occurs in the liver, with approximately half of all 
TPO produced by the liver in steady-state conditions(Qian et al., 1998).  Smaller amounts 
are also made in the kidney and bone marrow stromal cells including 
osteoblasts(Yoshihara et al., 2007).  While hepatic production of TPO is largely 
unresponsive to alterations in platelet count, systemic inflammation is usually associated 
with enhanced thrombopoiesis due to upregulation of TPO production in response to IL-6 
stimulation(Kaser et al., 2001; Wolber et al., 2001).  Conversely, platelet granule proteins 
inhibit bone marrow stromal cell transcription of the TPO gene, regulating TPO 
production in the bone marrow according to platelet levels(McIntosh and Kaushansky, 
2008; Sungaran et al., 2000).     
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The receptor for TPO, c-Mpl, is present on HSCs, HPCs, immature and mature 
megakaryocytes and platelets.  TPO binding to c-Mpl initiates a cascade of intracellular 
signaling events, involving JAK2 and STAT5 phosphorylation and MAPK activation, 
promoting cellular proliferation, differentiation and cell survival(Kuter, 2007).  In 
homeostasis, TPO levels are largely determined by an autoregulatory loop in which 
circulating TPO levels are balanced according to megakaryocyte/platelet mass by c-Mpl 
receptor-mediated uptake and destruction. 
 
1.3.1.1. TPO-/- mouse model 
 
In mice deficient in TPO or c-Mpl, megakaryocyte number, ploidy and maturity 
are reduced and megakaryocyte and platelet counts are ~10% of wild-type values(de 
Sauvage et al., 1996; Gurney et al., 1994b).  However, the fact that a degree of 
megakaryopoiesis and platelet production continues in the absence of TPO signaling 
demonstrates that additional factors may also support thrombopoiesis in certain contexts.  
 
Ultrastructural studies have shown that the residual megakaryocytes and platelets 
are morphologically normal in TPO-/- and c-Mpl-/- mice.  An examination of the bone 
marrow of TPO-/- and c-Mpl-/- mice by electron microscopy demonstrated that all the 
normal maturational stages of megakaryocyte progenitors were present, platelet 
demarcation channels were observed and intracellular granules were not different from 
wild-type mice in terms of their number and appearance(Bunting et al., 1997).  Similarly, 
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the ultrastructure of platelets is unchanged, and platelet activation in response to agonist 
stimulation ex vivo has been shown to be normal(Bunting et al., 1997).  This is in keeping 
with data that TPO does not induce platelet activation, although it appears to potentiate 
platelet response to physiological agonists such as ADP and thrombin(Oda et al., 1996).  
Despite their low platelet counts, TPO-/- mice do not exhibit spontaneous or excessive 
bleeding, although bleeding times as measured by the tail-cut technique are prolonged by 
three- to fourfold(Bunting et al., 1997).   
 
In addition to the reduction in thrombopoiesis, disruption of TPO signaling is 
associated with more widespread effects on the haematopoietic stem cell reservoir(Borge 
et al., 1998; Carver-Moore et al., 1996; Kimura et al., 1998; Matsunaga et al., 1998).  
While TPO- or c-Mpl-null mice have normal red cell counts, haemoglobin, and white cell 
counts, the number of long-term repopulating stem cells is decreased by around 7-8 
fold(Alexander et al., 1996; Gurney et al., 1994a; Jacobsen et al., 1996; Solar et al., 
1998).  Furthermore, patients with congenital amegakaryocytic thrombocytopenia 
(CAMT) who have a genetic loss of function of the c-Mpl gene not only have severe 
thrombocytopenia from birth but also subsequently develop aplastic anaemia and bone 
marrow failure as HSC numbers decline(Ballmaier and Germeshausen, 2009; Geddis, 
2009).  
 
Two recent reports explored the mechanism for TPO regulation of HSC cell 
cycling in the TPO-/- mouse model.  Qian et al examined the number and repopulating 
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ability of HSCs isolated from TPO-/- mice, and found that HSCs numbers start to decline 
from a few weeks after birth and continue to do so throughout life(Qian et al., 2007).  
TPO-/- HSCs also displayed increased cell cycling(Qian et al., 2007).  However, while 
postnatal HSC numbers decline, both the numbers of foetal liver HSCs and their potency 
for reconstitution following serial transplants was normal, suggesting that foetal HSCs do 
not require TPO for their survival and maintenance while postnatal HSCs do.  One 
explanation for this would be that the regulatory effect of TPO on cell cycling is 
mediated by a microenvironmental factor occurring after the transition of haematopoiesis 
to the bone marrow from prenatal extramedullary sites.  This notion was supported by a 
supporting study demonstrating that c-Mpl-expressing long term repopulating HSCs are 
located in close association with osteoblasts in murine bone marrow, and that TPO 
expression by osteoblasts increased entry of HSCs into G0, an effect that was specifically 
abolished by treatment with a c-Mpl receptor antibody(Yoshihara et al., 2007).   
 
1.3.2. Stem cell factor (SCF) 
 
SCF, also known as cKit-ligand, has synergistic and non-overlapping effects with 
TPO in the regulation of megakaryopoiesis(Antonchuk et al., 2004).  Mice with double 
inactivation of c-Mpl and the SCF receptor, c-kit, (c-Mpl-/- c-kit-/-) have lower levels of 
megakaryocyte progenitors in the bone marrow and spleen than c-Mpl-/- c-kit+/+ 
mice(Antonchuk et al., 2004).  Recent data also indicate that SCF promotes the survival 
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of immature megakaryocytes by activating Akt kinase which thereby inhibits the 
mitochondrial apoptotic pathway(Zeuner et al., 2007).   
 
1.3.3. Stromal cell-derived factor 1 (SDF1) 
 
SDF1 is the major chemokine that directs haematopoietic cell trafficking and site-
specific migration patterns throughout ontogeny and adult life via interactions with its 
primary receptor, CXCR4(Hamada et al., 1998; Kaplan et al., 2007).  SDF1 and CXCR4 
knockout mice have identical embryonic lethal phenotypes, due to widespread 
haematopoietic, angiogenic and neurological defects and placental insufficiency(Jaleel et 
al., 2004; Ma et al., 1998; Nagasawa et al., 1996).  
 
Although no data exists about megakaryopoiesis in SDF1 knock-out mice(Wang 
et al., 1998), there are several lines of evidence indicating that SDF1 may be important in 
TPO-independent thrombopoiesis.  Expression of CXCR4 has been identified on human 
megakaryocyte progenitors, and addition of SDF1 to in vitro cultures of human CD34+ 
cells enhanced production of megakaryocytes in the presence of TPO by around 40%, 
although no thrombopoietic effect of SDF1 was observed when it was administered 
alone(Wang et al., 1998).  In this study, SDF1 treatment was found to induce 
megakaryocyte progenitor migration and adhesion to endothelium(Wang et al., 1998).  
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In TPO-/- mice, SDF1, together with FGF-4, increases the interaction of 
megakaryocytes with the specialized bone marrow sinusoidal cells at the vascular stem 
cell niche, providing signals for megakaryocyte survival and maturation (see Section 
1.2.3)(Avecilla et al., 2004). Administration of SDF1 together with FGF-4 can nearly 
normalize the platelet count of c-Mpl-deficient mice and enhance platelet recovery 
following chemotherapy-induced myelosuppression(Avecilla et al., 2004).  Expression of 
the PECAM receptor is required for correct polarization of megakaryocyte CXCR4 
receptors and the chemotactic response to SDF1(Dhanjal et al., 2007).  Furthermore, 
SDF1 stimulation induces secretion of MMP9 from megakaryocytes, enabling their 
migration through the bone marrow extracellular matrix(Lane et al., 2000).  
 
1.3.4. Other cytokines that promote megakaryopoiesis and thrombopoiesis 
 
In addition to TPO, SCF, and SDF1, multiple other cytokines including LIF, IL-1, 
IL-3, IL-6, IL-11, GM-CSF and erythropoietin promote megakaryopoiesis although are 
not essential for the achievement of normal platelet counts(Kaushansky, 2005; 
Kaushansky, 2008; Kuter, 2007).  IL-3 is a T-cell derived cytokine that promotes 
megakaryocyte colony formation and proliferation of pluripotent stem cells in mice.  IL-6 
is primarily a megakaryocyte maturation factor, increasing cell size and ploidy and 
enhances hepatic TPO synthesis.  IL-11 is a multifunctional cytokine that supports 
formation of megakaryocyte colonies and also stimulates later stages of megakaryocyte 
development(Du and Williams, 1997).   
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Table 1.4. Growth Factors and Cytokines affecting megakaryopoiesis  
 
Thrombopoietin (TPO) (de Sauvage et al., 1994; Kaushansky et al., 1994) 
Stem cell factor (SCF)(Antonchuk et al., 2004) 
Stromal cell-derived factor 1 (SDF1)(Avecilla et al., 2004; Lane et al., 
2000) 
Fibroblast growth factor 4 (FGF-4)(Avecilla et al., 2004) 
Granulocyte macrophage-colony stimulating factor (GM-
CSF)(Kaushansky, 2008) 
Interleukins, (IL-3, IL-6, IL-11)(Kaushansky, 2008) 
Vascular endothelial growth factor (VEGF)(Rafii et al., 1995) 
Thrombopoietic 
promoters  
Bone morphogenic protein (BMP) 4, a member of the TGFβ 
family(Jeanpierre et al., 2008) 
Thrombospondin 1 (TSP1)(Kopp et al., 2006) 
Platelet factor 4 (PF4)(Lambert et al., 2007) 
Neutrophil-activating peptide 2 (NAP-2)(Pillai et al., 2006) 
Interleukin 8 (IL-8)(Gewirtz et al., 1995) 
Regulated upon activation, normal-T cell expressed and secreted 
chemokine (RANTES)(Majka et al., 2001) 
Thrombopoietic  
inhibitors 
Macrophage inflammatory peptide (MIP)-1α(Gewirtz et al., 1995; Majka 
et al., 2001) 
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1.3.5. Negative regulators of megakaryopoiesis and thrombopoiesis 
 
Megakaryocyte and platelet α-granules contain several negative regulators of 
megakaryopoiesis (Table 1.4.), including the CXC-family chemokines PF4 (CXCL4), 
neutrophil-activating peptide (NAP)-2, and IL-8, CC chemokines RANTES and MIP-
1α(Lambert et al., 2007), other proteins including thrombospondins(Kopp et al., 2006), 
and inhibitors of nuclear factor (NF)-kappa-b (I-kappa-b)(Spinelli et al., 2009).  PF4 and 
thrombospondin are of particular interest as they are also involved in the regulation of 
new blood vessel formation, in angiogenesis and vasculogenesis (see Section 1.5).   
 
1.3.5.1. Platelet factor 4 (PF4)  
 
PF4 inhibits megakaryocyte colony formation in vivo, and the release of large 
amounts of PF4 due to megakaryocyte lysis following bone marrow ablation is thought to 
impede megakaryocyte regeneration(Lambert et al., 2007).  In transgenic mice there is a 
negative correlation between platelet counts and PF4 levels, and treatment with anti-PF4 
blocking antibodies has been shown to accelerate platelet recovery following 
chemotherapy(Lambert et al., 2007).  
 
 The mechanism of action of PF4 on megakaryocytes was unknown until recent 
studies demonstrated a role for the low-density lipoprotein (LDL) receptor-related protein 
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1(LRP1).  LRP1 was found to be highly expressed on mature megakaryocytes (although 
absent on immature megakaryocyte-erythroid progenitors)(Lambert et al., 2009).  
Blockade of LRP1 signalling with an anti-LRP1 antibody or treatment with an LDL-
receptor family antagonist reversed PF4-induced inhibition of human megakaryocyte 
colony growth in vitro(Lambert et al., 2009).  Furthermore, shRNA knockdown of PF4 
lead to restoration of normal megakaryocyte-colony formation in bone marrow cultures 
from mice overexpressing human PF4(Lambert et al., 2009).  LRP1 has also been shown 
to mediate the effect of PF4 on endothelial cells(Yu et al., 2005).  The antiangiogenic 
activity of PF4 is further considered in Section 1.6 below.    
 
1.3.5.2. Thrombospondin (TSP)  
 
The TSPs are a group of 5 proteins expressed primarily by megakaryocytes and 
platelets and also some other cell types including stromal fibroblasts, endothelial cells, 
immune cells and some tumour cells(Kazerounian et al., 2008).  TSP1 and TSP2 (but not 
TSP3, 4 or 5) negatively regulate megakaryopoiesis and bone marrow vascularity.  Mice 
deficient in both TSP1 and TSP2 have significantly higher numbers of megakaryocytes, 
platelets and enhanced bone marrow vascularity(Kopp et al., 2006).  In the absence of 
TSP1 and TSP2, regeneration of thrombopoiesis following 5-FU treatment occurs faster 
suggesting that an increased number of bone marrow progenitors are able to differentiate 
into megakaryocytes(Kopp et al., 2006).  Notably, this phenotype is transplantable, 
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indicating that TSP expression by thrombopoietic cells overrides that of the host stromal 
cells.  The role of TSPs in cancer are discussed in Section 1.5 and Table 1.6.   
 
1.4. MEGAKARYOCYTE AND PLATELET STRUCTURE AND INTRACELLULAR 
PROTEIN PACKAGING 
 
The biogenesis and transport of megakaryocyte-derived factors is complex.  
Certain proteins, such as vWF and glycoprotein fibrinogen receptors, are synthesized and 
sent to the megakaryocyte surface.  Other proteins are either synthesized, endocytosed 
and/or pinocytosed and selectively loaded into specific granules.  Therefore, the bone 
marrow microenvironment may alter the protein content of megakaryocytes and platelets 
either by altering megakaryocytic gene transcription or by increasing the availability of 
proteins for cellular uptake.  During proplatelet extension, megakaryocytes package 
secretory granules into platelets via bidirectional movement of intracellular components 
along the shafts of proplatelets(Richardson et al., 2005).    
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1.4.1. Megakaryocyte and platelet intracellular storage granules 
 
Platelets contain two main types of secretory granules - α-granules and dense 
bodies, as well as enzyme-containing lysosomes.  α-granules are the major protein 
storage vehicle, and comprise ~10% of the total platelet volume, which is 10x more than 
dense bodies(Blair and Flaumenhaft, 2009).  α-granules and dense bodies initially 
develop from budding vesicles in the Golgi apparatus within megakaryocytes, and are 
eventually packaged into nascent platelets (Figure 1.5).  The vesicles mature into 
multivesicular bodies (MVB), which is where organization of specific proteins into 
distinct subclasses of α-granules is thought to take place(Italiano and Battinelli, 2009).  
Granular cargo can be newly synthesized and stored in the trans-Golgi network (TGN) or 
taken up from the external microenvironment via pinocytosis (nonspecific uptake) or 
receptor-mediated endocytosis (molecule-specific transport) (Figure 1.5.).  
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Figure 1.5. α-granule formation by megakaryocytes ((Blair and Flaumenhaft, 2009) 
α-Granule cargo derives from budding of the trans-Golgi network (TGN), endocytosis of 
the plasma membrane, or pinocytosis. Vesicles can subsequently be delivered to 
multivesicular bodies (MVBs), where sorting of vesicles occurs.  Vesicles may also be 
delivered directly to α-granules. Some vesicles within MVBs contain exosomes.  MVBs 
mature to produce α-granules. 
 69 
Dense bodies contain haemostatically active components including serotonin, 
adenosine 5’diphosphate (ADP), adenosine 5’triphosphate (ATP), catecholamines and 
calcium.  Less is known about the origin and packaging of dense bodies, however 
immunoelectron microscopy studies on cryosections of in vitro cultured human 
megakaryocytes have suggested that, like α-granules, dense bodies are also sorted by 
megakaryocyte MVBs(Youssefian and Cramer, 2000).   
 
1.4.1.1. Regulation of granule release 
 
Although many aspects remain unclear, recent developments in intracellular 
confocal microscopy with immunolabelling and in vivo imaging techniques have greatly 
advanced our understanding of megakaryocyte and platelet granule biology.  It was 
originally assumed that megakaryocyte and platelet granular contents were universally 
and randomly deployed upon cellular activation.  However, there is now substantial 
evidence to indicate that α-granules are heterogeneous and highly organized, and that 
selective deployment of granules containing certain protein families may occur(Italiano 
and Battinelli, 2009).  
 
Preliminary evidence for the notion that platelets were able to differentially 
secrete certain proteins over others was apparent from data showing that the relative 
release of SDF1 as compared to serotonin was higher by platelets from TSP-/- mice than 
by platelets from wild-type mice(Kopp et al., 2006).  This finding was supported and 
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dramatically extended by subsequent reports indicating that pro- and anti-angiogenic 
proteins are organized into distinct platelet α-granules(Italiano et al., 2008).  Using 
double immunofluorescence labelling of VEGF or FGF2, stimulators of angiogenesis, 
and endostatin or TSP1 (angiogenesis inhibitors) in human platelets and in vitro cultured 
mouse megakaryocytes, it was shown that stimulators and inhibitors were segregated into 
distinct subpopulations of α-granules(Italiano et al., 2008).  Similar granule heterogeneity 
has been reported in studies of the adhesive proteins vWF and fibronectin in human 
platelets by confocal microscopy(Sehgal and Storrie, 2007) and of tissue inhibitors of 
MMPs (TIMPs)(Villeneuve et al., 2009).   
 
Selective binding of specific proteinase-activated receptors (PARs) counter-
regulated the release of endostatin (an antiangiogenic protein) and VEGF-A from human 
platelets(Italiano et al., 2008; Ma et al., 2005).  Treatment of human platelets with a 
selective PAR-1 agonist specifically induced release of VEGF granules, while a selective 
PAR-4 agonist resulted in the release of endostatin-containing granules but not 
VEGF(Italiano et al., 2008).  Therefore, it is possible that tumours may modulate the 
release of angiogenic factors from platelets by the secretion of PAR ligands or, 
alternatively, by proteolytic degradation of certain PAR receptors(Ma et al., 2005).  Many 
tumor cell lines express PAR-1(Nierodzik et al., 1998) and overexpression of PAR-1 in 
B16 melanoma cells increases experimental pulmonary metastasis 5-fold(Nierodzik et al., 
1996).  Whether ligation of PAR receptors or indeed other signaling pathways on 
megakaryocytes may alter the packaging of proteins into nascent platelets by 
megakaryocytes is not known.   
 71 
1.4.2. α  granules: the pro-angiogenic vs. anti-angiogenic balance 
 
Given the implications for therapeutic manipulation, the hypothesis that platelets 
may selectively release pro-angiogenic mediators over anti-angiogenic factors and 
enhance tumour growth or healing is an area of intense interest.  The factors that 
determine the net balance between release of VEGF-A and SDF1 over anti-angiogenic 
factors such as endostatin, PF4 or TSPs are not yet fully understood.  The numerous 
angiogenic regulatory proteins contained within megakaryocytes and platelets are listed 
in Table 1.5. 
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Table 1.5. Angiogenic regulatory factors contained by platelets and megakaryocytes 
Proangiogenic 
Name Description 
Vascular 
endothelial 
growth factor 
(VEGF) 
The VEGF family proteins, predominated by VEGF-A, are the major angiogenic growth 
factors.  VEGF influences physiological bone marrow homeostasis and promotes 
mobilization of endothelial/haematopoietic progenitor cells under stress conditions.  The 
VEGF receptors, VEGFR1, 2, 3, neuropilin (NP) 1 and NP2 have independent and 
synergetic functions.  VEGFR1 signaling primarily mediates mobilization, chemotaxis and 
release of tissue-specific growth factors, whereas VEGFR2 is important for endothelial cell 
growth, survival and vascular permeability(Rafii et al., 2003).  Megakaryocytes express both 
VEGFR1 and VEGFR2.  In an autoregulatory loop, VEGF stimulation of megakaryocytes 
promotes MK maturation and cellular synthesis and release of further VEGF(Casella et al., 
2003).   
Platelet-
derived growth 
factor (PDGF) 
The 4 isoforms of PDGF (A-D) act through two protein tyrosine kinase receptors, 
PDGFRα and PDGFRβ, and have an essential role in the maturation of nascent blood 
vessels, stimulating migration and sprouting of preexisting endothelial cells and enhancing 
mobilization of progenitor cells from the bone marrow(Dimmeler, 2005).   
Transforming 
growth factor 
(TGF)β   
Members of the TGFβ superfamily have an integral role in embryonic vascular assembly 
and establishment and maintenance of vascular integrity(Pepper, 1997).  Excessive 
megakaryocyte secretion of TGFβ and PDGF are thought to play a pivotal pathogenic role 
in the pathogenesis of idiopathic myelofibrosis(Ciurea et al., 2007).    
Insulin-like 
growth factor 
(IGF)-2 
IGF-2 is highly expressed by a number of human tumours and acts directly by stimulating 
migration and differentiation of endothelial cells and indirectly by increasing VEGF 
production(Kim et al., 1998).  Non-malignant cells also produce IGF-2.   
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Basic 
fibroblast 
growth factor 
(b-FGF, or 
FGF2) 
FGF2 is a multifunctional polypeptide with angiogenic, trophic and mitogenic properties, 
although its biological significance in angiogenic tumour growth in vivo remains 
controversial(Rak and Kerbel, 1997).  
Hepatocyte 
growth factor 
(HGF) 
HGF (also known as scatter factor) is a regulator of the pro-angiogenic vs. anti-angiogenic 
balance through positive VEGF regulation and negative TSP1 regulation(Zhang et al., 
2003b).  
 
Epidermal 
growth factor 
(EGF) 
EGF receptor signaling promotes tumour progression via both direct effects on tumour cell 
proliferation and enhancing angiogenesis(van Cruijsen et al., 2005) 
Stromal cell-
derived growth 
factor (SDF1, 
CXCL12) 
The major chemokine regulating haematopoietic cell trafficking via binding to CXCR4.  
SDF1 mRNA is low in mature megakaryocytes, although SDF1 protein in α-granules is 
evident by immunostaining(Kopp et al., 2006; Migliaccio et al., 2008). This suggests that 
SDF1 may be taken up into megakaryocyte secretory granules rather than expressed.  
  
Lipid 
mediators  
Platelets also contain lipid mediators of angiogenesis, including sphingosine-1-phosphate 
(S1P) and lysophosphatidic acid (LPA)(Gupta and Massague, 2004) 
 
Matrix 
metalloprotein
ases (MMP) -9 
and MMP-2 
MMPs (especially MMP9) are required for matrix degradation and release of other 
cytokines and proteins from internal cellular stores(Lane et al., 2000) 
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Antiangiogenic 
Name Description 
Thrombospon
dins (TSPs) 1 
and 2  
TSP1 is the most abundant protein in platelet α-granules.  TSPs are inhibitors of 
endothelial survival and migration, and TSP-/- mice exhibit increased vascular density 
during tumour and ischaemic angiogenesis(Varner, 2006).  TSPs bind to MMP-9 and SDF1 
thereby limiting the extent of vascularization(Kopp et al., 2006). Within the bone marrow, 
TSP1 and TSP2 negatively regulate megakaryocyte proliferation and consequently regulate 
platelet numbers in the blood(Kopp et al., 2006).  TSPs are required for vascular stability, 
therefore optimal levels of TSP expression are required for vascular maintenance. 
Endostatin Via direct and indirect actions, endostatin downregulates pathological angiogenesis and 
interfere with VEGF and FGF2 signalling(Folkman, 2006).   
 
Plasminogen 
activator 
inhibitor (PAI) 
type 1  
Regulator of angiogenesis and can both enhance and inhibit tumour growth depending on 
the local concentration(McMahon et al., 2001).  
TGFβ  Similar to PAI and TSP, TGFβ has complex functions and can inhibit as well as enhance 
angiogenesis depending on the context(Akhurst and Derynck, 2001).  
 
Platelet Factor 
4 (PF4, 
CXCL4) 
A physiological inhibitor of megakaryopoiesis, angiogenesis, and tumour growth(Maurer et 
al., 2006) 
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1.5. PLATELETS IN MALIGNANCY  
 
 Platelets and cancer have been associated since the observation of Trousseau in 
the 1860s that a migratory thrombophlebitis due to blood clotting and inflammation of 
the blood vessels was indicative of an occult carcinoma.  He later diagnosed the same 
syndrome in himself and died soon after of gastric carcinoma(Siegelman and Needleman, 
1993).  It has since been well established that many patients with advanced malignancy 
have platelet abnormalities and hypercoagulability.  Although platelet counts may both 
increase or decrease in malignancy, both animal models and clinical studies indicate that 
higher platelet counts correlate with poor prognosis in cancer, and depletion of platelets 
in animal models reduces metastases in both xenograft and syngeneic tumour models and 
for a wide range of cancerous cell lines(Gasic et al., 1968; Gupta and Massague, 2004; 
Karpatkin and Pearlstein, 1981).  Roles for platelets in cancer progression that have been 
identified include in mediating: angiogenesis of the primary tumour; tumour cell survival 
and immune evasion during haematogenous dissemination; arrest and lodgment at distant 
sites; and interaction with extracellular matrix and tissue invasion(Honn et al., 1992; 
Nieswandt et al., 1999).  These pathways are considered in more detail below.     
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1.5.1. Platelets and tumour angiogenesis  
 
The development of a vascular supply is a fundamental step in tumour 
progression.  The transition of tumours from an avascular state to the active recruitment 
of blood vessels into the tumour, termed the ‘angiogenic switch’, marks the onset of 
aggressive and invasive growth(Folkman, 1971; Folkman, 2002; Folkman, 2004; 
Hanahan and Folkman, 1996).  Platelets are the major carriers of the major circulating 
proangiogenic factor VEGF, and the platelet-associated angiogenic regulatory proteins 
VEGF and PF4 appear to be more reliable indicators of cancer growth than plasma or 
serum levels(Cervi et al., 2007).  A dose-responsive relationship exists between blood 
platelet levels and new vessel sprouting in angiogenesis.  It is possible that the relative 
levels of angiogenic regulatory proteins within platelets may change significantly in 
malignancy, although this has not yet been definitively shown. 
 
As well as the direct effects of delivering angiogenic growth factors (Table 1.5.), 
platelets contribute to the ‘angiogenic switch’ by mediating the recruitment of bone 
marrow-derived endothelial progenitors to sites of vasculogenesis(Rafii et al., 2008).  
Traditionally, it was thought that once an intact vascular system was established, further 
vessel growth occurred only by sprouting of endothelial cells from existing vessels, in 
angiogenesis and arteriogenesis.  However, in 1997, Asahara et al isolated a population 
of CD34+ endothelial cells with progenitor-like activity from human peripheral blood, 
indicating that vasculogenesis, or progenitor cell-driven de novo generation of vessels, 
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may occur postnatally(Asahara et al., 1999; Asahara et al., 1997).  Since these pivotal 
studies, a wealth of literature has described the recruitment of bone marrow-derived 
haematopoietic and endothelial cells to sites of tumour angiogenesis(Benezra et al., 2001; 
Carmeliet and Luttun, 2001; De Palma et al., 2005; De Palma et al., 2003; Grant, 2002; 
Hattori et al., 2001; Lyden et al., 2001; Moore, 2002; Nolan et al., 2007; Shi et al., 1998).  
Because of their low numbers, much controversy has surrounded the physiological 
significance of bone marrow-derived progenitor cells in the angiogenic process.  
However, very recent evidence indicates that the contribution of these cells is both 
instructive (paracrine) and structural (vessel incorporation), and that their recruitment to 
the tumour bed is a pathological hallmark of the onset of the ‘angiogenic switch’(Gao et 
al., 2008; Rafii and Lyden, 2008).   
 
1.5.1.1. Platelets mediate the ‘angiogenic switch’ by influencing homing, lodgment and 
differentiation of bone marrow-derived cells at sites of vasculogenesis 
 
There is evidence to indicate that platelets mediate the effect of haematopoietic 
cytokines to recruit bone marrow-derived cells to sites of vasculogenesis.  Studies using 
real-time in vivo fluorescence microscopy in animal models have shown that platelet 
aggregation is necessary for homing and lodgment of bone marrow-derived, c-Kit+ Sca1+ 
lin- progenitor cells and CD34+ cells to sites of endothelial disruption(Massberg et al., 
2006).  In these models, bone marrow-derived cells are unable to bind directly to 
endothelium, but are tethered to platelet surface P-selectin via P-selectin glycoprotein 
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ligand (PSGL-1) binding(Massberg et al., 2006).  Furthermore, platelet release of SDF1 
provided an ongoing retention signal for the CXCR4+ haematopoietic cells at these sites.  
The role of platelet-derived SDF1 in HPC homing to nascent tumour vasculature was 
confirmed and extended in later studies(Jin et al., 2006a).  In addition to directing 
progenitor cell migration and adherence, platelet-derived factors may also induce the 
differentiation of endothelial progenitor cells (EPCs) into mature endothelial cells(Daub 
et al., 2006; de Boer et al., 2006; Langer et al., 2006; Langer et al., 2007).  
 
 
1.5.2. Platelets ‘shield’ tumour cells from immune destruction 
 
 It is thought that circulating tumour cells travel through the circulation coated 
with platelets that ‘shield’ them from immune destruction.  Experimental animal models 
of haematogenous metastasis suggest that platelets interfere with natural killer (NK) cell 
antitumoural activity.  In a study using NK cell-sensitive (B16 melanoma and CFS1 
fibrosarcoma) and NK-insensitive (ESb lymphoma) tumour cell lines, depletion of 
platelets inhibited metastasis only when the tumour cells were susceptible to NK-
mediated tumour cell lysis(Nieswandt et al., 1999).  B16 cells were found to strongly 
activate platelets (as measured by the ability of tumour cells to induce platelet surface 
GPIIb/IIIa expression in vitro), and platelet depletion led to a 95% reduction in lung 
metastasis following intravenous inoculation with B16 cells(Nieswandt et al., 1999).  
Other studies have also shown that the capability of both mouse and human tumour cell 
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lines to activate platelets correlates with their metastatic efficiency(Heinmoller et al., 
1995; Heinmoller et al., 1996).   
 
More recent data suggests a mechanism for the immunoprotective effect of 
platelets against NK-mediated antitumoural activity(Kopp et al., 2009).  Following 
tumour-induced platelet activation, platelet release of TGFβ was found to downregulate 
the expression of NK cell activating immunoreceptor group 2 member d (NKG2D)(Kopp 
et al., 2009).  Notably, it has been reported that platelets release about 40 times more 
TGFβ than does any other cell type(Blakytny et al., 2004).  
 
 
1.5.3. Platelets enhance tumour cell lodgment and invasion at metastatic sites 
 
1.5.3.1. Platelet-mediated tumour cell adhesion to vessels 
 
Formation of platelet-tumour cell aggregates has been shown to enhance 
lodgment at metastatic sites via platelet expression of adhesion integrins (Figure 
1.6)(Burdick and Konstantopoulos, 2004; Karpatkin et al., 1988).  Platelet integrin 
GPIIb-IIIa (αIIbβ3) appears to be particularly important for tumour cell-platelet 
interactions, as antibody inhibition of vWF and/or fibronectin binding to platelet surface 
GPIIb-IIIa was associated with a 50% reduction in pulmonary metastasis in mice 
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following haematogenous delivery of tumour cells in studies using murine colon, bladder 
and carcinoma cell lines (CT26, T241 and B16-F10 cell lines)(Karpatkin et al., 1988).  A 
role for platelet surface GPIb-IX was also identified in studies of B16 melanoma 
metastasis in mice deficient in GPIb-IX, in which a dramatic reduction in lung metastases 
was observed(Jain et al., 2007).         
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Figure 1.6. Platelets mediate tumour cell lodgement in blood vessels.  
The interactions between metastatic colon carcinoma cells and platelets were examined 
using a dynamic perfusion-flow chamber to mimic intravascular tumour-platelet 
interactions.  (a) Under flow conditions, colon carcinoma cells adhere to surface-
anchored platelets via platelet-surface P-selectin, which mediates tumour cell 
tethering/rolling via the CD44 transmembrane receptor (b) Subsequent platelet αIIbβ3 
(GPIIb-IIIa), von Willebrand factor, and fibrin involvement converts these transient 
interactions into stable adhesion. (c) Platelet αIIbβ3 can directly capture and 
instantaneously stabilize free-flowing tumour cells at low shear stress 
conditions(Konstantopoulos and Thomas, 2009). 
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1.5.3.2. Platelet-derived factors that promote tumour invasion at metastatic sites 
 
Once bound to the endothelial cell surface, platelets provide a rich 
microenvironment of growth factors, coagulation factors and matrix metalloproteinases 
(Table 1.6.), which support the accumulation of more platelets, leukocytes and tumour 
invasion.  
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Table 1.6. Roles of platelet/megakaryocyte-derived proteins in carcinogenesis and 
metastasis  
 
Protein Function in carcinogenesis/metastasis 
TGFβ • Suppresses growth of early tumours but later promotes tumour invasion 
and migration(Akhurst and Derynck, 2001).   
• Inhibits NK cell-mediated tumour cell destruction(Kopp et al., 2009) 
 
SDF1 • Recruits CXCR4+ tumour cells, bone marrow-derived HPCs and 
endothelial progenitors to sites of vasculogenesis(Jin et al., 2006a).    
 
PF4 • Inhibits growth and metastasis of murine models of melanoma and colon 
carcinoma(Kolber et al., 1995; Sharpe et al., 1990; Tanaka et al., 1997).  
• Regulates vasculature by inhibiting endothelial cell proliferation and 
migration(Gentilini et al., 1999; Gupta and Singh, 1994).  
 
TSP1 Both pro- and anti-metastatic effects have been reported.   
• Inhibits endothelial cell migration, proliferation(Dawson et al., 1997) and 
tumour angiogenesis(Kopp et al., 2006; Lawler et al., 2001)  
• TSP1 mRNA and protein expression is higher in metastatic breast 
carcinoma than in patients with locally invasive, non-metastatic 
disease(Bertin et al., 1997; Brown et al., 1999).   
• Stimulates tumour cell adhesion to vessel walls(Tuszynski et al., 1987) 
• TSP1 knock-down was associated with reduced metastasis to blood and to 
lung in spontaneous mouse models of breast cancer metastasis, thought to 
be due to TSP1-induced activation of TGFβ. (Yee et al., 2009). 
• Mediate haplotaxis and chemotaxis of human melanoma and carcinoma 
cells in vitro(Taraboletti et al., 1987)  
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P-selectin, vWF, 
GPIIbIIIa and 
Ib-IX 
• Mediate initial rolling/tethering of circulating tumour cells to endothelium 
in vessels of metastatic organs(Burdick and Konstantopoulos, 2004; Jain et 
al., 2007; Karpatkin et al., 1988).         
MMP9, MMP2 • Digestion of local tissue matrix enabling invasion of local tissues and 
activation via cleavage of surface-bound factors(Ko et al., 2007) 
Angiogenic 
growth factors 
(VEGF, TGFβ)  
 
 
See Table 1.4 
Coagulation 
factors: 
Thrombin, tissue 
factor 
• In tumour cells lines B16-F10 and UMCL, thrombin promotes GRO-a and 
Twist gene expression leading to a more malignant phenotype, enhancing 
cell motility and angiogenesis.  
• Inhibition of thrombin decreased tumour growth and metastasis in 4TI 
mice that develop spontaneous breast carcinoma(Caunt et al., 2006; Hu et 
al., 2008a; Hu et al., 2008b) 
• Tissue factor expression mediates haematogenous metastasis of melanoma 
and generation of thrombin(Fischer et al., 1995; Mueller et al., 1992).   
Bioactive lipids: 
S1P and LPA 
• S1P promotes vascular maturation by mediating N-cadherin function(Paik 
et al., 2004).   
• LPA receptors are found in human breast cancer and platelet LPA 
stimulates osteolytic bone metastases in studies using the breast cancer cell 
line MDA-BO2 (Brill et al., 2005). 
• LPA mediates proliferation, migration, and invasion of MDA-BO2 
cells through activation of a Ga/ERK1/2-dependent signaling 
pathway(Boucharaba et al., 2009). 
• LPA and S1P act directly on endothelial cells to stimulate angiogenesis 
and also induce breast cancer cells to VEGF(Boucharaba et al., 2009) (See 
Table 1.4.)  
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1.5.4. TPO levels in malignancy 
 
Reports are conflicting regarding changes to TPO levels during malignancy.  
There is some evidence from animal models and human studies that plasma TPO levels 
are increased during pathological angiogenic processes, such as ischaemic tissue repair 
and malignancy(Dymicka-Piekarska and Kemona, 2007; Jin et al., 2006a; Sasaki et al., 
1999), and TPO levels were found to also correlate with tumour stage in colorectal 
carcinoma (Dymicka-Piekarska and Kemona, 2007).  The source of the increase in 
circulating TPO is not known; in addition to an increase in hepatic and/or bone marrow 
stromal cell TPO synthesis, TPO production by carcinoma cell lines may also occur.  In 
one report examining human carcinoma cell lines, the presence of TPO and SCF mRNA 
was detected in 24 out of the 27 cell lines examined(Sasaki et al., 1999).  In addition to 
its effect on platelet number, TPO also enhances megakaryocyte expression of VEGF, 
thought to be via induction of hypoxic-inducible factor 1α (HIF-1α)(Kirito and 
Kaushansky, 2005).  
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1.6.  THE BONE MARROW AS A ‘METASTATIC MICROENVIRONMENT’  
 
1.6.1. The ‘metastatic microenvironment’  
 
Malignant cells, and in particular tumour-initiating cells (also termed ‘cancer stem 
cells’), share many of the properties of normal stem cells (Table 1.7).  Similarly, there is 
considerable homology between the tumour microenvironment and the physiological 
stem cell niche (Table 1.7).  Components of the stem cell niche promote cell survival and 
regulate cell fate and differentiation (See Section 1.1.).  Important functions of the 
tumour microenvironment include directly supporting tumour cell proliferation, 
dissemination and malignant progression, and the niche may enhance tumour cell 
resistance to chemotherapy and radiotherapy(De Toni et al., 2006; Dick and Lapidot, 
2005; Garcia-Barros et al., 2003).   
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Table 1.7. A comparison of normal and malignant cells and their 
microenvironments  
 
Normal stem cells  Tumour cells 
Regulated quiescence vs. proliferation and 
expansion 
Capacity for dormancy and active 
proliferation 
Site-specific migration  Site-specific homing of disseminating cells 
in metastasis 
Self-renewal and repopulation capacity Tumour-initiating capacity (may be a sub-
set of tumour cells) 
Stem cell niche Tumour microenvironment  
Nurture and regulate stem cell kinetics May promote or inhibit tumour progression 
Protect stem cells from environmental 
insults 
May confer resistance to therapeutic 
targeting or immune attack 
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1.6.1.1. The metastatic niche model 
 
Steven Paget's 'seed and soil' hypothesis for metastasis was an important 
milestone in the study of malignant disease as it introduced the concept that a receptive 
microenvironment was required for malignant cells to engraft distant tissues and form 
metastases(Paget, 1889).  This microenvironment is now known to comprise supportive 
(non-malignant) stromal cells, soluble factors, vascular networks, nutrients and metabolic 
components, and the structural extracellular matrix (ECM) architecture(Folkman, 2002; 
Joyce and Hanahan, 2004; Weigelt and Bissell, 2008).  A ‘tumour-permissive’ 
inflammatory microenvironment is also required to downregulate antitumoural immunity 
(Mantovani et al., 2008).  The metastatic niche model (Figure 1.7) suggests that a suitably 
conducive microenvironment, or pre-metastatic niche, must evolve in order for tumour 
cells to be able to engraft (forming the metastatic niche) and proliferate at secondary sites 
(micrometastatic to macrometastatic transition)(Gao et al., 2008; Kaplan et al., 2005).  
These niches form as a result of tumour-secreted factors, and could either be newly 
induced or be adaptations of pre-existing physiological niches such as stem cell niches in 
haematopoietic organs.  This hypothesis builds on Paget's ‘seed and soil’ hypothesis by 
suggesting a temporal evolution for the development of the ‘soil’(Psaila and Lyden, 
2009). 
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Figure 1.7. A model for the evolution of the metastatic niche(Psaila and Lyden, 
2009) 
The pre-metastatic, micrometastatic to macrometastatic transition occurring in a 
metastatic organ. [A] In response to growth factors secreted by the primary tumour, 
including vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and 
TGFβ, inflammatory S100 chemokines and serum amyloid A3 (SAA3) are upregulated in 
pre-metastatic sites leading to clustering of bone marrow-derived haematopoietic 
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progenitor cells (HPCs).  Platelet-deployed SDF1 is chemotactic for CXCR4-positive 
HPCs and metastatic tumour cells (MTCs).  HPCs secrete a variety of factors including 
tumour necrosis factor-alpha (TNFα), matrix metalloproteinase (MMP)9 and 
transforming growth factor (TGF)β.  Activated fibroblasts, possibly derived from bone 
marrow mesenchymal stem cells (MSC)s, secrete fibronectin (Fn), an important adhesion 
protein in the niche, and lysyl oxidase (LOX) expression is increased, modifying the local 
extracellular matrix.  [B] Metastatic tumour cells (MTCs) engraft the niche to populate 
micrometastases.  [C] Recruitment of endothelial progenitor cells (EPCs) to the early 
metastatic niche mediates the angiogenic switch and enables progression to 
macrometastases. 
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1.6.2. The bone marrow vascular niche as a site of preferential engraftment for 
malignant cells 
 
The bone marrow is the natural and ubiquitous home for malignant 
haematological cells, and a common site for malignant spread of solid tumours.  
Although the precise localization of tumour cells within the bone marrow 
microenvironment has not been fully examined in many human malignancies, there is 
evidence that tumour cells preferentially home to and engraft the vascular stem cell 
niche(Colmone et al., 2008; Sipkins et al., 2005).  Studies in mice using dynamic, intra-
vital confocal imaging indicated that fluorescently-labeled human Nalm-6 leukaemic 
cells injected into immunodeficient mice preferentially home to and engraft the bone 
marrow vascular niche, suggesting analogous dependence on niche-specific signals to 
those required by physiological bone marrow-derived cells(Sipkins et al., 2005).  The 
migration patterns of leukaemic cells was found to be mediated by SDF1, and subsequent 
leukaemic cell proliferation continued in a perivascular pattern(Sipkins et al., 2005).  
Other cell lines, including murine and human leukaemias, multiple myeloma, prostate 
and melanoma cell lines similarly engrafted similar perivascular microdomains in the 
bone marrow(Sipkins et al., 2005).  It is well established from both human and animal 
studies that expression of the CXCR4 receptor on breast, prostate and other carcinomas 
increases the risk of bone marrow metastases (reviewed in Burger and Kipps, 2006 and 
Taichman et al., 2002).  
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1.6.2.1. Bone marrow vascular niche in haematological malignancy  
 
Long recognized as a fundamental pathological factor in ‘solid’ tumours, tumour 
vascularization has also been studied in haematological malignancies.  Increased 
angiogenesis of the bone marrow has been reported in patients with acute and chronic 
myeloid leukaemia(Hussong et al., 2000), acute and chronic lymphoblastic 
leukaemia(Perez-Atayde et al., 1997), myelofibrosis and myelodysplastic 
syndromes(Lundberg et al., 2000; Mesa et al., 2000; Pruneri et al., 1999) and multiple 
myeloma(Vacca et al., 1995).   
 
Although the role of angiogenesis in bone marrow malignancy is less clear-cut 
than for solid tumours, there is evidence that the progression of haematological 
malignancy also requires the induction of new blood vessels within the bone marrow.  
Bone marrow of acute and chronic leukaemia patients shows enhanced VEGF expression 
as well as increased microvessel density(Hussong et al., 2000; Lundberg et al., 2000; 
Perez-Atayde et al., 1997; Shanafelt and Kay, 2006).  Leukaemic cells may secrete 
VEGF and can induce upregulation of VEGF production by BM stromal cells including 
megakaryocytes(Ghannadan et al., 2003).   
 
In addition to promoting the formation of new blood vessels, VEGF secretion has 
autocrine effects on leukaemic cells, which may express any of the three VEGF receptors 
VEGFR1, 2 and 3(Fragoso et al., 2006).  VEGF signaling, and also direct contact with 
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the sinusoidal endothelium, has been shown to promote survival, proliferation, motility of 
human leukaemia cells and also resistance to chemotherapy(Dias et al., 2000; Fragoso et 
al., 2006; Veiga et al., 2006).  Furthermore, localization of malignant cells at the vascular 
niche mediates anti-apoptosis signaling promoting resistance to chemotherapy and 
radiotherapy(Gallay et al., 2007; Yin and Li, 2006; Zeng et al., 2006).  However, the 
details of the cellular interactions and signaling pathways that mediate the cell survival 
advantage conferred by localization at the vascular niche are not well understood.  
 
 
1.6.3. Megakaryocytes/platelets in bone marrow metastasis  
 
 There have been very few studies examining bone marrow histology, specifically 
megakaryocytes, in metastatic disease.  This is perhaps in part due to limited availability 
of clinical specimens and technical challenges associated with isolation of intact cells 
from the bone marrow.   
 
An early histological study examined megakaryocyte ploidy in postmortem bone 
marrow aspirates from 30 patients with metastatic carcinoma (15 with and 15 without 
paraneoplastic thromboembolic events) and compared these to biopsies from 3 control 
groups: 15 patients with localized carcinoma, 15 patients with thromboses but no 
carcinoma, and 15 healthy controls(Winkelmann et al., 1984).  Megakaryocyte ploidy 
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was found to be significantly higher in all patients with metastatic disease, regardless of 
whether they had associated thromboembolic disease, than in any of the control 
groups(Winkelmann et al., 1984).   The authors speculated that the increased 
megakaryocyte ploidy resulted in increased platelet production and altered platelet 
heterogeneity, although this was not specifically examined in this study.   
 
After the bone marrow and the spleen, the next main reservoir for 
megakaryocytes is the lung, where they may be observed within alveolar capillaries albeit 
in low numbers.  An increase in the numbers of pulmonary megakaryocytes associated 
with lung metastases and pulmonary tumour emboli as compared to lungs from patients 
with localized carcinomas and healthy individuals has been reported(Aabo and Hansen, 
1978; Sharnoff and Kim, 1958; Soares, 1992). 
 
In study of mammary carcinoma metastasis in rats, it was reported that highly 
metastatic cell line clones implanted in the mammary fat pad induced increased numbers 
of megakaryocytes in the bone marrow which was attributed to secretion of a growth 
factor with GM-CSF/IL-3-like effect(McGary et al., 1995).  The increase in 
megakaryocytes was not apparent in animals bearing poorly metastatic tumours.  
Notably, despite the increase in megakaryocytes, no change in platelet count was 
observed in these mice(McGary et al., 1995).  Although the changes to the bone marrow 
cellularity were correlated with metastatic efficiency of the tumour clone, the presence of 
tumour cells within the bone marrow was not reported in this study.   
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Megakaryocyte/platelet surface integrin αIIb/β3 appears to be especially critical 
for tumour colonization of the bone marrow(Bakewell et al., 2003).  Mice deficient in β3 
or mice receiving specific αIIb/β3 inhibitors were strongly protected from bone 
metastases.   In this study, 26 of 35 β3+/+ mice developed bone metastases following 
intra-arterial tumour cell delivery as compared to only 1 of 24 of β3-/- mice(Bakewell et 
al., 2003).  Interestingly, following direct intrafemoral tumour cell delivery, although 
tumour growth occurred in the bone marrow of β3-/- mice, associated bone destruction 
was not apparent, suggesting that interactions between platelets/megakaryocytes and 
tumour cells support tumour-mediated bone destruction(Bakewell et al., 2003).  
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1.7. CONCLUDING REMARKS  
 
Many questions remain unanswered.  Firstly, the functional contribution of 
megakaryocytes to the vascular niche has not been fully clarified, and the pathways that 
determine the net effects of megakaryocyte-derived factors (e.g. the pro- versus anti- 
angiogenic stimulus) remain to be fully understood.  Secondly, the pathways that mediate 
homing of circulating tumour cells to the bone marrow vascular niche are not fully 
known.  A wealth of evidence supports an integral role for platelets in metastasis and in 
the recruitment and retention of bone marrow-derived haematopoietic cells in sites of 
vasculogenesis, but the role of megakaryocytes in the recruitment of malignant cells to 
the bone marrow vascular niche is unclear.   
 
Once in the bone marrow, tumour cells may co-opt the fertile supply of growth 
factors, accessory cells and extracellular matrix proteins provided by the vascular niche.  
It is possible that tumour-derived factors, either acting systemically from distant tumours 
or more directly via tumour cells resident in the bone marrow, may influence the 
megakaryocyte ‘phenotype’.  Furthermore, as well as altering megakaryocyte secretion of 
vascular regulatory proteins, immunomodulatory proteins and chemokines within the 
bone marrow microenvironment, an alteration in the packaging of these factors into 
nascent platelets would modulate the pro-metastatic platelet phenotype with widespread, 
systemic effects.   
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Finally, insights into the factors that mediate site-specific homing of tumour cells 
to supportive niches within the bone marrow microenvironment may also advance our 
understanding of residual disease following chemotherapy in haematological 
malignancies and of tumour dormancy.   
 
These areas are the focus of study in this project, as outlined in the aims and 
objectives discussed below.   
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1.8. AIMS 
 
The general aim of this project was to investigate whether interactions between 
megakaryocytes and tumour cells at the vascular stem cell niche in the bone marrow 
promote tumour progression.    
 
The specific aims were as follows: 
 
1.  To investigate the role of megakaryocytes in homing and engraftment of tumour 
cells to the bone marrow vascular niche in mouse models of metastasis 
 
2.  To examine the mechanisms of megakaryocyte-tumour cell interactions in vitro 
 
3.  To correlate these findings in human studies of bone marrow biopsies from 
patients with cancer.  
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2.  METHODS  
  
2.1. TUMOUR CELL LINES 
 
B16-F10 melanoma (CRL-6475)(Fidler, 1973) and EL4 T cell 
leukaemia/lymphoma (TIB-39)(Gorer, 1950) cell lines were purchased from ATCC 
(Manassas, VA, USA, www.ATCC.org).  B16mCherry cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Invitrogen, Paisley, UK or Carlsbad, CA, USA. # 
41965-062) supplemented with 10% Foetal Bovine Serum (FBS, ATCC or Invitrogen) 
and 1% penicillin/streptomycin (pen/strep, Invitrogen) at 37oC, 5% CO2.   Cells were 
passaged every 2-3 days; media was aspirated, the adherent cell layer washed in sterile 
Phosphate Buffered Saline (PBS), 850µl of 0.25% Trypsin + 0.52mM 
ethylenediaminetetraacetic acid (EDTA) (Cellgrow, Mediatech Inc, Manassas, VA, USA 
# 25-052-C) applied for 2-3 minutes at 37oC to detach the adherent cell layer and then 
9mls of DMEM + 10% FBS added and the cells tritrated against the walls of the flask 
several times to collect all the cells and break up any cell clumps.  1-2ml aliquots of this 
cell suspension were replated in 8-9mls of growth serum in fresh T75 culture flasks to 
propagate the culture.   
 
EL4 cells were cultured in suspension in DMEM (ATCC, USA # 300-2040) with 
10% horse serum (ATCC, USA # 30-2041) and 1% pen/strep, and maintained between 
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105 – 106 cells/ml concentration by passaging every 2 days.  For re-plating a confluent 
flask, the cell suspension was collected into a 15ml falcon tube, the cells pelleted by 
centrifugation for 5 minutes at 300G (relative centrifuge force in gravity, G), medium 
aspirated and the pellet resuspended and diluted in fresh medium as appropriate for 
ongoing cultures.  
 
Cell cultures were propagated for a maximum of 2 weeks, at which point a fresh 
culture was established from stock stored at -80oC.  For preservation of the cell lines, 
aliquots of 3 x 106 cells in 0.5ml serum, 100µl dimethyl sulfoxide (DMSO) and 0.4ml 
medium were slowly frozen in cryo vials in an isopropanol freeze-down container and 
then transferred to liquid nitrogen for long-term storage.  Cell vials were thawed in a 
40oC water bath for 2-3 minutes, immediately washed once in normal culture medium 
and then plated in 10mls of medium in a T75 flask.  Cells were re-plated 24 hours later to 
remove any cells that had died during freeze-thawing process.   
 
 
2.1.1. Preparation of tumour-conditioned media 
 
To generate tumour-conditioned media (TCM), tumour cells from an ~85% 
confluent T75 culture flask were washed and re-plated with serum-free DMEM + 1% 
pen/strep and incubated for 8-12 hours.  Subsequently, the TCM was harvested and 
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centrifuged for 5 minutes at 300G to remove all cells and cellular debris.  TCM was 
either used immediately or flash frozen in liquid nitrogen and stored at -80oC in 1-2ml 
aliquots.   
 
 
2.1.2. Measurement of tumour cell proliferation using the MTS assay  
 
 To assess tumour proliferation rate, the CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay (Promega, Madison, WI, USA) was used.  This is a 
colourimetric system for determining the number of viable cells in culture, analogous to 
the [3H]-thymidine-incorporation proliferation assay but without radioactivity.  The assay 
is composed of solutions of a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and the 
electron coupling reagent phenazine methosulfate (PMS).  MTS is bioreduced by 
dehydrogenase enzymes found in metabolically active cells into a formazan product that 
is soluble in tissue culture medium. The absorbance of the formazan product at 490nm 
can be measured using a 96-well plate reader, and the quantity of formazan product as 
measured by the amount of 490nm absorbance is directly proportional to the number of 
living cells in culture. 
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 To assess the effect of megakaryocyte-conditioned medium (MCM, See Section 
2.4.3) on tumour cell proliferation, optimization experiments were performed to 
determine the correct starting number of cells per well for each cell line in order to 
maximize the sensitivity of the assay (Section 4.4.1.).  B16 cells were plated in 300µl of 
DMEM with no added serum (serum-free medium, SFM) in each well of a 96-well plate 
with the aim of letting the cells adhere to the wells and synchronizing the cell population 
in G0 phase.  The following morning, 200µl was removed from each well and 100µl of 
‘test’ medium added to the remaining 100µl [SFM (negative control); 20% FBS (positive 
control); or MCM (test)] and the plate incubated for 24-48 hours depending on the 
experiment at 37oC, 5% CO2. Subsequently, 100µl media was removed from each well, 
20µl of Promega MTS solution was added, and the plate incubated at 37oC for 2 hours, 
after which absorbance measured using a 96-well plate reader at 490nm as per the kit 
protocol.      
 
 For EL4 cells (which are non adherent), the residual growth medium was 
removed by washing once in sterile PBS, resuspending in SFM and serum-starving in a 
T75 or T25 culture flask overnight.  The following morning, the required starting cell 
number was suspended in 100µl of test medium per well of a 96-well plate.  24 hours 
later, 20µl of Promega MTS solution was added and the number of viable cells measured 
as described in the paragraph above.   
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2.1.3. Generation of vector-tagged tumour cell lines by lentiviral transduction 
 
To enable detection of tumour cells within the bone marrow by flow cytometry 
and RNA analysis, EL4-GFP, B16-GFP and B16-mCherry tagged cell lines were 
established.  While mCherry fluorescent protein is readily visible by immunofluorescence 
microscopy and permits co-staining of other markers using GFP-labelled secondary 
antibodies, GFP-tagged cell lines were more useful for detection of tumour cells by flow 
cytometry.  
 
Lentiviral vectors for GFP and mCherry had previously been generated in the 
Lyden laboratory by transient transfection of 293T cells(Kaplan et al., 2005).  For 
transduction of the EL4 and B16 tumour cells with the desired vector, 5 x 104 cells were 
plated in each well of a 6-well plate in Iscove’s modified DMEM (IMDM)(Won et al., 
1999).  B16 cells were left to adhere overnight prior to addition of viral supernatant.   In 
each well, dilutions of viral supernatant were added at the required multiplicity of 
infection with 10µl of polybrene in a total volume of 1ml IMDM.  Cells were incubated 
overnight to allow transduction to occur, and then diluted by adding 3mls of IMDM the 
following day.  After 36-72 hours, cells were examined by fluorescent microscopy and 
flow cytometry.   
 
The efficiency of transduction with either the GFP or the mCherry vector was 
60%-80%, depending on the volume of viral supernatant used.  For example, the highest 
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transduction efficiency of EL4 cells with the GFP vector was achieved using 500µl of 
virus (Figure 2.1.).  GFP+ or mCherry+ cells were selected by flow cytometry-assisted 
cell sorting (FACS) using a Becton Dickinson FACSVantage SE cell sorter (BD 
Biosciences, Franklin Lakes, NJ, USA) to obtain a 100% positive population, and % 
positivity was checked by flow cytometry every 2-3 months.  
 
 
 
 
 
 
 
 
 
Figure 2.1. Transduction of EL4 cells with a GFP vector.   
EL4 cells were transduced overnight with a lentiviral vector generated by transient 
transfection of 293T cells.  72 hours later, the efficiency of transduction was assessed by 
flow cytometry.  As shown by the plots above, the highest proportion of GFP+ cells 
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(84%, the lower right quadrant, gated on live cells) was achieved using 500µl of vector.  
The GFP+ cells were then selected by FACS to obtain a 100% GFP+ population.       
 
2.2. IN VIVO MODELS OF METASTASIS  
 
All animal studies at Cornell, New York were performed in accordance with 
IACUC protocols(IACUC, 2007) and at Imperial College, London in accordance with the 
Animals (Scientific Procedures) Act of 1986 under Project License 70/6874 and Personal 
License 70/22375.  B16 melanoma and EL4 T cell lymphoma/leukaemia cell lines were 
selected for this project as they are syngeneic for C57Bl/6 mice and have a wide 
metastatic profile including to the bone marrow(Fidler, 1973; Kaplan et al., 2005; Won et 
al., 1999). 
 
 
2.2.1. Spontaneous metastasis from intradermal tumours 
 
For a spontaneous model of metastasis, 2 x 106 tumour cells were washed twice in 
SFM, resuspended in 300µl of SFM and intradermally implanted into the right flank of 6-
8 week old mice using insulin syringes with a 27G needle under general anaesthesia 
(Kaplan et al., 2005).  Control animals were injected with an equal volume of SFM alone.  
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Tumour growth was monitored by measurement of tumour length, width and depth using 
calipers to calculate the tumour volume every 48 hours.   
Following inoculation with either tumour cell line, primary tumours were 
palpable by around day 8 and large tumour nodules developed within 18-22 days.  B16-
F10 metastases to lung, liver, spleen, bone marrow, ovaries, and kidneys were detectable 
from around day 15(Kaplan et al., 2005).  Mice inoculated with EL4 tumours developed 
bulky contiguous and distant lymph node metastases and the tumour disseminated to 
spleen and bone marrow.  In both models, the metastatic cancer is fatal around 25 days 
following tumour implantation.  
 
 
2.2.2. Intravenous delivery of tumour cells  
 
 As a model of haematogenous metastasis that “bypasses” invasion and 
extravasation from the primary tumour, B16mCherry or B16-GFP tumour cells were 
directly delivered intravascularly via the lateral tail vein.  5 x 105 cells were washed 2x in 
sterile PBS, resuspended in 100µl of sterile PBS and injected using an insulin syringe and 
27G needle.  Mice were warmed under a heat lamp or in a heat chamber prior to injection 
and immobilized in a Tailveiner® restrainer (Figure 2.2.) to facilitate venous access.  
Control mice received 100µl of sterile PBS alone.  In this model of metastasis, extensive 
lung metastases occurred although metastases were not seen in other organs, and the mice 
died around 15-18 days following tumour injection.   
 107 
 
 
 
 
 
 
Figure 2.2. Rodent ‘Tailveiner’ (TV-150) immobilization device used for tail vein 
injections.   
Photograph from Bioseb catalogue.  
 
2.2.3. Direct intra-medullary tumour cell delivery  
 
To model bone marrow malignancy more directly, a model for direct intra-
medullary inoculation of tumour cells was established.  Under continuous inhalational 
anaesthesia, 5 x 105 washed EL4 tumour cells in 30µl of SFM were delivered directly 
into the marrow cavity using a 0.5cc insulin syringe.  The right hind leg was maximally 
flexed at the knee, and a 26G needle was used to create an osteotomy prior to tumour cell 
delivery(Jin et al., 2006b; Krause et al., 2006).  Animals were monitored by daily review 
for signs of ill health (reduced movement, poor grooming, reduced body temperature 
when moribund).     
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2.3. ANIMAL STUDIES: TISSUE SAMPLING AND ORGAN PROCESSING 
 
2.3.1 Venesection for FBC analysis and preparation of platelet-rich plasma (PRP) 
 
For full blood count analysis, 65µL blood was collected using a heparinized tube 
by retroorbital venipuncture under anaesthesia, diluted 1:3 in an EDTA buffer and run on 
a Bayer ADVIA 120 haematology analyzer standardized for C57Bl/6 mice.   
 
For analysis of platelet-rich plasma (PRP), mice were terminally bled via 
retroorbital venipuncture under anaesthesia using heparinized tubes into EDTA tubes.  
Blood was immediately centrifuged for 10 minutes at 10,000G in a tabletop centrifuge at 
4oC, plasma aspirated and stored in 100µl aliquots at -80oC until analysis. 
 
2.3.1.1. Quantification of proteins in PRP by enzyme-linked immunosorbant assay 
(ELISA)  
 
 Concentrations of proteins including TPO, SCF, VEGF and SDF1 in PRP were 
quantified using Quantikine® Colorimetric sandwich ELISAs (R&D Systems, Abingdon, 
Oxfordshire, UK).  Briefly, microtitre plates precoated with a monoclonal antibody 
specific for the protein of interest were employed.  Dilutions of standards, controls, and 
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test samples were pipetted into the wells so that any protein in the sample would bind to 
the immobilized antibody.  After multiple wash steps to remove any unbound substances, 
an enzyme-linked polyclonal antibody specific for the protein of interest was added to the 
wells.  Following further washing to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells.  The enzyme reaction yields a blue product that 
turns yellow when the provided Stop Solution is added.  The intensity of the colour 
measured using a 96-well plate reader at a specific absorbance is in proportion to the 
amount protein bound in the initial step.  The ‘standard’ dilutions were then used to draw 
a standard curve from which the protein concentration of test samples was calculated 
using Excel software.  
 
 To quantify plasma PF4, a DuoSet ELISA development kit was used which 
contained appropriate capture and detection antibodies, standard and streptavadin-HRP 
reagents (also from R&D systems).  Briefly, a 96-well microplate was coated with the 
capture antibody overnight.  The following morning, a block buffer was applied for 1 
hour, the samples were added for 2 hours, and the detection antibody was applied for 2 
hours followed by visualization of bound antibody using the streptavidin-HRP reagents.  
All incubations were performed at room temperature and the plate was washed between 
each step using the wash buffer supplied.   
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2.3.2 Organ processing for RNA analysis  
 
The presence of disseminated tumour and the expression of angiogenic regulatory 
proteins in the primary tumour and in target organs of metastasis was examined by RNA 
analysis.  For soft organs, tissue sections of around 100µg weight were snap frozen in 
liquid nitrogen and stored at -80oC until RNA extraction.  Tibias and/or femurs were 
flushed with 10ml of 2% bovine serum albumin (BSA)/PBS with 2mmol EDTA using a 
3ml syringe and 27G needle.  Cells were counted using acetic acid and 107 cells pelleted 
by centrifugation for 5 minutes at 300G.  Medium was carefully aspirated and the dry 
pellet resuspended in 750µl of Trizol and stored at -80oC until RNA extraction.   
 
2.3.2.1. RNA extraction from tissues using Trizol®-chloroform   
 
 This procedure was performed in a chemical hood with appropriate protective 
clothing.  All surfaces were cleaned with RNAaseOUT™ (Invitrogen, Paisley, UK) and 
RNAse-free pipettes and eppendorfs used.  Tissues were first homogenized in a power 
homogenizer (spleen, liver, lung, tumour) or vigorous pippetting (bone marrow cells).  
Homogenized samples were then incubated for 5 minutes at room temperature to permit 
dissociation of nucleoprotein complexes.  200µL of chloroform (VWR, West Sussex, 
UK) was added per 750µl of Trizol (Invitrogen, Paisley, UK), the eppendorf cap shut 
tightly and the sample shaken vigorously by hand for 15 seconds then incubated at room 
temperature for up to 15 minutes while other samples were processed.  Samples were 
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then centrifuged at 12,000g for 15 minutes at 4oC, following which the mixture would 
have separated into a lower red, phenol-chloroform phase, a white interphase (containing 
DNA), and a colourless upper aqueous phase (containing the RNA).  To precipitate the 
RNA, the aqueous phase was carefully transferred by hand pipette to a clean eppendorf 
containing with 500µl isopropyl alcohol (VWR), and incubated for 10 mins at room 
temperature.  The samples were then centrifuged at 12,000 for 10 minutes at 4oC.  A 
pellet of RNA would now be visible on the side of the eppendorf tube.  The supernatant 
was removed, and the RNA pellet washed by adding 1ml of RNAse free 75% ethanol and 
vortexing.  The sample was centrifuged again at 7,500 G for 5 minutes at 4oC, the 
supernatant aspirated, the pellet dried and dissolved in 50µl RNAse-free water.  The 
RNA concentration and purity was assessed using a NanoDrop 8000 spectrophotometer 
(Thermo Fisher Scientific, Wilmington, U.S.A.).  Samples with probable protein or 
solvent contamination as indicated by poor 260/280 or 260/230 ratios were excluded 
from analysis.     
 
2.3.2.2. cDNA synthesis and quantification of gene expression by RT-PCR 
   
The expression of genes of interest was assessed by RT-PCR.  RNA was reverse-
transcribed using Superscript III (Invitrogen, Paisley, UK) and PCR amplification was 
performed using TaqMan or SYBR Green primer probes, as indicated in Table 2.1.  Gene 
expression was normalized to the endogenous housekeeping gene β-actin to standardize 
the amount of sample cDNA added to the reaction.  Relative quantification was 
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performed using the comparative CT method.  The CT value for b-actin was subtracted 
from the CT for the target gene to obtain the normalized CT value, ΔCT.  The relative 
expression was calculated as follows: fold increase in expression = 2-ΔCT.  ‘No template’ 
and ‘minus RT’ controls were run as appropriate.    
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Table 2.1. Primers used for RT-PCR 
 
Primer Probe Reporter Source Product details / sequence 
β-actin VIC Applied Biosystems 4352341E 
VEGF FAM Applied Biosystems Mm00435304_m1 
TGFβ FAM Applied Biosystems Mm03024653_m1 
BMP4 FAM Applied Biosystems Mm00432087_m1 
FGF4 FAM Applied Biosystems Mm00438917_m1 
SDF1 FAM Applied Biosystems Mm445552_m1 
MMP9 FAM Applied Biosystems Mm00600164_g1 
PF4 (CXCL4) FAM Applied Biosystems Mm0045135_g1 
TSP1 FAM Applied Biosystems Mm00449022_m1 
Endostatin  FAM Applied Biosystems Mm00487131_m1 
PDGFα FAM Applied Biosystems Mm00833533_m1 
SCF FAM Applied Biosystems Mm00442972_m1 
IL3 FAM Applied Biosystems Mm00439631_m1 
IL6 FAM Applied Biosystems Mm00446191_m1 
IL11 FAM Applied Biosystems Mm00434162_m1 
mCherry  FAM Integrated DNA 
Techologies (IDT) 
F1: AGA TCA AGC AGA GGC TGA 
AGC TGA. R1: TGT GGG AGG TGA 
TGT CCA ACT TGA. Probe: /5'-
FAM/AGG TCA AGA CCA CCT ACA 
AGG CCA AGA A/ 3'-TAMRA/ 
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2.3.2.3. Detection of tumour metastasis by RNA analysis and flow cytometry  
 
 In mice inoculated with tumour cell lines tagged with GFP or mCherry, bone 
marrow, spleen, liver and lung were examined for the presence of tumour metastasis by 
RNA analysis for the presence of mCherry mRNA using the primer/probe sequences 
described in Table 2.1.  RNA extraction, cDNA synthesis and RT-PCR were performed 
as described in Sections 2.3.2.1 and 2.3.2.2 above.  
  
To obtain bone marrow cells for analysis by flow cytometry, femurs and tibias 
were flushed using 1% BSA/PBS + 2mM EDTA.  106 bone marrow cells in 500µl of 1% 
BSA/PBS were analyzed by flow cytometry for fluorescent tumour cells.   
 
 
2.3.3. Immunostaining of tissue sections (mouse and human)  
 
2.3.3.1. Preparation of tissue for OCT and paraffin embedding 
 
For immunostaining with immunofluorescence, tissues were fixed for 24 hours in 
20% sucrose/1.6% paraformaldehyde (PFA, Sigma Aldrich, St Louis, MO, USA) prior to 
embedding in Tissue-Tek® Optimal Cutting Temperature (OCT) medium (Electron 
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Microscopy Supplies, Hatfield, PA, USA) and stored at -80oC.  For 
immunohistochemistry, tissue sections were fixed in 4% PFA for 24 hours, dehydrated in 
graded ethanol and embedded in paraffin.  For analysis of the bone marrow, femurs and 
tibias were cleaned of soft tissue, fixed in 4% PFA for 24 hours and then decalcified at 
room temperature for 5-7 days (or until bend under light pressure using fingers alone) 
using 0.5M EDTA decalcification solution (90µl ammonium hydroxide and 140g EDTA 
in 1L of distilled water, pH adjusted to 7.1-7.4) prior to embedding in either OCT or 
paraffin.  
 
2.3.3.2. Immunohistochemistry of paraffin- and OCT-embedded samples  
 
5µm sections of paraffin-embedded femurs and tibias were dewaxed by warming 
overnight on a 56oF hotplate, cooled to room temperature and then rehydrated in 
histoclear and graded ethanol washes (Histoclear, 100% ETOH, 95% EtOH, 85% ETOH, 
70% ETOH, all obtained from VWR) followed by ddH20.  Endogenous peroxidase was 
quenched using 0.1% hydrogen peroxidase (H2O2, VWR) in PBS for 15 minutes at room 
temperature.  Antigen retrieval was performed either with a citrate buffer or with EDTA 
(see Table 2.2).  For the citrate antigen retrieval, the slides were put into a high-
temperature steam antigen retrieval machine for 40 minutes or in the microwave for 5 
minutes (or until solution reaches 90oC) in antigen retrieval buffer (0.01M citric acid 
Target Retrieval Buffer, DAKO, Carpinteria, CA, USA).  Slides were cooled slowly for 
2-3 hours in the citric acid buffer and then washed in PBS.  For the EDTA antigen 
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retrieval method, tissue culture EDTA (Cellgrow) was applied to the sections for 10 
minutes at 37oC.   
 
  Samples stored at -80oC in OCT were sectioned by cryostat at  -20 to -16oC, 
applied to superfrost slides and left to air-dry overnight in a sterile tissue culture hood 
prior to staining.  The following day, tissues sections were circled using a hydrophilic pen 
and fixed by plunging into ice-cold acetone for 20 minutes.   
 
Both OCT and paraffin sections were then stained according to the following 
protocol. 10% normal serum from the species in which the secondary antibody was raised 
diluted in 2% BSA was applied for 30 minutes for protein block, the primary antibody 
was applied in the appropriate dilution, and slides were incubated either for 1 hour at 
room temperature or at 4oC overnight as determined by optimization experiments with 
each antibody.  Slides were washed several times in PBS (3 x 5 minutes), and the 
secondary ‘link’ biotinylated-IgG antibody was applied for 1 hr at room temperature.  
The ABC tertiary reagent (Vector Labs, Peterborough, UK) was then used, and slides 
washed in PBS prior to staining with diaminobenzidine (DAB, Vector Labs) for the 
appropriate time as determined by optimization experiments (this ranged from 2 – 20 
minutes depending on the primary antibody used).  The slides were then dipped into 0.5% 
copper sulphate (CuSO4) in distilled water for 1-2 minutes to enhance the staining, 
counterstained with Harris’ or Mayer’s Haematoxylin (VWR) and mounted using 
Vectormount permanent mounting medium (Vector Labs).    
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For immunostaining of the human bone marrow trephine biopsies using primary 
antibodies raised in mouse or rabbit (VEGF, PF4, TSP1, CD42b), the Biogenex Super 
Sensitive Polymer-HRP detection system was used (Biogenex, Kent, UK).  Following 
application of the primary antibody, the slides were treated with Super Enhancer™ prior 
to incubation with a universal secondary antibody conjugated to an HRP polymer.  
Positive staining was then visualized with DAB as per the protocol described above. 
 
The antibodies used are listed in Table 2.2.   
 
2.3.3.3. Immunofluorescent staining  
 
Primary antibodies were applied in the appropriate dilution (as determined in 
optimization experiments) and left at 4oC overnight covered with a plastic coverslip.  
Subsequent steps were carried out in the dark.  Fluorescent-conjugated secondary 
antibodies (all obtained from Jackson ImmunoResearch, supplied by Stratech Scientific, 
Suffolk, UK) were applied for 1 hour at room temperature.  After several washes in PBS, 
slides were mounted with DAPI [ProLong® Gold Antifade Reagent (with DAPI), 
Invitrogen].  Slides were reviewed using an upright Nikon Eclipse E800 upright 
microscope and images captured either directly with a Qimaging camera or using a Leica 
TCS SP5 II confocal system. 
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2.3.3.4. Megakaryocyte counting, measurement of megakaryocyte cell width and vessel 
diameter 
  
 The number of megakaryocytes per 200x field view was counted in paraffin-
embedded bone marrow sections.  Between 10 and 20 field views were randomly selected 
from across the entire femur section.  To measure megakaryocyte cell diameter and blood 
vessel diamater, photographs of femur sections were taken and all cells or vessels 
identified in each photograph were measured using ImageQ software.  Mean + SEM 
values for all measurements were calculated for each mouse.  A blinded investigator 
independently verified my data.       
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Table 2.2.  Antibodies used for immunohistochemistry 
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2.4. IN VITRO MEGAKARYOCYTE CULTURE 
 
For in vitro megakaryocyte cultures, femurs and tibias were harvested from wild-
type 6-12 week old C57Bl/6 mice, cleaned of soft tissue and stored in sterile PBS on ice 
for up to 2 hours prior to further processing.  Bones were sprayed with 70% ethanol, the 
very distal ends removed with a scalpel and then flushed under sterile conditions using 
10mls of sterile-filtered 1% BSA/PBS with 2mM EDTA and a 3ml syringe with 27G 
needle.  A single cell suspension was obtained by passing the cell solution several times 
through a syringe with 27G needle.  
 
 
2.4.1. Selection of lineage-negative bone marrow cell fraction and first-stage 
megakaryocyte culture 
 
Isolated bone marrow cells were centrifuged and re-suspended at a concentration 
of 108/ml in a buffer of PBS, with 2% FBS, 1mM EDTA and 2% normal rat serum 
(StemCell technologies, Vancouver, BC, Canada). The immature, lineage negative (Lin- 
Sca1+c-Kit+, LSK) cells were enriched using a lineage depletion antibody cocktail, biotin 
selection cocktail, and anti-biotin magnetic microparticles (EasySep® Mouse 
Hematopoietic Progenitor Cell Enrichment Kit, StemCell technologies, catalogue number 
19756).  This technique allows for 6-fold enrichment of the Lin- fraction and 14-fold 
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enrichment of colony forming cells (CFCs,) as confirmed by flow cytometry analysis.  
The LSK-enriched fraction was immediately re-suspended in Stemspan (StemCell 
technologies, Vancouver, BC, Canada) at 5 x 105 cells/ml and supplemented with 1% 
pen/strep, 50 ng/ml recombinant murine thrombopoietin (TPO) and 20 ng/ml stem cell 
factor (SCF) (see Results 4.2 for cytokine optimization).  Both cytokines were purchased 
from Peprotech, London UK or Peprotech, Rocky Hill, NJ, USA.  Cultures were 
incubated at 37oC with 5% CO2 and reviewed daily using an inverted Nikon Eclipse 
TE2000-U microscope.  Phase contrast images of developing megakaryocytes were 
obtained with a Coolsnap cf camera (Roper Scientific, Tucson, AZ, USA).  
 
 
2.4.2 Enrichment of mature megakaryocytes using a BSA gradient  
 
Using the protocol described above in 2.4.1., a heterogeneous culture was 
obtained which contained primarily megakaryocytes at various stages of development but 
also a small number of cells of non-megakaryocyte lineage.  To purify the culture for co-
culture experiments where total cell culture mRNA was examined, a BSA gradient was 
used to isolate and enrich mature megakaryocytes (Figure 2.3).  Care was taken to use 
room temperature solutions to avoid activating the megakaryocytes/platelets. 
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Figure 2.3. BSA gradient used to obtain enriched population of mature 
megakaryocytes.   
4mls of 3% BSA was carefully pipetted into the bottom on a 15ml falcon tube, and 4mls 
of 1% BSA gently layered on top using a automated pipette set at standing gravity.  4mls 
of a 72-hour megakaryocyte culture was carefully layered on top.  The cell suspension 
should be seen mixing only with the top 5-6mls of BSA if the BSA gradient is well set 
up.  Only mature megakaryocytes are large and dense enough to fall through to the lower 
2mls of 3% BSA.  The suspension is left standing for 40 minutes at room temperature in 
a sterile culture hood, after which the top 10mls is aspirated leaving an enriched 
population of mature megakaryocytes.  
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2.4.3. Preparation of megakaryocyte-conditioned medium (MCM) 
 
To generate MCM, mature megakaryocytes enriched over a BSA gradient 
(Section 2.4.2.) were resuspended in SFM with 50ng/ml TPO (Peprotech, Rocky Hill, NJ, 
USA) and 1% pen/strep and incubated at 37oC, 5% CO2.  ‘Control’ medium was prepared 
as SFM with 50ng/ml TPO and 1% pen/strep with no cells added.  After 24 hours, the 
megakarycyte culture cell suspension was then centrifuged at 300G and the supernatant 
harvested and used immediately or stored at -80oC.  
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2.5. MEGAKARYOCYTE-TUMOUR CELL COCULTURES 
 
In optimization experiments, I found that tumour cells could not migrate through 
0.4µm-sized membrane pores and therefore Corning 6.5mm Transwell® plates with 
0.4µm pore polycarbonate membrane inserts (Product #3413, Corning Life Sciences, 
Lowell, MA, USA) was selected for coculture experiments to allow exchange of 
secretory products while maintaining the cells in separate culture systems.  600-750µl of 
a day 3 megakaryocyte culture (purified by BSA gradient and resuspended in SFM + 
50ng/ml TPO, see 2.4.2) at ~5 x 105 cells/ml was placed in the bottom chamber, and 
250µl of fluorescently-labelled tumour cells at 5 x 105 cells/ml in SFM were carefully 
pipetted into the top chamber (Figure 2.4).   Wells were reviewed using an inverted 
microscope with fluorescent lamp to ensure that no tumour cells had fallen to the bottom 
chamber and the cells were co-incubated for 24-36 hours depending on the experiment.       
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Figure 2.4. Coculture of tumour cells with megakaryocytes.   
600-750µl mature megakaryocytes at ~5 x 105 cells/ml was placed in the bottom 
chamber, and 250µl of fluorescently-labelled tumour cells at 5 x 105 cells/ml in SFM 
were carefully pipetted into the top chamber of a Corning transwell coculture chamber 
with a 0.4µ membrane that allows exchange of secreted factors but no cells to pass 
between the compartments.   
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2.5.1. RNA isolation from in vitro cultured megakaryocytes 
 
Following coculture (Figure 2.4.), the top well containing the tumour cells was 
carefully removed and the megakaryocyte cell suspension was transferred to RNAse free 
eppendorf tubes and centrifuged at 200G for 5 minutes in a table-top centrifuge.  RNA 
was isolated using Trizol-Qiagen column extraction (as previously 
described(Papaspyridonos et al., 2007)) or Qiagen RNeasy Micro Kit spin columns 
(Qiagen, West Sussex, UK), depending on the number of cells.  Using the Micro kit 
columns, 75µl of the cell lysis buffer used per well; prior to resuspending the cell pellet, 
the buffer was passed a few times over the culture well to collect any megakaryocytes 
that remained adherent to the bottom of the well.  On-Column DNase digestion was 
performed as per the kit protocol.  RNA purity was assessed using a NanoDrop 8000 
spectrophotometer.  cDNA synthesis and RT-PCR was performed as described above in 
Section 2.3.2.2.  
 
The effect of coculturing tumour cells with megakaryocytes on gene expression 
was then calculated by calculating the change in fold expression for the target gene in the 
cocultured megakaryocytes from that of ‘control’ megakaryocytes, which had been 
cultured with cell-free media in the top well alone.  
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2.6. CHEMOTAXIS ASSAYS USING TRANSWELL MIGRATION  
 
Tumour cell chemotaxis was performed using either Costar® Transwell 
Permeable Supports (Corning, Massachusetts, USA) or the Neuroprobe disposable 
chemotaxis system (Gaithesburg, MD USA).  Costar® Transwell Permeable Supports 
were used initially for experiments with EL4 cells (8µm pore size, 24 well plates) and 
B16 cells (12µm pore size, 24 well plates).  600µl of MCM was placed in the bottom 
chamber, the insert carefully fitted in place and 250µl of B16 or EL4 cells at 5 x 105 
cells/ml plated in the top chamber.  After incubation for 4 hours at 37oC, 5% CO2, the 
number of cells that had migrated to the bottom chamber were counted using a 
haemocytometer.  Trypsin was used to collect the B16 cells that had adhered to the 
bottom of the well.  
 
Using the Neuroprobe system, the 3.2µm diameter, 96 well plate design was used 
(product #101-12), Figure 2.5.  This system consists of a microplate with 30µl capacity, 
filter (with migration pores) and lid.  Each filter test site is surrounded by a hydrophobic 
mask, which restricts the cell suspension to the test site thereby eliminating the need for 
upper wells and reducing the amount of test medium required for each migration 
replicate.  The test migration medium was placed in the lower wells, the filter membrane 
fitted and then the cell suspension was pipetted directly onto the top-side of the filter 
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where it balances in hemispherical drops.  A lid on top prevents evaporation, and the 
plate was incubated for 4 hours at 37oC, 5% CO2.  
 
 
 
 
Figure 2.5.  Migration assay using Neuroprobe chemotaxis system.   
Photograph from Neuroprobe Catalogue.  
 
 
 At the end of the incubation period, the hemispherical drop of cell suspension was 
aspirated and tumour cells on the top-side of the filter area were removed using a cell 
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scraper or cotton wool buds (taking care not to tear the membrane).  The membrane was 
then inverted, and cells that had migrated to the underside were first washed 3x in PBS 
and then fixed using ice-cold 4% PFA for 15 minutes.  The filter circles were then cut out 
using a scalpel, carefully placed onto Suprafrost slides and mounted using DAPI 
mounting media.   
  
 The migration test sites were then visualized and photographed by fluorescence 
microscopy.  The number of cells migrated was quantified by selecting for DAPI+ nuclei 
(blue pixels) using Photoshop software.   
 
 
2.6.1. Pre-treatment of B16 cells with Pertussis toxin prior to chemotaxis assay 
 
 To determine whether the chemotactic effect of MCM on B16 cells was mediated 
by pertussis-toxin sensitive G-protein chemoreceptors, B16 cells were pre-treated for 30 
minutes prior to the migration assay.  200ng/ml pertussis toxin (Sigma Aldrich, St Louis, 
MO USA, Catalogue # P2980) was added to the culture medium and the cells incubated 
for 30 minutes. The cells were then washed once in either sterile PBS or SFM before 
preparation for the migration assay as described in Section 2.6. 
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2.7. VISUALIZATION OF MEGAKARYOCYTE GRANULES BY CONFOCAL 
MICROSCOPY.   
 
4% PFA was directly added to the megakaryocyte cultures in order to fix the cells 
in situ and minimize the effect of handling activation on the megakaryocytes(Sehgal and 
Storrie, 2007).   Cells were maintained at temperatures > 18oC at all times to avoid 
activation.  The cell suspension was centrifuged for 5 minutes at 300G, re-suspended in 
PBS, and cytospun onto Superfrost glass slides at 700G for 4 minutes, low acceleration.  
4% PFA was dropped onto the slide and left for 15 minutes to fix the cells on the slide 
prior to staining.  All wash steps were done using PBS, and following the introduction of 
the fluourescent-conjugated secondary antibodies all steps were performed in the dark.  
10% normal serum was used for blocking, primary antibodies were left for either 1-hour 
at room temperature or overnight at 4oC, and conjugated secondary antibodies were 
applied for 1 hour at room temperature.  Slides were mounted using DAPI to visualize the 
nuclei (ProLong® Gold Antifade Reagent (with DAPI), Invitrogen).   
 
Cells were imaged using a Nikon Eclipse Confocal Spectral Imaging CIsi system 
mounted on a Nikon Eclipse TE2000-U microscope (Nikon Precision Inc, Belmont CA, 
USA).   The imaging settings (pixel dwell, power and gain) were optimized at the start of 
viewing, and not changed between slides to enable valid comparison between culture 
conditions.  ‘Averaging’ was used to remove the detection of background / nonspecific 
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fluourescence.  3D reconstruction images were created by Z-stacking.  No image 
manipulation was performed.      
 
 
2.8. STATISTICAL ANALYSIS  
 
The data were analyzed and charts were drawn using Prism and Excel software.  
Means, medians, standard deviation and standard errors were calculated, and populations 
compared using 2-sided T-tests or one-way ANOVA as appropriate.  A P-value of < 0.05 
was used to indicate a statistical difference between two groups.   
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CHAPTER 3. THE ROLE OF MEGAKARYOCYTES IN HOMING AND 
ENGRAFTMENT OF TUMOUR CELLS TO THE BONE MARROW VASCULAR 
NICHE IN MOUSE MODELS OF METASTASIS 
 
3.1. INTRODUCTION 
 
 Circulating malignant cells preferentially engraft vascular niches in the bone 
marrow(Sipkins et al., 2005), suggesting that the vascular niche supports tumour cell 
homing and survival in the bone marrow.  Although the contribution of megakaryocytes 
to the function of the vascular niche has not been fully explored, there is both in vitro and 
in vivo evidence to suggest that megakaryocyte-derived factors regulate the proliferation 
and survival of the bone marrow endothelium (Section 1.2.4).  Furthermore, while 
multiple roles for platelets in metastatic progression have been well established (Burdick 
and Konstantopoulos, 2004; Heinmoller et al., 1995; Jain et al., 2007; Jin et al., 2006a; 
Karpatkin et al., 1988; Kopp et al., 2009; Nieswandt et al., 1999) (Section 1.5), the role of 
megakaryocytes in bone marrow metastasis has not been specifically examined.  
Therefore, the aim of this part of my work was to characterize the megakaryocyte-
vascular niche in the bone marrow in normal physiology and in metastasis, and to 
investigate whether megakaryocytes promote metastasis to the bone marrow.   
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In vivo systems for the study of tumour metastasis are broadly classified into two 
approaches: ‘experimental’ and ‘spontaneous’ models (Table 3.1)(Welch, 1997).  
‘Spontaneous’ models of metastasis involve the injection of tumour cells into tissue sites 
(subcutaneous, intradermal, or into specific organs or tissues) to initiate primary tumours 
that will spontaneously metastasize to distant organs.  The ‘experimental’ approach 
involves direct intravascular delivery of tumour cells, thereby circumventing the 
processes of primary tumour growth, local tissue invasion and intravasation that normally 
occur before tumour cells disseminate into the circulation.  Both systems have certain 
advantages and limitations.  These are discussed below in Table 3.1.        
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Table 3.1. Animal models of metastasis 
System Specific advantages/disadvantages 
Orthotopic e.g. melanoma, 
breast cancer, leukaemia 
Tumour cells are 
injected into the 
autochthonous site of 
tumour development, 
e.g. intradermal injection 
of melanoma, injection 
of breast cancer cells 
into mammary fat pads, 
and therefore 
interactions between 
tumour and stroma are 
similar to those 
occurring in spontaneous 
tumour development 
Intradermal  
‘Spontaneous' 
models 
Ectopic 
Subcutaneous  
Incorporates initial stages 
of metastasis occuring 
during primary 
tumourigenesis - i.e. 
invasion of local tissues 
and extravasation.    
‘Experimental' 
models 
Intravenous 
In spontaneous tumours, 
not all tumour cells have 
metastatic potential. 
These models artificially 
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Intra-arterial / intra-
cardiac 
Technically challenging 
- a proportion of animals 
will not survive the 
injection or will develop 
tumours at the site of 
injection  
bypass steps that many 
tumour cells may not 
normally be capable of 
achieving (e.g. invasion, 
intravasation).  
Bolus injection of tumour 
cells does not accurately 
represent spontaneous 
release of cells from 
primary tumour.   
Does not model systemic 
'conditioning' of mouse 
that results from factors 
released by primary 
tumour prior to 
metastasis.  Enables focus 
on specific steps in the 
metastatic cascade e.g. 
tumour cell engraftment 
Transgenic 
models of 
metastatic 
cancer  
e.g. HER-2/neu and 
Polyoma middle T models 
of breast cancer, RIP-Tag 
(rat insulin promoter 
regulated simian virus 40 
Tag) model of pancreatic 
cancer 
'Gold' standard model encapsulating all aspects of 
spontaneous tumourigenesis and metastasis.  
Syngeneic Do not elicit abnormal host anti-tumoural immunity; 
therefore used in immunocompetent mouse Tumour cell 
lines Primary human cancer 
cells or cell lines 
Require immunocompromised host, which may 
interfere with tumour-host interaction.  
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For the majority of studies, I chose to use a model of spontaneous metastasis from 
syngeneic, orthotopic B16 melanoma tumours intradermally-injected into C57Bl/6 mice.  
B16 melanoma is a well-characterized model of metastasis(Fidler, 1973; Giavazzi and 
Garofalo, 2001; Kaplan et al., 2005), and using a spontaneous model of metastasis 
enables assessment of ‘pre-metastatic’  / early metastatic changes to the bone marrow 
microenvironment occurring during the early stages of primary tumour development.  
EL4 lymphoma is also a well-characterized, widely metastatic tumour model syngeneic 
for C57Bl/6 mice(Gorer, 1950).    
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3.2. ESTABLISHING MOUSE MODELS OF METASTASIS 
  
In order to investigate the role of megakaryocytes in metastasis, I established in 
vivo mouse models of metastasis.  Three experimental systems were employed; 
spontaneous metastasis from intradermal tumours, haematogenous metastasis following 
intravascular delivery of tumour cells via the lateral tail vein, and delivery of tumour cells 
to the bone marrow by direct intrafemoral injection.  In order to be able to identify 
tumour cells within the bone marrow reliably and quantitatively, the tumour cell lines 
were transduced with retroviral vectors expressing the fluorescent markers GFP and 
mCherry (See Methods 2.1.3.).  Both B16mCherry and B16-GFP were detectable by flow 
cytometry and RT-PCR, providing a sensitive means for early detection of tumour cells 
in the bone marrow and for quantifying the metastatic burden in specific organs.  
mCherry is very bright by fluorescence microscopy, and therefore I found B16mCherry 
to be particularly suitable for identification of metastases in bone marrow, which is 
highly auto-fluorescent.  
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3.2.1. Spontaneous metastasis from intradermal (orthotopic) injection of B16 
melanoma cells in the flank 
 
For a spontaneous model of metastasis, I established a system wherein peripheral 
primary tumours were initiated by injecting B16-F10 melanoma intradermally in the right 
flank.  Following inoculation with B16 melanoma cells, primary tumours grow rapidly 
and are palpable from ~day 7-10 (Figure 3.1).  Melanoma disseminates widely to lymph 
nodes, lung, liver, bone marrow, spleen, intestine and brain, and the mice typically die 
~24-28 days following tumour injection.   
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Figure 3.1. Tumour weights following intradermal B16 melanoma injection in the 
flank on study day 0.  
50 mice were intradermally injected with B16 melanoma on study day 0 and 4-5 mice 
were sacrificed every 2-3 days.  Tumour weight (g) was measured after dissection of 
tumour.  Mean + SEM, n=4-5 per timepoint.  
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It has previously been reported by the Lyden Laboratory that metastases to lymph 
node, lung and liver are detectable ~14-18 days following tumour inoculation(Kaplan et 
al., 2005).  However, the timecourse of tumour dissemination to the bone marrow was not 
known.  Following injection of 2 x 106 B16mCherry cells in the flank, mCherry was 
detected by RNA analysis by RT-PCR of whole bone marrow cells flushed from femurs 
and tibias, with increasing mCherry expression detected 8 days after tumour inoculation 
(Figures 3.2).  Metastasis of B16mCherry cells to the bone marrow was also confirmed 
by flow cytometry, which demonstrated that an average of 5% of bone marrow cells were 
positive for mCherry in mice 22 days following tumour inoculation (Figure 3.3).   
By immunofluorescence microscopy, occasional mCherry+ cells were seen in the 
bone marrow at day 8, these were scattered throughout the bone marrow at day 15, and 
diffusely present in the bone marrow by day 24 (Figure 3.4).  These data confirmed that 
the B16mCherry tumour cell line metastasizes to bone marrow, and validated these 
techniques for detection and quantification of tumour metastasis.      
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Figure 3.2. Quantification of mCherry expression in the bone marrow of mice with 
intradermal B16mCherry melanoma by RT-PCR.   
RNA extracted from bone marrow cells flushed from femurs and tibias of mice analyzed 
by RT-PCR for expression of mCherry.  Mean + SEM fold expression calculated relative 
to β-actin, n=4-5 per timepoint. 
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Figure 3.3. Detection of metastatic B16mCherry in bone marrow of mice with day 
22 intradermal flank tumours by flow cytometry  
Bone marrow cells flushed from femurs and tibias of mice 22 days following intradermal 
inoculation with B16mCherry cells.  n=4, representative analyses shown. 
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A. Day 15       B. Day 24 
 
 
 
 
 
  
 
Figure 3.4. Detection of B16mCherry cells in the bone marrow at days 15 and day 
24 by confocal microscopy.    
mCherry-expressing B16 cells were visible in the bone marrow in increasing numbers 
from day 12 following tumour implantation.  Images captured using a Leica TCS SP5X 
confocal system mounted on a Leica DMI6000B microscope.  No image manipulation 
was performed.  n=4/5 per timepoint, representative images shown. 
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3.2.2. ‘Experimental’ model of haematogenous metastasis following tail vein 
injection of B16 melanoma cells 
 
As a direct model of haematogenous metastasis, I injected tumour cells 
intravascularly via the lateral tail vein.  Following intravenous injection of B16 
melanoma cells, mice developed extensive lung metastases (Figure 3.5) and the mice died 
at day ~15-18.  In this model, no metastases were detected in the bone marrow, liver or 
spleen by RT-PCR analysis for expression of mCherry following intravenous injection of 
B16mCherry cells.   
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A.        B.  
 
 
 
 
 
 
 
Figure 3.5. Melanoma metastases to lung 14 days after tail vein injection of 
B16mCherry cells.   
(A) Lungs were harvested 14 days following tail vein injection of B16 melanoma cells.  
Macroscopic melanoma metastases were widespread over the lung surface (black lesions 
(melanin), left image, representative images from 2 of 4 mice shown).  (B) Expression of 
mCherry in lung was quantified by RT-PCR using RNA extracted from whole R lung.  
Mean + SEM fold expression relative to β-actin, n=4. 
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3.3. CHANGES IN PLATELET SIZE AND MEGAKARYOCYTE NUMBER DURING 
THE TIMECOURSE OF PRIMARY TUMOUR GROWTH AND BONE MARROW 
METASTASIS IN THE B16 MELANOMA MODEL 
 
3.3.1. Peripheral blood count analysis during intradermal B16 melanoma tumour 
growth 
 
In order to analyze peripheral blood counts during the timecourse of tumour 
growth and metastasis, I inoculated 50 mice with B16mCherry melanoma cells and 
sacrificed 4-5 mice every 2-3 days.  Control mice were inoculated with sterile PBS on 
Day 0 and sacrificed at each timepoint alongside the tumour mice.   
 
From 15 days after tumor inoculation, mean platelet volume (MPV) was 
significantly higher in mice with B16 melanoma than in control mice, and further 
increased during the subsequent tumour timecourse (MPV: 5.2 + 0.05 vs. 7.4 + 0.7 fL; 
control mice vs. B16-injected mice days 21-24, P<0.0001, Figure 3.6).  Although there 
was no change in platelet count (Figure 3.6), the increase in MPV was suggestive of 
increased thrombopoiesis.   
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Mice with B16 melanoma also developed progressive anaemia (haemoglobin: 
14.4 + 0.1 vs. 4.5 +/- 0.7 dL; control mice vs. B16-injected mice days 21-24, P<0.0001, 
Figure 3.6) and splenomegaly due to increased splenic erythropoiesis (spleen weight: 
0.06 +/- 0.004 vs. 0.25 +/- 0.04g; control mice vs. B16-injected mice days 21-24, 
P<0.0001, Figure 3.7 & Figure 3.8).  This suggests that extravascular platelet destruction 
may have prevented thrombocytosis secondary to the increase in bone marrow 
megakaryocytes.  There was no change in white cell count (Figure 3.6) and no change in 
liver weight or evidence of extramedullary haematopoiesis in the liver (Figure 3.7).    
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Figure 3.6.  Peripheral blood counts during intradermal B16 melanoma timecourse.  
Mean platelet volume (MPV) for mice with B16 melanoma was significantly higher than 
for control mice from study day 15 (P <0.0001).  There was no change in platelet count.  
Haemoglobin was lower in mice with melanoma than control mice from day 12 
(P<0.0001).  No change in total white cell count (WBC).  n=4-5 per timepoint for mice 
with melanoma; n=10 for controls (1 per timepoint).  
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Figure 3.7.  Spleen and liver weights in control mice and mice with intradermal B16 
melanoma.   
Spleen weight was significantly higher in mice with B16 melanoma from day 15 of 
tumour growth.  Mean + SEM, n=4-5 per timepoint for mice with melanoma; n=10 for 
controls. ** P <0.02, *** P < 0.0001. No difference in liver weight was observed in mice 
with melanoma compared to control mice.   
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A. Control, 100x mag    B. B16mCherry day 22, 100x mag 
 
 
 
 
 
 
 
Figure 3.8.  Spleen histology from control mouse (A) and mouse with intradermal 
B16 melanoma (B).   
Extramedullary erythropoiesis in the spleen of mice with B16 melanoma, with 
effacement of the lymphoid follicle architecture and expansion of the red pulp and 
occasional extramedullary megakaryocytes.  H&E stained OCT-embedded frozen spleen 
sections.  
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3.3.2. Identification of megakaryocytes by TSP1 and MECA32 immunostaining of 
paraffin-embedded bone marrow sections  
 
The increase in platelet size in mice with intradermal B16 melanoma suggested 
that platelet production in the bone marrow was increased from 15 days following tumour 
injection.  Therefore, I sought to examine the histology of the bone marrow over the 
tumour timecourse.  Immunohistochemical study of the murine bone marrow vascular 
niche is challenging, as the architecture of the fragile bone marrow sinusoids is poorly 
preserved in frozen OCT bone sections.  However, I found that visualization of the 
vascular niche was significantly improved by immunostaining of paraffin-embedded 
bones, although antigen retrieval treatment was necessary to break the protein cross-links 
caused by aldehyde-based fixation and heat treatment performed during paraffin 
embedding (See Methods 2.3.3.).   
 
Using this technique, megakaryocytes were found to be highly immunoreactive 
for TSP1 and MECA32 (equivalent to CD31-PECAM in human cells.  TSP1 expression 
in the bone marrow was specifically localized to megakaryocytes and platelets and to 
endothelial sinusoids (Figure 3.9A), with weak positivity of the endosteal bone surface.   
The MECA32 antibody also enabled reliable identification and quantification of both 
bone marrow vessels and megakaryocytes (Figure 3.9B & C).  It was noted that the 
megakaryocytes localized adjacent to the blood vessels tended to display higher intensity 
staining for MECA32 as compared to the megakaryocytes in the interstitial areas (Figure 
 152 
3.9C).  This is consistent with previous reports that PECAM is required for migration of 
megakaryocytes to the bone marrow vascular niche(Dhanjal et al., 2007).     
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A. TSP1  
 
 
      
  
 
 
B. MECA32      C. MECA32 
 
Figure 3.9. TSP1 and MECA32 immunostaining of bone marrow identifies 
megakaryocytes and endothelium.   
(A) Megakaryocytes (red arrow) and endothelium (yellow arrow) are positive for TSP1. (B) 
Strong MECA32 positivity for megakaryocyte adjacent to blood vessel (red arrow), compared to 
weakly stained megakaryocyte located away from vessel (purple arrow). (C) MECA32 staining of 
endothelium (yellow arrows).  Paraffin-embedded femur sections, DAB stain (brown), 200x 
magnification. 
Figures 3.1.1c Differential 
staining of MKs with MECA32 
stain.  High intensity stain at 
sinusoid (red arrow) and lower 
intensity stain of MK not 
associated with vasculature (black 
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3.3.2.1. Increase in megakaryocyte number in mice with B16 melanoma 
 
Histological analysis of the bone marrow indicated that from 6 days following 
tumour implantation, the number of megakaryocytes was significantly higher in the bone 
marrow of mice with B16 melanoma as compared to control mice (P<0.001, Figure 3.10).  
Numbers of megakaryocytes increased further at day 10 and remained significantly 
higher in animals with late-stage B16 tumours as compared to control mice (number of 
megakaryocytes per 200x field view: 7.8 + 0.7 vs. 13.6 + 1.3; controls vs. B16-injected 
mice on day 24).   
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Figure 3.10. Number of megakaryocytes per 40x optical field view during B16 
tumour timecourse.  
The megakaryocyte count per field view was significantly higher for mice with 
intradermal B16mCherry melanoma than for control mice from study day 6 (* P < 0.05, 
** P < 0.02). n=4-5 per timepoint, 15-20 field views/femur     
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3.3.2.2. Increase in megakaryocyte size and vessel diameter in mice with B16 melanoma 
 
Megakaryocytes also appeared to be larger in size in the bone marrow of mice 
with B16 melanoma than in bone marrow from control mice.  Therefore, the maximum 
cell diameter was measured in random field view images of femur sections.  This analysis 
demonstrated that megakaryocyte size was also significantly increased in mice with B16 
melanoma (megakaryocyte size: 71.7 + 1.3 vs. 95.5 + 1.4 pixels; controls vs. Day 24 
melanoma, P<0.0001, Figure 3.11A-C).  In addition, it was noted that the mean diameter 
of MECA32+ blood vessels was significantly higher in the bone marrow of mice with 
B16 melanoma (Figure 3.11D)   
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A. Control       B. B16 melanoma day 24 
 
 
 
 
 
 
C.        D.  
 
 
 
 
Figure 3.11. (A-C) Comparison of megakaryocyte size in control mice and mice with 
intradermal B16 melanoma (D) Diameter of MECA32+ blood vessels.   
Larger megakaryocytes seen in mice with B16 melanoma.  H&E stain, paraffin-embedded bone 
marrow femur sections, 400x magnification. Mean megakaryocyte cell diameter and vessel 
diameter in control mice and mice with B16mCherry melanoma on Day 24.  16 images of random 
field views for each femur section per mouse (n=3 per group) were analyzed. n=2 per group.  
Measurments taken using ImageQ software.  Mean + SEM, *** P<0.0001 
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3.4.  CHANGES IN PERIPHERAL BLOOD COUNTS AND MEGAKARYOCYTE 
NUMBER DURING PRIMARY TUMOUR GROWTH AND METASTASIS USING THE 
EL4 LYMPHOMA MODEL  
 
EL4 tumours also grew rapidly following intradermal implantation (Figure 3.12), 
disseminating to contiguous and distant lymph nodes, lung, liver and bone marrow.  
Metastases were clearly visible in the bone marrow 18 days after tumour inoculation in 
H&E-stained sections of mouse femur/tibia (Figure 3.13).   
 
   
 
 
 
 
 
Figure 3.12. Tumour volume (length x breadth x width) following intradermal 
injection of EL4 cells on study day 0.   
Tumour volume was measured using calipers.  Mean + SEM, n=5.  
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(A) Normal Control 
 
 
 
 
 
(B) Day 19 EL4 Lymphoma (intradermal) 
 
 
 
 
 
 
Figure 3.13.  EL4 lymphoma in the bone marrow 19 days following tumour 
inoculation.   
Bone marrow sections from control mouse and mouse with day 19 intradermal flank EL4 
tumour. A monomorphic infiltrate is apparent on the right side of the field of view in the 
lower image (yellow star), with a residual megakaryocyte (arrow).  H&E stained paraffin-
embedded femurs, 200x magnification.   
  
*  
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Intravenous injection of EL4 lymphoma cells resulted in widespread metastases to 
lung, kidney, spleen, testes/ovaries, bone and bone marrow (Figure 3.14).   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14.  EL4 lymphoma metastasis to bone marrow following tail vein injection 
of EL4-GFP cells.   
(A) Representative plots of GFP+ cells in bone marrow from control mouse (left) and 
mouse 14 days following tail vein injection of EL4 cells (n=3). (B) Percentage of GFP+ 
cells in bone marrow 14 days following tail vein injection of EL4-GFP cells.  Mean + 
SEM, n=3.  
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3.4.1. Intrafemoral delivery of tumour cells 
 
In order to examine the changes to the bone marrow microenvironment during 
primary bone marrow tumourigenesis, I developed a model in which EL4 cells were 
delivered directly into the bone marrow cavity via intrafemoral injection.  Histological 
examination of the bone marrow 11 days following intrafemoral injection demonstrated 
EL4 engraftment of the femur (Figure 3.15.).  However, the intrafemoral tumour model 
was limited by the technical challenges of injection, which resulted in a proportion of the 
mice developing intraarticular / intradermal tumours around the knee joint.  Furthermore, 
histological evaluation of tumour-associated changes to the bone marrow 
microenvironment was complicated by the mechanical disruption of the bone marrow 
space as a result of the injection trauma.   
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Figure 3.15. Lymphoma engraftment of bone marrow following intrafemoral 
injection of EL4 cells.   
Diffuse infiltrate of large mononuclear monomorphic EL4 cells.  H&E stained paraffin-
embedded femur 11 days following intrafemoral injection, 100x magnification.    
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3.4.2. Full blood count analysis of mice with intradermal EL4 lymphomas 
  
There was no difference in the platelet count or platelet size in mice with early or 
late-stage EL4 tumours as compared to control mice.   Hb levels were lower in mice with 
EL4 lymphoma at day 19, although the difference was not statistically significant (Figure 
3.16).  However, mice with EL4 tumours developed an increased white cell count due to 
marked neutrophilia (white cell count: 10.3 + 1.7 vs. 27.9 + 3.5 x 109/L; controls vs. day 
19 EL4, P=0.002, Figure 3.17).  
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Figure 3.16. Peripheral blood count parameters for control mice and mice with  
intradermal EL4 lymphomas.   
No significant difference in MPV, platelet count or haemoglobin in mice with early (day 
6) or late-stage (day 19) intradermal injection of EL4 cells as compared to controls.  Total 
white cell count was significantly higher in mice with EL4 tumours (** P = 0.006).  
Mean + SEM, n=4-5 per group.  
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Similar to the B16 melanoma model, a significant increase in megakaryocytes 
was observed in mice with early EL4 tumours (megakaryocyte numbers: Controls – 27 + 
2; EL4 Day 6 – 44 + 2, P=0.0008, Figure 3.17, left graph), although the difference was 
not significant at later stages of tumour growth (megakaryocyte numbers: Controls – 11 + 
1; EL4 Day 19 – 13 + 1, P=0.25, Figure 3.17, right graph). 
  
 
                
 
 
 
 
Figure 3.17. Increased megakaryocyte numbers in mice with early (day 6) EL4 
lymphoma.   
Megakaryocyte numbers per field of view.  Of note, for this figure, identical optical field 
views were used to count control mice and tumour-animal sections at each time point 
although the optical field size varied between experiments as this was optimized 
according to the size and quality of the bone marrow sections.   
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3.5. TUMOUR-ASSOCIATED CHANGES IN THROMBOPOIETIC FACTORS  
 
To elucidate the mechanism for the increase in megakaryocyte number and 
platelet production that was observed in mice with tumours, I examined tumour, liver and 
bone marrow expression of thrombopoietic growth factors by RT-PCR, and measured the 
circulating levels of thrombopoietic growth factors by ELISA. 
 
3.5.1. Expression of thrombopoietic factors by B16 melanoma cells in vitro and in 
vivo 
B16 melanoma cells were found to express several thrombopoietic growth factors, 
including SCF, VEGF, TGFβ, and low amounts of TPO, IL6 and IL11 (Figure 3.18).  No 
expression of IL3 or bone morphogenic protein 4 (BMP4) was detected (Figure 3.18).  
The very high level of expression of VEGF was mirrored by an increase in plasma VEGF 
during tumour growth (Figure 3.19).  By contrast, there was no significant change to 
plasma SCF or TPO during the tumour timecourse (Figure 3.19 & 3.20).  However, since 
TPO synthesis occurs primarily in the liver, and to a lesser degree by bone marrow 
stroma, I also examined expression of TPO in the liver and the bone marrow during the 
B16 tumour timecourse.  As expected, levels of TPO expression in the liver were 
substantially higher (1000 fold) than in the bone marrow (Figure 3.20).  There was no 
change in expression of TPO in either liver or bone marrow in mice with melanoma as 
compared to controls (Figure 3.20).  These data suggest that tumour production of 
thrombopoietic factors, especially VEGF and SCF and also IL6, IL11 and TPO, may 
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mediate the increase in megakaryocytes during tumour growth.  Even though expression 
levels were low and changes to plasma concentrations of these factors were not detected, 
it is possible that SCF, TPO, IL6 and IL11 produced by metastatic tumour cells in the 
bone marrow may be of sufficient concentrations in the local microenvironment to affect 
megakaryopoiesis.  
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Figure 3.18. B16 cell expression of thrombopoietic and angiogenic growth factors.  
 RNA was extracted from in vitro cultured B16 melanoma cells and analyzed by RT-
PCR.  Fold expression (using β-actin as housekeeping gene). Experiment repeated 2x, 
representative data shown. [Thrombopoietin (TPO); stem cell factor (SCF); vascular 
endothelial growth factor (VEGF); transforming growth factor-β (TGFβ); bone 
morphogenic protein 4 (BMP4); interleukin (IL)].    
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 A. Plasma VEGF 
 
 
 
 
 
B. Plasma SCF 
 
 
 
 
 
 
Figure 3.19 Plasma concentration of (A) vascular endothelial growth factor (VEGF) 
and (B) stem cell factor (SCF) during B16 timecourse.   
Concentration of VEGF and SCF in control mice and mice with intradermal B16 
melanoma tumours measured by ELISA of platelet-rich plasma. Mean + SEM, n=4-5 per 
timepoint.  ** P<0.002; *** P<0.0001 compared to values for control mice.  
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 A. Plasma TPO 
 
 
 
 
 
B. Expression of TPO in bone marrow and liver 
 
 
 
 
 
Figure 3.20.  Plasma concentration of thrombopoietin (TPO) (A) and TPO 
expression in the liver (B) during B16 timecourse.   
(A) Concentration of TPO in mice with intradermal B16 melanoma measured by ELISA 
of platelet-rich plasma. (B) Expression of TPO in liver and bone marrow during B16 
timecourse.  RNA extracted from whole bone marrow cells and liver biopsies in control 
mice and mice with intradermal B16 melanoma analyzed by RT-PCR.  Mean + SEM fold 
expression relative to b-actin.  n=4-5 per timepoint.   
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3.5.2. EL4 lymphoma expression of thrombopoietic factors 
 
 EL4 cells expressed a similar profile of thrombopoietic factors to B16 cells, 
although, with the exception of TGFβ, expression of these factors was markedly lower in 
EL4 cells than in B16 cells (Figure 3.21).   
 
 
 
 
 
 
 
 
Figure 3.21. EL4 cell expression of thrombopoietic and angiogenic growth factors.  
RNA was extracted from in vitro cultured EL4 lymphoma cells and analyzed by RT-
PCR.  Fold expression (using β-actin as housekeeping gene). [Thrombopoietin (TPO); 
stem cell factor (SCF); vascular endothelial growth factor (VEGF); transforming growth 
factor-β (TGFβ); bone morphogenic protein 4 (BMP4); interleukin (IL)].    
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3.5.3. Decreased megakaryocyte-derived PF4 in bone marrow and plasma 
 
  Since megakaryocyte-derived PF4 is an autocrine negative regulator of 
megakaryopoiesis(Lambert et al., 2007),  I measured plasma PF4 concentration and PF4 
expression in the bone marrow.  Expression of PF4 was significantly reduced in the bone 
marrow of mice with melanoma (Figure 3.22A) and that this was mirrored by decreased 
plasma PF4 concentrations (Figure 3.22B).   This suggests that a reduction in negative 
regulation of megakaryopoiesis by PF4 might mediate or contribute to the increased 
megakaryocyte numbers in mice with tumours.  
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A. Bone marrow PF4 expression 
 
 
 
 
 
B. Plasma PF4 concentration 
 
 
 
 
 
Figure 3.22. Expression of platelet factor 4 (PF4) in bone marrow (A) and plasma 
PF4 concentration (B) during B16 timecourse.   
RNA extracted from bone marrow cells flushed from femurs & tibias of control mice and 
mice with intradermal B16 melanoma analyzed by RT-PCR. Fold expression relative to 
β-actin.  (B) Plasma PF4 concentration during B16 timecourse.  ELISA of platelet-rich 
plasma, mean + SEM, n=4-5 per timepoint. * P<0.05 compared to values for control 
mice.  
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 3.6.  CHARACTERIZING THE MEGAKARYOCYTE-VASCULAR NICHE IN 
NORMAL PHYSIOLOGY AND IN METASTASIS  
 
3.6.1. Histology of the megakaryocyte-vascular-tumour niche  
  
Examining the histology of the bone marrow, I found that nearly all the vascular 
sinusoids were surrounded by one or more megakaryocytes, and that megakaryocytes 
were almost exclusively located adjacent to bone marrow vessels (Figures 3.11A & B and 
3.23).  Megakaryocytes frequently appeared to be continuous with the vessel wall 
suggesting that they tightly abutted the endothelial cells, and proplatelet protrusions were 
visualized extending in to the vessel lumen (Figure 3.23).  These data suggest that 
megakaryocytes are integral components of the bone marrow vascular niche, and are 
appropriately positioned to influence the homing of cells to the bone marrow.    
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A. 
 
 
 
 
 
B.           C.  
 
Figure 3.23. Histology of the megakaryocyte –vascular niche.   
(A) Anatomical association between sinusoids and megakaryocytes.  Bone marrow 
vessels were nearly always seen surrounded by one or more megakaryocytes.  Yellow 
arrow indicates megakaryocyte extending proplatelet protrusions into the vessel lumen. 
400x magnification. (B) Cluster of megakaryocytes in the vascular niche. 1000x 
magnification. (C) Large, polyploid megakaryocyte closely associated with the 
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endothelial cell wall (black arrow) 1000x magnification.  H&E stain, paraffin-embedded 
femurs.  
 
I next examined the localization of metastatic B16mCherry melanoma cells in the 
bone marrow by light microscopy and confocal imaging.  For immunofluorescent 
imaging, megakaryocytes were identified by their specific expression of citrulline(Kopp 
et al., 2006).  B16mCherry cells were observed adjacent to megakaryocytes in the bone 
marrow vascular niche (Figure 3.24), consistent with a role for megakaryocytes in 
mediating the engraftment of tumour cells to the bone marrow.     
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A.  
   
 
 
 
 
 
 
 
 
 
 
Figure 3.24. Metastatic B16mCherry cells adjacent to megakaryocytes in the bone 
marrow vascular niche.   
(A) H&E section of femur showing metastatic B16 melanoma cell (yellow arrow) 
adjacent to megakaryocyte in the vascular niche. 400x magnification. (B) Confocal 
images of mCherry-tagged B16 cells (red) adjacent to citrulline-FITC+ megakaryocytes 
(green) in mouse femur.  Blue=DAPI (nuclei). 
B. 
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3.6.2. Functional role of megakaryocytes at the vascular niche 
 
 Given the anatomical association of megakaryocytes and the bone marrow 
sinusoidal endothelium, I next sought to examine the functional contribution of 
megakaryocytes to the bone marrow vascular niche using the TPO-/- mouse model. TPO-/- 
mice have ~10% of the normal number of megakaryocytes and platelets (Platelet counts: 
1462 + 38 vs. 211 + 15 x 109/L; wild-type vs. TPO-/- mice, P<0.0001, Figure 3.25).  
 
 
 
 
 
 
 
Figure 3.25. Platelet count and size in TPO-/- mice.   
Platelet count in TPO-/- mice is around 10% of wild type values (P < 0.0001), but there is 
no difference in platelet size (n=4).  
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3.6.2.1. Expression of megakaryocyte-derived angiomodulatory factors in TPO-/- and wild 
type one marrow  
 
  To gain insight into the proportion of angiomodulatory growth factors in the bone 
marrow microenvironment that derives from megakaryocytes, I measured the relative 
expression of pro- and antiangiogenic factors known to be synthesized by 
megakaryocytes, VEGF, TGFβ, TSP1, PF4 and MMP9, in RNA extracted from bone 
marrow of megakaryocyte-deficient, TPO-/- mice and wild type mice (Figure 3.26).   
 
Expression of TSP1 was reduced by >90% (P < 0.0001, Figure 3.26) in bone 
marrow cells from TPO-/- mice as compared to wild type mice, indicating that bone 
marrow TSP1 is almost entirely produced by megakaryocytes.  Expression of TGFβ, 
MMP-9 and PF4 were reduced by >70% suggesting that these factors are also 
predominantly megakaryocyte-derived (P < 0.0001, Figure 3.26).  Expression of VEGF 
was reduced by only ~40%, consistent with significant MK-independent VEGF synthesis.  
Expression of SDF1 was not significantly different from wild type mice (Figure 3.26), in 
keeping with previous reports that SDF1 is not synthesized by megakaryocytes but 
absorbed from the microenvironment(Kopp et al., 2006).  Together these data suggest 
that the reduced numbers of megakaryocytes in TPO-/- mice results in an overall 
deficiency of angiomodulatory factors.   
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Figure 3.26.  Expression of angiogenic regulatory factors in wild type and TPO-/- 
bone marrow.   
RNA extracted from bone marrow cells flushed from femurs/tibias from age/sex-matched 
wild type and TPO-/- mice was analyzed by RT-PCR.  Except for SDF1, expression was 
significantly lower in TPO-/- bone marrow.  Mean + SEM fold expression relative to β-
actin, n=5 per group.   *** P < 0.0001; ** P < 0.02.      
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3.6.2.2. Histological appearance of the bone marrow vasculature in TPO-/- and wild type 
mice: comparison of vessel diameter 
 
Given the reduced expression of angiomodulatory factors in the bone marrow of 
TPO-/- mice, I examined the vascularity of the bone marrow by immunohistochemisty, 
using the panendothelial cell antigen MECA32 to identify bone marrow endothelium.     
 
  The number and size of MECA32+ bone marrow vessels in femur sections from 
TPO-/- mice were compared with wild type mice.  While there was no difference in vessel 
frequency, the vessels in TPO-/- bone marrow were significantly larger in diameter and 
appeared to be more tortuous (Figure 3.27).  This suggests that megakaryocyte-derived 
angioregulatory factors are important for regulating and maintaining the integrity of the 
bone marrow vascular niche.   
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A. Wild type      B. TPO-/-  
 
C.  
 
 
 
 
 
Figure 3.27. MECA32+ bone marrow vessels in wild type and TPO-/- bone marrow. 
 Comparing (A) wild type and (B) TPO-/- mice illustrates an increased vessel diameter in 
TPO-/- bone marrow. DAB staining of paraffin-embedded femur sections, 200x mag. (C) 
Mean maximum diameter of MECA32+ bone marrow vessels in wild type and TPO-/- 
mice.  Mean + SEM, n=3.  * P=0.01  
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3.6.3. Expression of megakaryocyte-derived angiogenic/oncogenic growth factors in 
the bone marrow of mice with intradermal B16 melanoma.  
 
Comparing gene expression in bone marrow from megakaryocyte-deficient, TPO-
/- mice with wild type bone marrow indicated that a large proportion (70 – 90%) of the 
angiogenic regulatory factors VEGF, TGFβ, PF4, and TSP1 expressed in the bone 
marrow is produced by megakaryocytes (Section 3.6.2.1).  I next sought to examine 
whether expression levels of these factors changed over the timecourse of tumour growth 
in the B16 melanoma model.   
 
For these experiments, all mice received intradermal injections of B16mCherry 
melanoma or PBS control on study day 0, and 4-5 tumour mice plus controls were 
sacrificed at each study timepoint.  Bone marrow from control mice (no tumour), mice 
with early metastatic/premetastatic tumours (day 15) and mice with late-stage/metastatic 
(day 21-24) B16 melanoma tumours were compared.   
 
There was a significant increase in expression of the pro-angiogenic factors 
VEGF (1.4 fold higher in late stage B16 melanoma than controls) and TGFβ (2.2 fold 
higher, Figure 3.28).  Meanwhile, expression of PF4 was significantly decreased (0.2x 
control levels, Figure 3.28).  Of note, there was no significant change in expression of 
TSP1 during the B16 melanona timecourse.       
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Figure 3.28. Expression of megakaryocyte-derived angiogenic / oncogenic factors 
during the timecourse of B16 melanoma growth.   
RNA was extracted from bone marrow cells flushed from femurs/tibias of control mice 
(no tumour), mice with premetastatic/early metastatic tumours (day 15) and mice with 
late-stage/metastatic tumours (days 21-24).  Mean + SEM fold expression relative to b-
actin is shown, n=4-5 per timepoint. * P < 0.05.             
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3.6.4. Tumour growth & metastasis is retarded in TPO-/- mice  
  
To further characterize the functional contribution of megakaryocytes to 
metastasis, I compared growth and metastasis (‘spontaneous’ and ‘experimental’) in 
TPO-/- mice with wild type mice using the B16 melanoma model.   
 
3.6.4.1. Comparison of spontaneous metastasis from intradermal melanoma in TPO-/- 
and wild type mice  
 
TPO-/- and wild type mice were orthotopcially-implanted with B16 melanoma in 
the flank.  The rate of tumor growth, tumor volume and tumor metastasis to lung and 
bone marrow were all significantly reduced in TPO-/- mice compared to wild type mice 
(Figure 3.29).  No mCherry+ cells were seen in the bone marrow of TPO-/- mice with 
B16mCherry tumours.  
 186 
 
 
 
 
 
 
 
 
 
 
Figure 3.29.  B16 melanoma tumour growth and metastasis in TPO-/- and wild type 
mice.   
Wild type and TPO-/- mice were intradermally injected with B16mCherry on Study Day 
0.  (A) Tumour volume (length x width x breadth) measured every 2 days. The rate of 
tumour growth was markedly reduced in TPO-/- mice (n=4). (B) Tumour mass (g) on 
study day 22 (n=3).  Metastasis to (C) bone marrow and (D) lung 22 days following 
intradermal tumour injection was reduced in TPO-/- mice (n=2).  RNA extracted from 
lung and bone marrow cells flushed from femurs/tibias and analyzed by RT-PCR for 
mCherry.  Fold expression relative to β-actin. 
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3.6.4.2. Comparison of haematogenous metastasis following tumour injection via the tail 
vein in TPO-/- and wild type mice  
 
Since primary tumour growth was retarded in the TPO-/- mice, I next sought to 
confirm that the reduction in metastasis in the TPO-/- mice was due to reduced metastatic 
efficiency rather than due to the smaller primary tumours.  I therefore used the 
‘experimental’ metastasis model wherein B16 cells are injected into the tail vein.  This 
model results in metastasis to lung but not to other organs (See Section 3.2.2). As shown 
in Figure 3.30, intravascular delivery of tumour cells resulted in a marked reduction in 
the number and size of lung metastases in TPO-/- mice as compared to wild type mice 
(Figure 3.30).  
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A.       B.  
 
 
 
 
 
 
 
Figure 3.30. Comparison of haematogenous metastasis following tumour injection 
via the tail vein in wild type and TPO-/- mice.   
(A) There were significantly fewer macroscopic melanoma metastases in lungs of  TPO-/- 
mice as compared to wild type mice 14 days after tail vein injection of B16mCherry 
melanoma cells.  (B) mCherry expression in lung 14 days following tail vein injection of 
B16mCherry cells.  RNA extracted from whole R lung and analyzed by RT-PCR.  Mean 
+ SEM fold expression relative to β-actin. N=2-3 per group 
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3.7. DISCUSSION 
 
3.7.1. Establishing mouse models of metastasis  
 
To investigate the role of megakaryocytes in the homing and engraftment of 
tumour cells to the bone marrow in mouse models of metastasis I used a number of 
mouse models.  The most useful model, which I used for the majority of studies, was the 
spontaneous model of bone marrow metastasis in which mice were injected intradermally 
with B16 melanoma.  Using this model, I observed a progressive increase in platelet size 
and in the size and number of megakaryocytes in the bone marrow; tumour cells were 
also seen in close association with megakaryocytes in the megakaryocyte-vascular niche.  
By contrast, direct intravascular delivery of B16 cells via the tail vein led to diffuse lung 
metastases, but no bone marrow metastases presumably because tumour cells lodged in 
the lung and the mice died from pulmonary metastases prior to the development of 
metastases elsewhere.  I therefore used the B16 tail vein injection model to examine 
metastatic efficiency in terms of tumour cell adhesion to the microvasculature, tissue 
invasion and tumourigenesis in the metastatic site.   
 
Since these data suggested that megakaryocytes played a role in tumour cell 
growth, I investigated this further using TPO-/- mice to provide a model of reduced 
megakaryocytes.  Tumour growth and metastasis were substantially retarded in 
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megakaryocyte-deficient, TPO-/- mice with intradermal tumours as compared to wild type 
mice; lung metastasis was also lower in TPO-/- mice following tail vein injection of 
tumour cells.  The TPO-/- model therefore strongly supported a role for megakaryocytes in 
tumour growth and metastasis.  Of note, however, TPO-/- mice also have reduced 
angiogenesis(Amano et al., 2005), which is likely to have contributed to the reduced rate 
of intradermal tumour growth.   
 
 In addition to B16 melanoma, I also initially studied the EL4 lymphoma model.  
However, I found that the EL4 lymphoma was associated with a marked neutrophilia and 
although bone marrow metastasis did occur, the predominant feature was bulky lymph 
node metastases suggesting that the route of tumour dissemination was predominantly 
lymphatic rather than haematogenous.  Therefore, I decided to focus on the B16 
melanoma model for subsequent in vitro and in vivo experiments.    
 
 
3.7.2. Changes in platelet size and MK number during B16 tumour growth and 
metastasis  
 
The increased MPV observed could either be due to the production of abnormal 
platelets (dys-megakaryopoiesis or -thromboopoiesis) or to the prouction of an increased 
number of younger, larger platelets and hence a marker of increased thrombopoiesis. 
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Megakaryocytes were also larger in the B16 tumour model.  However, megakaryocyte 
morphology was otherwise normal and there were no other features of dyshaemopoiesis. 
In addition, B16-injected mice all developed progressive splenomegaly due to markedly 
increased erythropoiesis secondary to severe anaemia. Taken together (the lack of 
dyshaemopoiesis plus splenomegaly) suggest that the failure to observe an increase in 
platelet number despite increased MPV is because of the hypersplenism secondary to the 
splenomegaly.   
 
 
3.7.3 Tumour-associated changes in thrombopoietic factors 
 
To determine whether the increase in megakaryocyte number and MPV was due 
to tumour production of thrombopoietic factors I measured the production of 
thrombopoietic factors by B16 cells before and after co-culture with megakaryocytes. 
B16 cells were found to express the thrombopoietic factors VEGF, SCF, IL6 and IL11 
suggesting that tumour-derived cytokines are responsible, at least in part for the increase 
in megakaryocytes during tumour progression.  Consistent with this, expression of VEGF 
and TGFβ in the bone marrow increased during tumour growth and metastasis. By 
contrast, there was no change in liver or bone marrow TPO expression suggesting that 
TPO is not involved in the increase in tumour-associated megakaryopoiesis. Interestingly, 
expression of PF4 expression decreased during tumour progression, consistent with 
decreased autocrine negative regulation of megakaryopoiesis.   
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3.7.4. Characterizing the megakaryocyte-vascular niche in normal physiology and in 
metastasis 
 
 The anatomical association of megakaryocytes with the bone marrow sinusoidal 
endothelium suggested they may be functionally important in regulating the vascular 
niche.  This observation was strengthened by the finding that expression of the 
angiogenic regulatory factors VEGF, TGFβ, TSP1 and PF4 was substantially reduced in 
megakaryocyte deficient, TPO-/- bone marrow.  Furthermore, the increase in VEGF and 
TGFβ, decrease in PF4, and no change in TSP1 expression in mice with B16 melanoma 
suggested that megakaryocyte expression of these factors is differentially regulated, and 
influenced by tumour-derived factors.    
 
 Metastatic B16 melanoma cells were detected in the bone marrow from day 8 
following tumour implantation by RT-PCR.  Examining histological femur sections for 
mCherry fluorescence revealed occasional tumour cells at day 8, scattered mCherry+ cells 
at day 15, and diffuse cellular infiltrates by day 24.  B16 cells were seen in 
megakaryocytes-vascular niches, consistent with this being an area of homing and bone 
marrow engraftment.  No B16 cells were seen in the bone marrow of TPO-/- mice with 
melanoma.   
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3.7.5. Tumour growth and metastasis is retarded in TPO-/- mice  
 
The reduced tumour growth and metastasis in TPO-/- mice suggested that the 
TPO-megakaryocyte-platelet axis is functionally important for tumourigenesis and 
metastasis.  Lower metastatic engraftment of the lung were seen in TPO-/- mice following 
tail vein injection of tumour cells as well as in mice with intradermal tumours, indicating 
that the role of megakaryocytes and platelets in metastasis is not limited to factors 
affecting angiogenic growth of the primary tumour.   
 
One limitation of using the TPO-/- mouse strain as a model of megakaryocyte 
deficiency is that other cell types in addition to megakaryocytes, in particular 
haemopoietic stem/progenitor cells, also express TPO receptors(Qian et al., 2007; 
Yoshihara et al., 2007) and therefore other abnormalities of bone marrow haemopoiesis 
and/or angiopoiesis (in addition to the deficiency of megakaryocytes) may have 
contributed to the results observed.  Furthermore, the specific contribution of 
megakaryocytes versus that of platelets to metastasis could not be studied using this 
model.  One approach to address this issue would have been to administer antiplatelet 
antibody treatment to wild type mice, or platelet transfusions to TPO-/- mice.  However, 
these models would have other limitations, for example that antiplatelet antibody 
treatment may effect megakaryocytes as well as platelets, and that the half-life of 
transfused platelets is very short therefore maintaining sufficient platelet counts 
throughout the duration of tumour growth may not have been feasible.   
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3.7.6 Conclusion 
 
 These experiments suggest that megakaryocytes influence the dynamics of bone 
marrow vascular niche in normal physiology and in metastasis.  B16 melanoma growth 
was associated with an increase in megakarocyte numbers and an alteration in expression 
of megakaryocyte-derived angiogenic / oncogenic factors in the bone marrow.  The 
mechanisms of tumour-megakaryocyte interactions were therefore further investigated in 
the work described in Chapter 4.   
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CHAPTER 4. MECHANISMS OF MEGAKARYOCYTE-TUMOUR CELL 
INTERACTIONS: IN VITRO STUDIES 
 
4.1. INTRODUCTION 
 
In order to metastasize, cells of the primary tumour must complete a complex 
series of steps including induction of tumour angiogenesis, local tissue invasion, 
intravasation and survival in the circulation(Chambers et al., 2002).  Circulating tumour 
cells must then home to receptive tissues in distant organs where they arrest, invade and 
initiate secondary tumour growths(Chambers et al., 2002).   
 
Several of these steps can be modeled in vitro.  In the first part of my project 
discussed in Chapter 3, I examined the in vivo evidence that megakaryocytes functionally 
contribute to the vascular niche in the bone marrow and promote metastasis to the bone 
marrow.  In this part of my project, I sought to examine the underlying mechanisms by 
which interactions between megakaryocytes and tumour cells may promote homing and 
engraftment of tumour cells to vascular niches in the bone marrow, and to explore 
whether ‘cross-talk’ between tumour cells and megakaryocytes in the vascular niche may 
increase metastasis.   
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I therefore examined the effects of megakaryocyte-conditioned medium (MCM) 
on tumour cells on chemotaxis and proliferation of tumour cells in vitro.  Subsequently, I 
studied the consequences of tumour-megakaryocyte coculture on the metastatic 
phenotype of tumour cells and also on megakaryocyte production of key proteins 
involved in the regulation of angiogenesis and particularly in malignancy.  
 
In order to do this, I first established a system for megakaryocyte culture from 
murine bone marrow and used this system to generate MCM and to examine the 
angiogenic properties of megakaryocytes by confocal microscopy and by analysis of gene 
expression by RT-PCR.   Protocols for studying tumour cell migration and proliferation, 
and a megakaryocyte-tumour cell coculture system were also established.   
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4.2. DEVELOPING SYSTEMS FOR IN VITRO STUDY OF MEGAKARYOCYTES  
 
4.2.1. Determining the most favourable conditions for in vitro culture of 
megakaryocytes from murine bone marrow 
 
To develop serum-free conditions for in vitro culture of megakaryocytes, I 
performed optimization experiments to determine the most favourable conditions for in 
vitro culture of megakaryocytes.  Bone marrow cells were flushed from femurs and tibias 
of 6-10 week old mice; the typical cell yield was 1 – 2 x 107 nucleated cells per femur 
and 0.5 – 1 x 107 cells per tibia (i.e. up to 6 x 107 cells were obtained per mouse using 
both femurs and tibias).  
 
Optimization experiments using different combinations of thrombopoietic 
cytokines were performed.  This demonstrated that the highest purity and yield of 
megakaryocytes was obtained using TPO at 50ng/ml together with SCF at 20ng/ml 
without addition of IL3, IL6 or IL11 (as these cytokines stimulated the growth of non-
megakaryocytic and endothelial-like cells (Figure 4.1).  I found that higher purity cultures 
were obtained by selecting for lineage-negative haematopoietic stem/progenitor cells 
prior to starting the culture rather than using whole (unselected) bone marrow cells 
(Figure 4.1).  Following depletion of cells expressing lineage markers (See Methods 
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2.4.1.), the typical yield of lineage-negative cells was between 3-7% of the starting 
number of whole bone marrow cells.     
 
Following 72 hours of culture, mature megakaryocytes could be further enriched 
by applying the culture to a 1% / 3% BSA gradient for 40 minutes at standing gravity 
(see Methods 2.4.2).  As predominantly mature megakaryocytes are the only cells dense 
enough to fall through to the higher concentration of BSA, these cells could be isolated 
by aspirating the column leaving only the lower 2ml in the falcon tube.  Using this 
approach, a culture of > 80% CD41+ megakaryocytes was achieved (Figure 4.2).   This 
system resulted in a relatively pure culture of large, polyploid megakaryocytes after 72 
hours of culture and proplatelet formation that increased over the subsequent 48 hours, 
with apoptosis occurring by day 7 (Figure 4.3).   
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A. No added cytokines    B. Whole bone marrow +TPO+  
IL3+IL6+IL11 
 
 
Figure 4.1. Optimization experiments to determine the most favourable conditions 
for in vitro culture of megakaryocytes.  
(A) Minimal cellular expansion without addition of cytokines.  Few surviving cells are 
seen.  (B). Many non-megakaryocytic cells and endothelial-like cells (red arrow) were 
evident in a culture system using whole (unselected) bone marrow supplemented with 
TPO, IL3, IL6 and IL11.  
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Figure 4.2. Flow cytometry of megakaryocyte culture for CD41 following 
enrichment over a BSA gradient.   
Enrichment of lineage-negative cells after 72 hours of culture with TPO and SCF over a 
BSA gradient results in a culture of  > 80% CD41+ platelet-producing megakaryocytes, as 
evident by flow cytometric analysis and direct microscopy (Figure 4.3).  Blank = no 
antibody control.   
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A. 72 hrs (prior to BSA enrichment)          B. After BSA enrichment at 72 hrs  
 
 
 
 
 
 C.       D.  
 
 
 
 
 
E.       F.  
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Figure 4.3. Differentiation of megakaryocytes from lineage-negative cells with TPO 
and SCF.   
(A) At 48 hours, scattered large megakaryocyte progenitors are visible; these increase in 
size and abundance by 72 hours.  100x magnification. (B) A relatively pure population of 
large, polyploid cells displaying proplatelet formation is obtained following enrichment 
over a BSA gradient. 100x magnification. (C-E) Proplatelet formation by mature in vitro 
cultured megakaryocytes enriched by BSA gradient at >72 hours of culture.  600x 
magnification. (F) Cellular apoptosis at culture day 5-7.  Megakaryocytes start to undergo 
cellular apoptosis from day 6 of culture, as evident by their irregular shapes and 
contracted cell membranes (yellow arrows).  Phase contrast images captured using a 
Nikon Eclipse TE 2000-U inverted microscope with a CoolSnap camera,  
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4.2.2. Imaging the content of angiogenic regulatory molecules in in vitro cultured 
megakaryocytes by confocal microscopy 
 
 In order to confirm the production and storage of angiogenic regulatory factors by 
in vitro cultured megakaryocytes, I performed immunocytochemical staining and 
confocal microscopy using antibodies against VEGF and TSP1.   
 
Both VEGF and TSP1 were found to have a punctate pattern of staining, 
indicating that they are stored within intracellular granules (Figure 4.4).  The majority of 
megakaryocytes displayed a peripheral rim of TSP1 in addition to intracellular granule 
stores.  Fixation with 4% PFA prior to harvesting the cells from culture confirmed that 
the peripheral pattern of TSP1 staining was not due to “handling activation”.   
 
By reconstructing a 3D image from z-stacks of images taken at different focus 
depths, it was apparent that the VEGF (FITC, green) and TSP1 (Cy1, red) granules were 
not co-localized but that proangiogenic (VEGF) and antiangiogenic (TSP1) factors 
appeared to be stored in separate granules within the cell (3D video reconstruction 
images not shown).     
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Figure 4.4. Confocal imaging of megakaryocytes cultured in vitro from lineage-
negative wild-type bone marrow cells stimulated with TPO and SCF.   
Cells were fixed with 4% PFA, cytospun onto glass slides and stained with VEGF-FITC 
(= green) and TSP1-Cy3 (= red).  Slides were mounted using DAPI to identify the nuclei 
(blue).  Images captured using a Nikon D-Eclipse CIsi confocal system.   
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4.3. THE EFFECT OF MEGAKARYOCYTE-CONDITIONED MEDIUM (MCM) ON 
TUMOUR CELL CHEMOTAXIS 
 
 Megakaryocytes isolated from 72-hour cultures of lineage-negative bone marrow 
cells from wild type mice were re-suspended in serum-free DMEM with 50ng/ml TPO.  
After 24 hours, the megakaryocyte culture was centrifuged and the MCM supernatant 
harvested.   
 
4.3.1. MCM is chemotactic for B16 melanoma cells  
 
I initially examined the chemotactic effect of MCM for tumour cells using 
Costar® transwell migration chambers.  These experiments showed that both B16 
melanoma and EL4 lymphoma cells migrated towards MCM (Figure 4.5).  However, I 
found that the Costar transwells were not ideal for these experiments, as a relatively large 
volume (600µl) of MCM was required for each well, limiting the number of technical 
replicates.  Furthermore, accurate quantification of the number of migrated cells in the 
lower chamber was difficult as B16 cells frequently remained adherent to the underside 
of the membrane or the bottom well following migration through the pores of the inserts.  
Therefore, I chose to use the Neuroprobe Disposable Chemotaxis System for subsequent 
experiments.  
 
 209 
 
 
 
 
 
 
 
 
Figure 4.5. Effect of MCM on migration of B16 tumour cells.   
Either serum-free DMEM (SFM) or megakaryocyte-conditioned medium (MCM) was 
plated in the lower chambers of a CoStar Transwell Migration chambers.  B16 cells were 
plated in the chamber above, separated by a semi-permeable membrane with 12µm pores.  
After incubation for 4 hours, the medium in the bottom chamber was harvested and 
adherent cells removed using trypsin.  Mean + SEM for 2-6 technical replicates per 
condition.  P = 0.1.  
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4.3.1.1. The chemotactic effect of MCM for B16 cells is mediated by pertussis toxin-
sensitive chemoreceptors 
 
 To investigate the molecular pathway underlying by the chemoattraction of MCM 
for B16 cells, I pre-incubated the B16 cells with pertussis toxin (PTX) for 30 minutes 
prior to the chemotaxis assay to determine whether the the migration of B16 cells towards 
MCM was mediated by G-protein linked chemokine receptors.  PTX uncouples the α-
subunit of the Gi (inhibitory) protein from its receptor, preventing signal 
transduction(Simon et al., 1991).  These studies demonstrated that MCM-induced 
chemotaxis of B16 cells was mediated by PTX-sensitive Gi-protein linked chemokine 
receptors (Figure 4.6).    
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A. SFM     B. MCM 
 
 
 
 
C.  
 
 
 
 
Figure 4.6. Migration of B16 cells towards either serum free medium (A, SFM) or 
megakaryocyte-conditioned medium (B, MCM).   
The underside of the semi-permeable membrane was removed and stained with DAPI 
(blue) to identify migrated cells.  Images captured using a Nikon Eclipse TE 2000-U 
inverted microscope with a CoolSnap camera, 100x magnification. (C) Migrated B16 
cells were quantified using Photoshop software to select for blue pixels.   Migration of 
B16 cells towards MCM was inhibited by pertussis toxin (PTX). Mean + SEM, n=8 per 
condition. Representative experiment shown, experiment repeated 3x.  * P=0.04; ** 
P=0.0099.    
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4.3.1.2. Chemotaxis of B16 melanoma cells towards MCM is abrogated if MCM is 
generated from TSP1-/- mice 
 
 It has previously been reported that TSP1 induces migration of vascular smooth 
muscle cells via Gi protein signaling.  Given that TSP1 is produced in abundance by 
megakaryocytes (Results Sections 3.5.2.1 and 4.5.2), I cultured megakaryocytes from 
lineage-negative cells harvested from femurs and tibias of TSP1-/- mice to generate TSP1-
deficient MCM.  Migration of B16 cells towards TSP-deficient MCM was significantly 
reduced as compared to normal MCM (Figure 4.7).  These data suggest that 
megakaryocyte-derived factors, in particular TSP1, may be important mediators of the 
homing of tumour cells to megakaryocyte-vascular niches in the bone marrow.   
 
 It has previously been reported that the SDF1-CXCR4 axis is important in the 
homing of physiological haematopoietic cells and CXCR4+ tumour cells to the bone 
marrow.  Therefore, B16 expression of CXCR4 was examined by RT-PCR.  However, no 
expression of CXCR4 was detected.   
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Figure 4.7.  Chemotactic effect of TSP1-deficient MCM for B16 cells.  
Migration of B16 cells towards MCM generated from megakaryocytes cultured from 
lineage-negative bone marrow of TSP-/- mice (TSP-- MCM) was significantly lower than 
for MCM from lineage-negative bone marrow of wild type mice.  * P = 0.05.  
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4.4.  THE EFFECT OF MCM ON TUMOUR CELL PROLIFERATION IN VITRO 
 
4.4.1. Establishing a system for quantification of tumour cell proliferation  
 
In order to examine whether megakaryocyte-derived factors could support tumour 
cell proliferation, I used the CellTitre96® MTS assay (See Methods 2.1.2), first 
performing optimization experiments to maximize the sensitivity of the assay.  Serial 
dilutions of tumour cells were plated in a 96-well plate, the MTS solution added and 
following a 2-hour incubation, absorbance at 490nm was read using a 96-well plate 
reader (Figure 4.8).  As shown in Figure 4.8 the assay was most sensitive for detecting 
changes in B16 cell number over the range 4,000-20,000, and therefore I chose 5000 
cells/well as the most appropriate starting cell number per well for proliferation assays 
using the B16 melanoma cell line.   
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Figure 4.8. Calculating correct starting number of B16 cells per well to maximize 
sensitivity of MTS proliferation assay.   
This serial dilution curve indicates that the assay is most sensitive to changes in B16 cell 
number over the range 4000-20,000 cells per well.  Therefore, 5000 cells were plated in 
each well for cell proliferation experiments.   
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 4.4.2. MCM induced the proliferation of B16 melanoma cells in vitro 
 
To examine the effect of MCM on B16 proliferation, 5000 B16 cells per well of a 
96-well plate were cultured in DMEM medium with no added serum (SFM) overnight to 
synchronize the cells in G0 phase.  The following morning, either 50% SFM or 50% 
megakaryocyte-conditioned SFM (MCM) was added, and the total cell number was 
quantified using the MTS assay 24-30 hours later.  These experiments demonstrated that 
B16 cells supplemented with MCM proliferated significantly faster than control cells 
cultured in SFM alone (P<0.001, Figure 4.9) and suggest that megakaryocyte-derived 
soluble factors are able to support the proliferation of tumour cells.   
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Figure 4.9. Effect of megakaryocyte-conditioned medium (MCM) on proliferation of 
B16 cells.   
B16 cells supplemented with MCM proliferated significantly faster than cells plated in 
DMEM medium with no added serum (SFM) alone.  *** P-0.0007. Cell number 24 hours 
after addition of MCM or SFM quantified using CellTitre 96 Aqueous Proliferation 
(MTS) assay (absorbance reading at 490nm).  Mean +/- SEM of 8 technical replicates / 
condition, representative data of shown (experiment repeated > 3 times).   
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4.4.2.1. Effect of pertussis toxin on MCM-induced B16 cell proliferation 
 
To examine whether the effect of MCM on B16 cell proliferation was mediated 
by G-protein-linked chemoreceptors, B16 cells that had been serum-starved overnight 
were treated with Pertussis toxin (PTx) at 200ng/ml or PBS for 30 mins.  B16 ells were 
washed, MCM or control medium was added, and the cells left for a further 30 hours 
before measuring cell proliferation using the MTS Aqueous proliferation assay.  PTX 
inhibited MCM-induced proliferation, although this did not achieve statistical 
significance (P = 0.057).   
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Figure 4.10. Effect of pre-treating B16 cells with pertussis toxin (PTX) on MCM-
induced B16 cell proliferation.   
Equal numbers of serum-starved B16 cells were treated with pertussis toxin (PTx) at 
200ng/ml or PBS for 30 mins prior to addition of MCM or SFM.  Total cell number was 
quantified after 30 hours using the MTS proliferation assay (absorbance reading at 
490nm).  There was a strong trend towards PTX inhibiting MCM-induced proliferation 
(P = 0.057). *P=0.01.  Mean + SEM for 6 technical replicates.   
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4.4.2.2. Effect of PF4 on B16 cell proliferation 
 
To examine the effect of PF4 on B16 proliferation, recombinant murine PF4 
(15µg/ml), MCM, or SFM was added to serum-starved B16 cells in a 96-well plate (5000 
cells/well).  The total cell number/well was quantified 24 hours later using the MTS assay 
(absorbance at 490nm).  There was no direct effect of PF4 on B16 cell proliferation 
(Figure 4.11).  
 
 
 
 
 
 
 
Figure 4.11. Effect of platelet factor 4 (PF4) on B16 cell proliferation.   
Equal numbers of serum-starved B16 cells were supplemented with recombinant murine 
PF4 (15µg/ml), MCM, or SFM for 24 hours after which cell number was quantified using 
the MTS assay (absorbance reading at 490nm).  No effect of PF4 on B16 cell 
proliferation was observed.  **P = 0.004. Mean + SEM for 4 technical replicates per 
condition.     
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4.5. PRE-TREATMENT OF B16 CELLS WITH MCM PRIOR TO TAIL VEIN INJECTION 
ENHANCED METASTATIC ENGRAFTMENT 
 
I next sought to explore whether localization of tumour cells in the 
megakaryocyte-vascular niche may enhance their malignant phenotype.  I therefore 
treated GFP- or mCherry-labelled B16 cells with MCM or control SFM prior to injection 
into mice via the tail vein.  The number of cells was standardized after MCM or SFM 
treatment prior to tail vein injection so that all mice received the same number of tumour 
cells (the MCM-treated cells proliferated faster than the SFM-treated cells).   
 
4.5.1. Effect of pre-treating B16 cells with MCM prior to tail vein injection on 
metastatic efficiency in early tumour engraftment of the lung  
 
First, I examined whether MCM treatment enhanced early tumour engraftment of 
the lung 48 hours following tail vein injection.  The timepoint of 48 hours was selected 
because of a previous report indicating that, following immediate arrest of tumour cells in 
the lung microvasculature, over 80% of injected B16 melanoma cells will have 
undergone apoptosis and been cleared from the lung by 48 hours, and therefore it can be 
presumed that the majority of B16 cells remaining in the lung at 48 hours have metastatic 
efficiency(Qiu et al., 2003).  Because at first I explored using flow cytometry to quantify 
the metastatic burden in the lungs, GFP-B16 cells were used instead of B16mCherry cells 
as a flow cytometer with the appropriate laser to detect mCherry fluorescence was not 
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accessible at that time.  In later experiments when I was able to use a Becton Dickson 
LSRII flow cytometer which had the appropriate laser, I used B16mCherry cells instead 
for consistency with the other experiments.  However, I found that analyzing the lung 
tissue by flow cytometry was not a useful way to quantify metastatic tumour cells as the 
toxicity of the lung digestion protocol resulted in very high levels of cell death (therefore 
this data is not shown).    
 
 There was a greater number of B16 cells in the lung 48 hours following tail vein 
injection of MCM-treated B16 cells than control B16 cells as assessed by RT-PCR for 
GFP, although the results were very variable and failed to reach statistical significance, 
perhaps because of the small number of experiments, or because 48 hours was too early a 
timepoint (Figure 4.12).    
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Figure 4.12.  Effect of MCM treatment on efficiency of initial metastatic 
engraftment of the lung in the B16 tail vein model.   
GFP expression detected in lungs appeared to be higher in mice that received MCM-
treated B16-GFP cells than in mice that received control B16 cells.  RT-PCR on RNA 
extracted from lungs harvested 48 hours following tumour cell injection via the tail vein.  
Expression relative to β-actin. Mean +/-SEM, n=3 per group. (P = 0.18) 
 224 
4.5.2. The effect of MCM pretreatment on metastasis 7 days following tail vein 
injection of B16 melanoma cells   
 
To confirm whether there was higher efficiency in tumour engraftment after 
MCM-treatment of B16 cells, I compared melanoma metastases in lungs of mice that 
received control B16 cells or MCM-treated B16 cells 7 days after tail vein injection.  The 
number of surface melanoma metastases macroscopically visible in the lung was 
significantly higher for MCM-treated B16 cells than control B16 cells when lungs were 
harvested 7 days following tail vein injection (Figure 4.13) and this was confirmed by 
RT-PCR for mCherry (Figure 4.13).  
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Figure 4.13. Macroscopic melanoma metastases 7 days following tail vein injection 
of control B16 cells or MCM-treated B16 cells.   
(A) Lungs isolated 7 days following intravascular injection of 6.5 x 105 B16 melanoma 
cells via the lateral tail vein.   Substantially more metastatic foci were visible in lungs 
from mice that received MCM-treated B16 cells than mice that received untreated B16 
cells.  (B) Number of surface metastases counted on ventral and dorsal surfaces of entire 
right lung using a dissection microscope.  Mean + SEM, n=4 per group. (C) Expression 
of mCherry in lung 7 days following tail vein injection of control B16 cells or B16 cells 
pre-treated with MCM.  RNA extracted from whole R lung and analyzed by RT-PCR for 
expression of mCherry. Fold expression calculated relative to β-actin.  n=3 per group. P = 
0.17
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4.6. ‘CROSS-TALK’ BETWEEN MEGAKARYOCYTES AND TUMOUR CELLS IN 
COCULTURE SYSTEMS 
 
To dissect the crosstalk between megakaryocytes and tumour cells, a system for 
tumour cell-megakaryocyte coculture was established (Figure 4.14).  Changes in gene 
expression by both megakaryocytes and B16 cells following 24 hours of coculture were 
examined by RT-PCR.   
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Figure 4.14. Megakaryocyte-tumour cell coculture system.   
In vitro cultured megakaryocytes enriched over a BSA gradient were placed in the lower 
chamber of a Costar transwell chamber (24 well plate, 0.4µm pore size transwell 
membrane).  B16mCherry were placed in the top chamber.  The 0.4µm pores enabled 
exchange of secreted factors (and microparticles) but not cells between the chambers.  
Using mCherry-expressing tumour cells permitted visual confirmation that the cell 
cultures remained separate at the end of the experiment.   
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4.6.1. Tumour cells: upregulation of angiogenic growth factors and adhesion 
integrins following coculture with megakaryocytes 
 
Following coculture of B16 cells with megakaryocytes for 24 hours, I measured 
B16 expression of angiogenic growth factors and adhesion integrins by RNA extraction 
and RT-PCR.  Megakaryocyte-B16 coculture led to upregulation of B16 cell expression 
of the proangiogenic factors, VEGF, PlGF (a VEGF receptor-1 specific VEGF family 
member involved in metastasis(Kaplan et al., 2005)) and TGFβ (Figure 4.15).  
Furthermore, B16 cell expression of the adhesion integrins α4, α5, and α6 was also 
increased.  There was no change in expression of β1 (Figure 4.15).   
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Figure 4.15. Expression of angiogenic growth factors and a-integrins by B16 cells 
following coculture with megakaryocytes.   
Coculture increased B16 cell expression of the angiogenic growth factors, vascular 
endothelial growth factor (VEGF), placental growth factor (PlGF, a subtype of VEGF 
that has been reported to mediate B16 metastasis) and TGFβ, and also expression of α-
adhesion integrins.  No change in expression of β1−integrin was seen.  Fold expression 
measured by RT-PCR for B16 cells cocultured for 24 hours with megakaryocytes 
calculated relative to control B16 cells (data normalized using β-actin as housekeeping 
gene).  Mean + SEM, n=3 per group (control B16 cells vs. cocultured B16 cells).  
Representative data shown, experiment repeated 3 times.  
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4.6.2. Megakaryocytes: upregulate angiogenic growth factors and decrease PF4 
following coculture with B16 cells  
 
Following coculture with B16 melanoma cells, megakaryocyte expression of 
VEGF, TGFβ and TSP1 significantly increased (% increase: VEGF – 211 + 9%; TGFβ 
82 + 17%; TSP1 130 + 7.5%).  Furthermore, megakaryocyte expression of the anti-
angiogenic growth factor PF4 was reduced (% decrease in PF4 – 25 + 2%, Figure 4.16).  
Notably, the reduction in PF4 was consistent with my observations from the in vivo 
studies of mice with intradermal B16 melanoma indicating decreased PF4 expression in 
bone marrow by RT-PCR and from the ELISA of platelet-rich plasma (Section 3.5.3.).  
There was no change in expression of MMP9 or endostatin.   
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Figure 4.16. Megakaryocyte expression of angiogenic regulatory factors following 
coculture with B16 cells.   
Expression of VEGF and TGFβ and TSP1 increased while expression of the 
antiangiogenic growth factor PF4 decreased following coculture with B16 cells.  Mean + 
SEM fold increase in gene expression measured by RT-PCR relative to β-actin.  3 
technical replicates, experiment repeated 3x, representative data shown. 
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4.7.  DISCUSSION 
 
4.7.1. Summary of results 
 
 To examine the interactions between tumour cells and megakaryocytes in vitro, 
mature, proplatelet-forming megakaryocytes were generated by culturing the lineage-
negative bone marrow cells for 72 hours in the presence of TPO and SCF, followed by 
enrichment over a BSA gradient.  I confirmed by confocal microscopy that in vitro 
cultured megakaryocytes synthesized pro- and anti- angiogenic regulatory proteins, 
which were stored in distinct intracellular α-granules.  The effect of megakaryocyte-
derived factors on tumour cell migration and proliferation was examined using MCM.  
B16 cells actively migrated towards MCM in chemotaxis assays; this was inhibited by 
pretreatment of B16 cells with pertussis toxin, indicating that this effect was mediated by 
G-protein linked chemoreceptors expressed on B16 cells.  The chemotactic effect of 
MCM for B16 cells was also abrogated using MCM from megakaryoctyes generated 
from bone marrow of TSP1-/- mice.  In addition, MCM stimulated B16 cell proliferation 
in vitro, and pretreatment of B16 cells with MCM prior to tail vein injection enhanced 
metastatic engraftment of the lung.   
 
Coculture of B16 cells with megakaryocytes resulted in parallel gene expression 
changes in both cell types.   Following coculture, B16 cell expression of the 
proangiogenic factors, VEGF, PlGF and TGFβ increased by 64 + 17%, 26 + 3% and 120 
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+ 22% respectively, and expression of the α-adhesion integrins α4, α4 and α6 increased 
by 41-68%.  Meanwhile, coculture with tumour cells led to increased megakaryocyte 
expression of VEGF (211 + 9%), TGFβ (82 + 17%) and TSP1 (130 + 7.5%), while PF4 
expression reduced by 25 + 2%.           
 
 
4.7.2. The effect of megakaryocyte-conditioned medium (MCM) on tumour cell 
chemotaxis 
 
Isolation of functionally intact mature megakaryocytes from murine bone marrow 
is technically challenging due to their low numbers and sensitivity to handling activation.  
Therefore, to obtain sufficient megakaryocytes to investigate their interactions with 
tumour cells, I used uncommitted (lineage-negative) bone marrow progenitor cells 
differentiated under megakaryocyte conditions in vitro to generate large numbers of 
megakaryocytes.  Using this approach, my data suggested that megakaryocyte-derived 
TSP1 attracts tumour cells to megakaryocyte-vascular niches.  I did not evaluate 
concentrations of other chemokines in MCM from TSP1-/- megakaryocytes, and it was 
reported by Kopp et al that absolute and relative release of SDF1 from platelets isolated 
from TSP1 and TSP2 double knock mice was higher than wild type platelets(Kopp et al., 
2006), therefore it is possible that other chemokines were altered in addition to TSP1.  
Differences in SDF1 expression between wild type MCM and TSP1-/- MCM are unlikely, 
as although platelets are the major source of plasma SDF1(Kopp et al., 2006), 
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megakaryocytes synthesize SDF1 in very low amounts therefore SDF1 is unlikely to be 
present in MCM from in vitro cultured megakaryocytes.  In addition, I did not detect any 
expression of the SDF1 receptor, CXCR4, by B16 cells by RT-PCR. 
 
 
4.7.3. The effect of megakaryocyte-conditioned medium (MCM) on tumour cell 
proliferation in vitro 
 
I found that MCM accelerated the proliferation rate of B16 cells in vitro, although 
I did not identify the specific factor(s) mediating this effect.  Pertussis toxin treatment 
inhibited MCM-induced B16 cell proliferation, although this effect did not reach 
statistical significance (P = 0.057).  The growth factor receptors expressed by B16 cells 
have not been reported, and a wide range of candidate growth factors are produced by 
megakaryocytes suggesting that more than one factor may mediate this effect.      
 
Selecting the appropriate control for this experiment was carefully considered.  
MCM was prepared by culturing mature megakaryocytes at 370C, 5% CO2 in DMEM 
with 50ng/ml TPO but no added serum for 24 hours.  I chose to use serum-free DMEM 
with 50ng/ml TPO that had similarly been incubated for 24 hours at 370C, 5% CO2 as the 
control.  Another approach would have been to use medium conditioned by cells of non-
megakaryocytic lineage.   
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4.7.4. The effect of megakaryocyte-conditioned medium (MCM) on tumour cell 
metastatic engraftment in vivo  
 
 The metastatic efficiency of B16 cells was enhanced by pretreatment with MCM 
in a model of direct haematogenous metastasis to lung., The mechanism of this effect is 
not clear and may have been due to intravascular tumour cell evasion of immune 
attack,or to effects on lodgment in the microvascular, tissue invasion and/or 
tumourigenesis at the metastatic site.  Of note, platelets were not removed from MCM, 
and therefore platelet coating of tumour cells may have contributed to the increased 
metastatic engraftment.  The implication of this finding is that tumour cells attracted to 
megakaryocyte-vascular niches may be more likely to survive and initiate metastatic 
lesions.     
  
 
4.7.5. Crosstalk between megakaryocytes and tumour cells in coculture systems 
 
  I used coculture systems to begin to examine the molecular crosstalk between 
tumour cells and megakaryocytes.  The finding of increased megakaryocyte expression of 
VEGF and TGFβ but decreased PF4 expression following coculture was consistent with 
my observations in vivo from RT-PCR of bone marrow from mice over the timecourse of 
B16 tumour growth and metastasis.  This finding strengthens the hypothesis that the in 
vivo changes are due to altered megakaryocyte production rather than changes in other 
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bone marrow cells.  Alternative approaches would have been to compare gene expression 
in megakaryocytes isolated from mice with metastatic tumours with healthy mice, either 
by FACS of bone marrow cells flushed from tibias/femurs or by laser capture from bone 
marrow sections.  The altered megakaryocyte gene expression following tumour cell 
coculture suggests that the array of growth factors contained within platelets may also be 
altered in malignancy, although this was not examined in this study.   
 
The decrease in megakaryocyte expression of PF4 is likely to have been a 
contributing factor to the increased numbers of megakaryocytes, as PF4 is an autocrine, 
negative regulator of megakaryopoiesis.  Although I did not find any direct effect of PF4 
on B16 proliferation, previous reports indicate that PF4 is a potent antiangiogenic factor 
and inhibits growth and metastasis of melanoma and colon carcinoma in mouse 
models(Gentilini et al., 1999; Kolber et al., 1995; Sharpe et al., 1990; Tanaka et al., 1997) 
(See Table 1.5).  The upregulation of angiogenic/oncogenic factors and adhesion 
integrins in the B16 cells following coculture were in keeping with the finding that MCM 
pretreatment of B16 cells enhanced their metastatic engraftment of the lung.  These 
conclusions are all based on data from mouse tumour models which may be distinctly 
different from human malignancy. To investigate whether similar principles may apply to 
human metastatic disease, in Chapter 5, I examined the numbers, location and 
characteristics of megakaryocytes in trephine biopsies from patients with a variety of 
cancers. 
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4.7.6. Conclusion 
 
 In conclusion, these studies suggest that megakaryocyte-derived factors, in 
particular TSP1, chemoattract tumour cells to bone marrow vascular niches.  
Furthermore, interactions between megakaryocytes and tumour cells in the niche promote 
tumour cell proliferation and enhance the tumour cell metastatic efficiency.  In parallel, 
occupancy of the niche by tumour cells alters megakaryocyte gene expression towards a 
more proangiogenic phenotype, with upregulation of VEGF and TGFβ and 
downregulation of PF4.   
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CHAPTER 5.  MEGAKARYOCYTE-TUMOUR INTERACTIONS IN PATIENTS 
WITH CARCINOMA 
 
5.1. INTRODUCTION  
 
 The results described in Chapters 4 and 5 suggested that megakaryocytes support 
the bone marrow vascular niche and may play a role in tumour metastasis in mouse 
models.  In the final part of my project, I sought to examine whether there was evidence 
of similar pathways in patients with carcinoma.  It is well established that many patients 
with advanced malignancy have platelet abnormalities and hypercoagulability, and higher 
platelet counts correlate with poor prognosis in several cancer types(Karpatkin and 
Pearlstein, 1981) (see Section 1.5).  However, very few studies have examined 
histological bone marrow changes or megakaryocytes in patients with non-
haematological malignancies.  A study of 30 postmortem bone marrow aspirates from 
patients with metastatic carcinoma found that megakaryocyte size and ploidy was 
significantly higher in patients with metastatic disease, regardless of whether they had 
associated thromboembolic disease, than in healthy controls(Winkelmann et al., 1984).   
Very recently, a study of 43 patients with newly-diagnosed metastatic disease prior to 
treatment reported that patients with metastasis had higher platelet counts than healthy 
controls, and circulating platelet surface P-selectin expression was also increased, 
indicating higher levels of platelet activation(Wiesner et al., 2010). 
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 To examine whether there was evidence of megakaryocyte-tumour interactions in 
patients with carcinoma, I examined megakaryocyte number, morphology and 
localization in patients with metastatic carcinoma with and without metastatic disease in 
the bone marrow.  In ongoing studies, I am extending this analysis to include larger 
numbers of patients in four groups: those with localized carcinomas, patients with 
metastatic disease with and without bone marrow metastases, and healthy controls (n=20 
for each group).  As well as analysis of megakaryocyte number and morphology in H&E-
stained, paraffin-embedded bone marrow trephine biopsies, immunohistochemistry of the 
bone marrow for CD41, VEGF, TSP1, TGFβ, SDF1 and PF4 will be performed to 
confirm megakaryocyte localization of these factors and to compare expression levels in 
healthy individuals and in patients with malignancy.   
 
 241 
5.2. CHANGES TO MEGAKARYOCYTE NUMBER, MORPHOLOGY AND 
LOCALIZATION IN PATIENTS WITH METASTATIC CARCINOMA 
  
Bone marrow trephine biopsies from 11 patients with metastatic carcinoma were 
examined.  This included patients with renal (n=4), prostate (n=2), lung (n=2), urinary 
(n=1), breast (n=1) and medullary carcinomas (n=1), 6 of whom (55%) had bone marrow 
metastases and 5 had metastatic disease in other organs but no carcinoma cells seen in the 
bone marrow.  Abnormalities in megakaryocyte number, morphology, clustering and/or 
localization were detected in 8 of the 11 patients (73%, Table 5.1. and Figure 5.2.).   
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Table 5.1. Abnormalities in megakaryocyte number, morphology or clustering in 
patients with metastatic carcinoma  
 
Megakaryocyte changes Patient  Site of 
primary 
carcinoma 
Metastases 
in BM  Number Morphology  
Clustering 
1 Renal No Marked excess Normal Yes 
2 Renal No Moderate excess Normal Yes 
3 Renal No Mild excess Abnormal with small, 
hyperlobulated and 
abnormal forms 
Yes 
4 Urinary  No Normal Variable size and 
nuclear lobulation 
Yes 
5 Renal No Reduced Abnormal with small 
forms 
Yes 
6 Prostate No Mildly reduced Normal No 
7 Prostate Yes Mild excess Normal Yes 
8 Lung Yes Moderate excess Normal Yes 
9 Breast Yes Moderate excess Normal Yes 
10 Medullary  Yes Reduced Normal No 
11 Lung Yes Reduced Normal No 
Total number with abnormal 
megakaryopoiesis 
6 3 8 
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Figure 5.1.  Bone marrow trephine biopsy from patient with breast carcinoma with 
bone marrow metastases.   
Infiltrating breast carcinoma is seen on the left had side of the image (green arrows), and 
clusters of megakaryocytes which are seen in increased numbers are seen in the residual 
haematopoietic tissue on the right (yellow arrows).  H&E-stained paraffin-embedded 
bone marrow section, 400x magnification.   
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Figure 5.2. Abnormal megakaryocyte morphology and clustering in a patient with 
metastatic renal carcinoma (no bone marrow metastasis).   
Increased nuclear lobulation (red arrow) with abnormal megakaryocyte clustering in a 
bone marrow trephine biopsy of a patient with metastatic renal carcinoma.  H&E stained 
bone marrow section, 400x.     
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5.3. DISCUSSION  
 
 
5.3.1. Abnormal megakaryocytes in patients with metastatic carcinoma with and 
without evidence of bone marrow metastasis 
 
These studies included two groups of patients: those without overt bone marrow 
metatstases and those with definite marrow metastatic disease. In 6 patients there were no 
known bone marrow metastases and yet 3 of them had a mild or moderate increases in 
megakaryocyte numbers and 5 of the 6 had abnormal megakaryocyte clustering, 
suggesting that changes in megakaryopoiesis can precede bone marrow metastases and 
may do so in the majority of patients.  Megakaryocyte clustering is strongly associated 
with myeloproliferative syndromes(Michiels et al., 2007) and is likely to reflect changes 
to the functional characteristics of these cells, although the factors that mediate this 
phenomenon are not known and studies in cancer have not been performed.   
Interestingly, in the 5 patients with histological evidence of bone marrow metastases, the 
findings were more variable, 3 showing increased megakaryocyte numbers together with 
clustering and 2 patients had reduced numbers of megakaryocytes. The latter group of 
patients also showed no megakaryocyte clustering suggesting that in these 2 patients 
megakaryopoiesis may have been reduced directly due to tumour cell infiltration as part 
of a general reduction in haematopoiesis.   
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 The high prevalence of megakaryocyte abnormalities in patients with metastatic 
disease suggests that, as in the mouse model, they may be directly involved in tumour 
progression.  It is interesting that 5/6 patients with no evidence of bone marrow 
metastases had abnormal megakaryopoiesis.  This may implicate systemic effects of 
tumour-produced cytokines rather than a local effects of tumour cells within the bone 
marrow.  On the other hand it is also possible that my findings represent the first stage in 
megakaryocyte-mediated  'preconditioning' of the vascular niches prior to metastatic 
spread of tumour cells to these sites.  The more variable findings in patients with evident 
bone marrow metastases make it difficult to determine whether the megakaryocyte 
changes observed preceded bone marrow metastatic disease, or are a local response 
secondary to the presence of adjacent tumour cells.  Serial studies and studies in a much 
larger number of patients would be required to investigate this further.  A larger study 
would also be required to identify whether any specific tumour types are associated with 
abnormal megakaryopoiesis since the prevalence of bone marrow metastases in different 
tumour types is highly variable, being especially high, for example for prostate cancer 
and to a lesser extent, breast cancer. 
 
A further limitation of my study is that details of chemotherapy treatment are not 
known for these patients.  It is possible that the patients with reduced megakaryocyte 
numbers had recently received cytotoxic chemotherapy treatment.  Other factors that may 
cause altered megakaryopoiesis include other drugs and/or radiotherapy treatment, co-
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morbidities including infection, and immune-mediated anti-platelet/megakaryocyte 
antibodies occurring secondary to the cancer.  In addition, due to the nature of the 
trephine biopsy, only a small section of bone marrow is examined for each patient, 
therefore it is possible that patchy or localized tumour infiltrates may have been missed 
by the biopsy.  Finally, the selection of these patients was not random; most likely, these 
patients were referred for bone marrow studies because of clinical suspicion of bone 
marrow involvement, usually deranged peripheral blood cell counts.  Therefore, it is 
possible that patients with reduced megakaryocytes were more likely to be selected for 
the study and that patients with increased numbers of megakaryocytes and normal or 
increased platelet counts were less likely to be studied.   
 
In my analysis of bone marrow histology in mice with intradermal melanoma 
tumours, megakaryocyte numbers were significantly higher in mice with pre-metastatic 
tumours and progressively increased during the course of metastatic progression (Section 
3.3.3).  However, few patients with premetastatic or early metastatic disease have bone 
marrow studies.        
 
5.3.2. Conclusion 
 
Although thus far the numbers of patients included in the study is small, my 
preliminary results indicate that in a proportion of patients with metastatic carcinoma, 
megakaryopoiesis is increased, similar to my observations in the mouse models of 
 248 
metastasis.  In future studies, larger numbers of patients and normal controls will be 
examined.  Ideally these would include patients with both early and late stages of 
metastatic disease prior to cytotoxic chemotherapy treatment.  Also, further 
immunohistochemical characterization of VEGF, TSP1, TGFβ and PF4 expression may 
indicate whether megakarocyte expression of these factors may be altered in the setting 
of metastatic disease in patients similar to my findings in the mouse models.  
Examination of platelet counts and the content of these growth factors in platelet 
releasate would also be interesting.    
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6. DISCUSSION 
 
6.1. THE ROLE OF MEGAKARYOCYTES IN HOMING AND ENGRAFTMENT OF 
TUMOUR CELLS TO THE BONE MARROW VASCULAR NICHE IN MOUSE 
MODELS OF METASTASIS 
 
 
The bone marrow vascular niche supports physiological haematopoietic cells and 
has been implicated as an area of preferential engraftment for metastasizing tumour cells 
(Sections 1.1.2. and 1.6.2.).  There have been few studies on the contribution of 
perivascular cells, including megakaryocytes, to the dynamics of the vascular niche.  It 
has previously been reported that megakaryocyte-derived TSPs regulate bone marrow 
angiogenesis and regeneration of vascular niches following irradiation(Kopp et al., 2006).  
However, this study is the first to consider more widely the structural and functional 
contribution of megakaryocytes to the bone marrow vascular niche in normal physiology 
and in malignancy. 
 
My examination of the histology of the bone marrow revealed that the vast 
majority of bone marrow sinusoids were surrounded by one or more megakaryocytes, and 
that megakaryocytes were virtually always observed in close association with endothelial 
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cells.  This suggests that megakaryocytes are vital cellular constituents of the vascular 
niche.  Situated here at the bone marrow-blood interface, megakaryocytes extend their 
proplatelet protrusions through the sinusoidal wall into the vessel lumen, shedding 
platelets, microparticles and deploying their granular contents.  Moreover, 
megakaryocytes are suitably positioned to directly influence the homing patterns of 
circulating cells to perivascular domains.  In accordance with this, B16mCherry cells 
were observed in close association with megakaryocytes in vascular niches.    
 
The bone marrow is a naturally rich source of growth factors and chemokines and 
therefore constitutes a highly permissive microenvironment for tumour engraftment.  My 
comparison of bone marrow from TPO-/- mice with wild type mice revealed that 
megakaryocytes contribute the major proportion of several key growth factors to the bone 
marrow milieu.  This included 70-90% of the proangiogenic/oncogenic factors TGFβ and 
MMP9 and the chemokines/antiangiogenic factors TSP1 and PF4, and 40% of VEGF.  
Strikingly, over 90% of bone marrow TSP1 appeared to be produced by megakaryocytes.  
In vitro experiments showed that megakaryocyte-derived TSP1 mediated the chemotaxis 
of tumour cells towards MCM.  This suggests that megakaryocytes may directly recruit 
circulating tumour cells to the bone marrow vascular niche.  This finding is consistent 
with previous reports that microenvironment-derived TSP1 promotes tumour cell 
migration in breast cancer and melanoma(Taraboletti et al., 1987; Yee et al., 2009).    
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The SDF1 chemokine is generally considered to be the major factor orchestrating 
the homing of physiological and malignant cells to the bone marrow(Aiuti et al., 1997; 
Burger and Kipps, 2006; Sipkins et al., 2005; Taichman et al., 2002).  I found that SDF1 
expression in TPO-/- bone marrow was no different from wild type bone marrow.  This is 
consistent with previous reports that although megakaryocytes do not synthesize SDF1, 
they absorb it from the microenvironment and package it into platelet granules(Kopp et 
al., 2006).  Platelet-derived SDF1 is known to recruit CXCR4+ haematopoietic cells to 
sites of neovascularization in ischaemic tissue and angiogenic tumours(Jin et al., 2006a), 
and high concentrations of SDF1 around the bone marrow sinusoids mediates the homing 
and engraftment of CXCR4+ leukaemia cells.  It is possible that by concentrating SDF1 at 
the perivascular region megakaryocytes may create SDF1 gradients within the bone 
marrow.  Of note, B16 melanoma cells were found not to express CXCR4 by RT-PCR.      
 
My data also suggest that megakaryocytes are the principal cellular source of 
TGFβ, which was reduced by 75% in TPO-/- mice.  TGFβ has multiple roles in cancer, 
promoting cell proliferation, angiogenesis and invasion, and recent data indicate that 
TGFβ derived from platelets coats tumour cells thereby preventing their recognition by 
natural killer (NK) cells(Kopp et al., 2009).  Similarly, TGFβ released by 
megakaryocytes may reduce NK-mediated destruction of tumour cells within in the bone 
marrow.  
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Although a wealth of data supports a role for platelets in metastasis (See Section 
1.5), very few studies have examined megakaryocytes or the bone marrow 
microenvironment in solid tumour metastasis.  Interestingly, a number of small studies 
published several years ago also support a role for megakaryocytes in metastasis.  
Increased megakaryopoiesis was described in rats with highly metastatic mammary 
carcinomas due to secretion of a growth factor with GM-CSF/IL3 activity; no change in 
platelet count was observed, similar to the findings in my study(McGary et al., 1995).  
Also, a study comparing bone marrow aspirates from patients with metastasis with 
healthy controls reported that megakaryocyte size and ploidy was increased in patients 
with metastatic cancer, in accordance with the increased megakaryocyte size observed in 
mice with late-stage B16 melanoma(Winkelmann et al., 1984).  Finally, a study published 
very recently reported that megakaryocyte numbers were in increased C57Bl/6 mice 
bearing early (day 15) lewis lung carcinomas in the flank(Zaslavsky et al., 2010).    
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6.2. MECHANISMS OF MEGAKARYOCYTE-TUMOUR CELL INTERACTIONS IN 
VITRO 
 
From my studies of the chemotactic properties of MCM for B16 melanoma cells, 
TSP1 emerged as a primary candidate for mediating tumour cell migration.  Both pro- 
and anti-metastatic effects of TSP1 have been described.  While TSP1 and TSP2 inhibit 
endothelial cell migration, proliferation and tumour angiogenesis(Kopp et al., 2006; 
Lawler et al., 2001), chemotaxis and haplotaxis of human melanoma and breast cancer 
cell lines appears to be mediated by TSPs, and TSP1-associated chemotaxis is mediated 
by a pertussis toxin-sensitive G-protein(Lymn et al., 2002; Taraboletti et al., 1987).  
Other studies indicate that TSP1 stimulates tumour cell adhesion to vessel 
walls(Tuszynski et al., 1987), and clinical studies comparing locally invasive with 
metastatic breast carcinoma reported higher expression of TSP1 mRNA and protein in 
metastatic disease, both in tumour cells and in the local stroma(Bertin et al., 1997; Brown 
et al., 1999).  In mouse model of spontaneous metastatic breast cancer, TSP1 knock-
down was associated with reduced metastasis to blood and to lung, thought to be due to 
TSP1-induced activation of TGFβ(Yee et al., 2009).  Very recently, it was reported that 
platelet TSP1 content is upregulated in mice with intradermal lewis lung carinoma and 
B16 melanoma and that this is due to an increase in megakaryocyte TSP1 synthesis by 
RT-PCR(Zaslavsky et al., 2010).  My finding that megakaryocyte-derived TSP1 mediates 
B16 cell migration and that megakaryocyte TSP1 expression increased following tumour 
cell coculture is in accordance with these data.   
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It has now been established that protein packaging within megakaryocyte and 
platelet granules is highly organized, and that α-granule contents may be selectively 
deployed following ligation of specific surface receptors(Italiano et al., 2008; Ma et al., 
2005; Villeneuve et al., 2009).  In this study, I demonstrated that in response to systemic 
signals from the primary tumour, megakaryocytes may modify their gene expression 
thereby altering the megakaryocyte/platelet phenotype in a manner that may promote 
tumour progression.  Megakaryocyte expression of VEGF, TGFβ and TSP1 increased in 
response to tumour, whereas PF4 expression decreased, indicating that megakaryocyte 
production of these key growth factors is individually regulated and that tumours may 
alter the megakaryocyte/platelet phenotype in a manner that supports their metastasis.   
 
PF4 (like TSP1) is an anti-angiogenic factor and an autocrine, negative regulator 
of megakaryocyte differentiation(Lambert et al., 2007), and therefore reduced PF4 may 
be in part responsible for the increased number of megakaryocytes observed during 
tumour growth.  Although I did not find any direct effect of PF4 on B16 proliferation, 
previous reports indicate that PF4 is a potent antiangiogenic factor and inhibits growth 
and metastasis of melanoma and colon carcinoma in mouse models(Gentilini et al., 1999; 
Kolber et al., 1995; Sharpe et al., 1990; Tanaka et al., 1997) (See Table 1.5).   
 
Following megakaryocyte coculture, B16 cells upregulated their expression of 
angiogenic factors and the adhesion integrins, α4, α5 and α6.  There are several lines of 
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evidence to indicate that α4β1 integrin expression on B16 cells is particularly important 
for haematogenous and lymphatic metastasis(Rebhun et al.).  α4β1 integrin enables B16 
melanoma cells to adhere to the VCAM receptor on activated vascular 
endothelium(Klemke et al., 2007; Martin-Padura et al., 1991) and organ-specific 
upregulation of VCAM in spontaneous models of B16 melanoma correlates with the 
pattern of metastatic dissemination(Langley et al., 2001).  Furthermore, pretreatment of a 
human melanoma cell line with anti-α4β1 has been shown to reduce metastatic 
engraftment of the lung in the tail vein metastasis model(Garofalo et al., 1995).  In 
studies of patients with melanoma, α4β1 expression levels correlate with metastasis and 
overall survival(Schadendorf et al., 1993).  In my studies, no change in β1 expression 
was seen following coculture.   
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6.3. THE MEGAKARYOCYTE-VASCULAR NICHE IN PATIENTS WITH 
METASTATIC CARCINOMA  
 
 
 The analysis of bone marrow biopsies from 11 patients with metastatic carcinoma 
was supportive of my observations in the mouse models, as an increased number of 
megakaryocytes and/or megakaryocyte clustering was seen in 73% of the patients.  
Although further studies are required to establish whether megakaryocytes have a 
functional role in human tumour metastasis, these observations suggest that interactions 
between megakaryocytes and tumour cells may also occur in the human setting.   
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6.4. A MODEL OF THE MEGAKARYOCYTE-TUMOUR CELL NICHE 
 
The data from both the murine and human studies suggest a model in which bi-
directional interactions between tumour cells and megakaryocytes may promote 
malignant progression (Figure 6.1).     
 
 
  
 
 
 
 
 
Figure 6.1. A model of the megakaryocyte-vascular-tumour cell niche.   
(A) In normal homeostasis, haematopoeitic cells occupy bone marrow megakaryocyte-vascular 
niches.  (B) In metastatic cancer, megakaryocyte-derived factors (eg TSP1) attract circulating 
tumour cells to the vascular niche.  (C) Tumour-derived thrombopoietic/angiogenic factors 
(VEGF, SCF and IL11 and the reducted PF4) stimulate expansion of megakaryoccyte-vascular 
niches and their co-option by tumour cells leading to increased megakaryocyte VEGF and TGFβ 
expression and reduced PF4. 
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It has been hypothesized that as well as inducing the formation of new niches, 
malignant cells may co-opt existing stem cell niches, modifying them to attract tumour 
cells and enhance their contribution to tumour progression(Scadden, 2006).  Tumour 
occupancy of the niche induces gene expression changes in both megakaryocytes and 
tumour cells that promote metastasis.  
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6.5. DIRECTIONS FOR FUTURE RESEARCH 
 
Several questions remain unanswered.  Firstly, although I have shown that 
megakaryocytes are universally present in vascular niches; whether they are a defining 
feature of the vascular niche remains unclear.  Secondly, whether the observations 
described here are specific to certain tumour types or whether they are applicable to all 
cancer metastasis is not known.  Finally, the specific molecular mechanism that underlies 
the tumour-megakaryocyte cross-talk leading to the changes in gene expression was not 
established in this study.    
 
Further studies would include a more extensive analysis of megakaryocyte-
tumour interactions in patients with carcinoma to confirm and extend the preliminary 
observations described here.  In studies that are currently in progress, bone marrow 
biopsies from a larger number of patients with localized and metastatic carcinoma are 
being compared to healthy controls.  In addition to assessing the number, morphology 
and localization of megakaryocytes in H&E-stained sections, immunohistochemistry for 
the megakaryocyte-derived factors TSP1, TGFβ, PF4 and VEGF will be performed.  
Additional experiments could include a comparison of platelet counts, platelet size, and 
the content of megakaryocyte-derived angioregulatory proteins in platelet releasate from 
patients with metastatic disease.   
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Additional murine studies could include examining the effect of anti-TSP1 
antibody treatment or gene knockdown on bone marrow metastasis to establish whether 
this factor plays an integral role of the in the homing and engraftment of tumour cells to 
the bone marrow.  Finally, other cell lines such as the 4TI breast cancer in BALB/c mice 
or ESb lymphoma in C57Bl/6 mice could be studied to confirm the observations in other 
mouse models of metastasis.   
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6.6. CLINICAL IMPLICATIONS AND CONCLUSION 
 
Bone marrow metastasis is common in melanoma, breast, prostate and other 
carcinomas, and is responsible for a large burden of morbidity and mortality due to 
intractable bone pain and impaired haematopoiesis.  To improve outcomes for patients, 
therapies that specifically target metastatic disease are likely to be required.  This 
necessitates a better understanding of the underlying cellular and molecular pathways in 
metastatic progression.  This study proposes a model in which megakaryocytes play a 
pivotal role in the homing and engraftment of malignant cells to vascular niches in the 
bone marrow, and moreover, that cross-talk between megakaryocytes and tumour cells 
augments the pro-tumourigenic phenotype of thrombopoietic cells and enhances the 
metastatic phenotype of tumour cells.  A better understanding of the interactions between 
tumour and host that are permissive for tumour dissemination may suggest new avenues 
for therapeutic development. 
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